WO2000038683A1 - THROMBIN OR FACTOR Xa INHIBITORS - Google Patents

THROMBIN OR FACTOR Xa INHIBITORS Download PDF

Info

Publication number
WO2000038683A1
WO2000038683A1 PCT/US1999/030737 US9930737W WO0038683A1 WO 2000038683 A1 WO2000038683 A1 WO 2000038683A1 US 9930737 W US9930737 W US 9930737W WO 0038683 A1 WO0038683 A1 WO 0038683A1
Authority
WO
WIPO (PCT)
Prior art keywords
occurrence
alkyl
phenyl
substituted
benzyl
Prior art date
Application number
PCT/US1999/030737
Other languages
French (fr)
Inventor
Ruth R. Wexler
Charles G. Clark
John M. Fevig
Robert A. Galemmo
Qi Han
Irina C. Jacobson
Patrick Yuk Sun Lam
Renhau Li
Donald J. P. Pinto
Original Assignee
Du Pont Pharmaceuticals Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharmaceuticals Company filed Critical Du Pont Pharmaceuticals Company
Priority to AU23816/00A priority Critical patent/AU2381600A/en
Priority to CA002320730A priority patent/CA2320730A1/en
Priority to EP99967554A priority patent/EP1058549A4/en
Publication of WO2000038683A1 publication Critical patent/WO2000038683A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
  • Activated factor Xa whose major practical role is the generation of thrombin by the limited proteolysis of prothrombin, holds a central position that links the intrinsic and extrinsic activation mechanisms in the final common pathway of blood coagulation.
  • the generation of thrombin, the final serine protease in the pathway to generate a fibrin clot, from its precursor is amplified by formation of prothrombinase complex (factor Xa, factor V,
  • factor Xa Ca 2+ and phospholipid
  • one object of the present invention is to provide novel nitrogen containing aromatic heterocycles, with ortho-substituted PI groups, which are useful as factor Xa inhibitors or pharmaceutically acceptable salts or prodrugs thereof .
  • the present invention provides a novel compound selected from the group:
  • G is selected from the group:
  • L n is a linker which is absent or is selected from O, S, CH 2 , *CH 2 NHC(0), *CH(R a )NHC(0) , *CH 2 NHC (O) CH 2 , and *CH(R a )NHC(0) CH 2 , provided that L n and M do not form an O-N or S-N bond and the * indicates where L n is bonded to G;
  • M 1 is absent or is CHR
  • M 2 is N or CR f ;
  • M 3 is N or CR d ;
  • R a is selected from C(0)C(0)OR 3 , C (0) C (O) NR 2 R 2a , and C(0)-A;
  • R b is selected from H, R, phenyl, C ⁇ _ ⁇ o alkyl, and C 2 - 5 alkenyl ;
  • R c is selected from H and C ⁇ - 6 alkyl
  • R b and R c together are -(0- 2 ) 4 -;
  • R d is selected from H, F, and Cl;
  • R e is selected from H, N(CH 3 ) (CH 2 C0 2 H) and S- (5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4 ) ;
  • R f is selected from H, F, and Cl ;
  • R9 is selected from H, CH 2 OR 3 , CH 2 C(0)OR 3 , C - alkyl,
  • R 1 is selected from S0 2 CH 2 C (0) OR 3 , C (0) CH 2 C (0) OR 3 , and C(0)OR 3 ;
  • R is selected from H, Cl, F, Br, I, (CH 2 ) t OR 3 , C ⁇ _ 4 alkyl, benzyl, 0CF 3 , CF 3 , C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 ; Z is selected from (CR 8 R 9 ) !
  • R 1 ' is selected from H, C ⁇ - 3 alkyl, F, Cl, Br, I, -CN, -CHO,
  • R 4 and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4 ;
  • R 1 " is selected from H, CH(CH 2 OR 2 ) 2 , C(0)R 2c , C(0)NR 2 R 2a , S(0)R 2b , S(0) 2 R 2b , and S0 2 NR 2 R 2a ;
  • R lb is selected from H, C ⁇ _ 6 alkyl, and C ⁇ _ 6 alkyl substituted with A;
  • R 2 at each occurrence, is selected from H, CF 3 , C ⁇ _ 6 alkyl, benzyl, C 3 - 6 carbocyclic residue substituted with 0-2
  • R 4b and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4b ;
  • R 2a is selected from H, CF 3 , C ⁇ - 6 alkyl, benzyl, C 3 - 6 cycloalkylmethyl substituted with 0-2 R 4b , C 3 -- 6 carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4b ;
  • R 2b at each occurrence, is selected from CF 3 , C ⁇ _ 4 alkoxy, C ⁇ _s alkyl, benzyl, C 3 - 6 carbocyclic residue substituted with 0-2 R 4b , and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4b ;
  • R 2c is selected from CF 3 , OH, C 1 - 4 alkoxy, C . ⁇ alkyl, benzyl, C 3 -.
  • S carbocyclic residue substituted with 0-2 R 4b and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4b ;
  • R 2 and R 2a together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4b and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
  • R 3 at each occurrence, is selected from H, C ⁇ _ alkyl, and phenyl ;
  • R 3a at each occurrence, is selected from H, C ! _ 4 alkyl, and phenyl ;
  • R 3b at each occurrence, is selected from H, C 1 _ 4 alkyl, and phenyl ;
  • R 3c at each occurrence, is selected from C - 4 alkyl, and phenyl ;
  • A is selected from:
  • a 1 is H or A
  • a and A 1 and the carbon to which they are attached combine to form fluorene
  • a 2 is selected from H, A, and CHA 3 A 4 ;
  • a 3 is selected from H, A, C ⁇ alkyl, and - (CH 2 ) r NR 2 R 2a ;
  • a 4 is H or A
  • B is selected from: H, Y, and X-Y
  • X is selected from C ⁇ _ 4 alkylene, -CR 2 (CR 2 R 2b ) (CH 2 ) t - ⁇ -C(O)-, -CR 2 (NR 1 "R 2 ) -, -CR 2 (OR 2 )-, ⁇ CR 2 (SR 2 )-, -C (O) CR 2 R 2a - , -CR 2 R 2a C(0), -OS(0) 2 -, -S(0) p -, -S(0) p CR 2 R 2a -, -CR 2 R 2a S(0) p -, -S(0) 2 NR 2 -, -NR 2 S(0) 2 -, -NR 2 S(0) 2 CR 2a - , -CR 2 R 2a S(0) 2 NR 2 -, -NR 2 S(0) 2 CR 2a - , -CR 2 R 2a S(0) 2 NR 2 -, -NR 2 S(0) 2 CR 2a - , -CR
  • Y is selected from:
  • Z-A-B combine to form S-C ⁇ _ 6 alkyl
  • one R 4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;
  • one R 4a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-1 R 5 ;
  • R 5 at each occurrence, is selected from CF 3 , C ⁇ _ 6 alkyl, phenyl substituted with 0-2 R 6 , and benzyl substituted with 0-2 R 6 ;
  • R 7 at each occurrence, is selected from H, OH, C]__ 6 alkyl, C ⁇ - 6 alkylcarbonyl, C ⁇ - 6 alkoxy, C ⁇ - 4 alkoxycarbonyl, (CH 2 ) n -phenyl, C 6 - ⁇ o aryloxy, C 6 - ⁇ 0 aryloxycarbonyl, C 6 _ ⁇ 0 arylmethylcarbonyl, C ⁇ _ 4 alkylcarbonyloxy C ⁇ _ 4 alkoxycarbonyl, Cg-io arylcarbonyloxy C ⁇ _ 4 alkoxycarbonyl, C ⁇ _ 6 alkylaminocarbonyl, phenylaminocarbonyl , and phenyl C 1 _ 4 alkoxycarbonyl; R 8 , at each occurrence, is selected from H, C ⁇ _g alkyl and (CH 2 ) n -phenyl;
  • R 7 and R 8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
  • R 9 at each occurrence, is selected from H, C ⁇ _ 6 alkyl and (CH 2 ) n -phenyl;
  • n at each occurrence, is selected from 0, 1, 2, and 3;
  • n 0, 1, and 2 ;
  • p at each occurrence, is selected from 0, 1, and 2;
  • r at each occurrence, is selected from 0, 1, 2, and 3;
  • s at each occurrence, is selected from 0, 1, and 2;
  • t at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a novel compound, wherein:
  • G is selected from the group:
  • the present invention provides a novel compound, wherein:
  • G is selected from:
  • the present invention provides a novel compound, wherein:
  • R is selected from H, Cl, F, Br, I, (CH 2 ) t OR 3 , C ⁇ -4 alkyl, OCF 3 , CF 3 , C(0)NR 7 R 8 , and (CR 8 R 9 ) t NR 7 R 8 ;
  • Z is selected from CH 2 0, OCH 2 , CH 2 NH, NHCH 2 , C(O), CH 2 C(0), C(0)CH 2 , NHC(O), C(0)NH, CH 2 S(0) , S(0) 2 (CH 2 ), S0 2 NH, and NHS0 , provided that Z does not form a N-N, N-O, NCH 2 N, or NCH 2 0 bond with ring M or group A;
  • A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl , pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl , triazolyl, 1, 2 , 3 -oxadiazolyl, 1,2, 4 -oxadiazolyl, 1,2, 5-oxadiazolyl, 1,3, -oxadiazolyl , 1,2, 3 -thiadiazolyl , 1,2, 4 -thiadiazolyl, 1,2, 5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4
  • Y is NR 2 R 2a or CH 2 NR 2 R 2a , provided that X-Y do not form a N-N or O-N bond;
  • Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3 -oxadiazolyl, 1,2, 4 -oxadiazolyl , 1,2, 5 -oxadiazolyl , 1,3, 4 -oxadiazolyl, 1,2, 3 -thiadiazolyl, 1,2, 4
  • Y is selected from the following bicyclic heteroaryl ring systems :
  • K is selected from O, S, NH, and N.
  • the present invention provides a novel compound, wherein:
  • Z is C(0)CH 2 and CONH, provided that Z does not form a N-N bond with group A;
  • A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R 4 ;
  • B is selected from Y, X-Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R 4a ;
  • B is selected from: Y and X-Y;
  • X is selected from CH 2 , -C(O)-, and 0;
  • Y is NR 2 R 2a or CH 2 NR 2 R 2a , provided that X-Y does not form an O-N bond;
  • Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R 4a ; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3- triazolyl; R 2 , at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl ;
  • R 2a at each occurrence, is selected from H, CF 3 , CH 3 , CH(CH 3 ) 2 , eyelopropylmethyl, benzyl, and phenyl;
  • R 2 and R 2a combine to form a ring system substituted with 0-2 R 4b , the ring system being selected from pyrrolidinyl, piperazinyl and morpholino;
  • R 4 at each occurrence, is selected from OH, (CH 2 ) r OR 2 , Cl ,
  • R 4a is selected from Cl, F, C ⁇ _ alkyl, CF 3 , (CH 2 ) r NR 2 R a , S(0) p R 5 , S0 2 NR 2 R 2a , and l-CF 3 -tetrazol-2-yl ⁇
  • R 4b at each occurrence, is selected from OH, Cl, F, CH 3 , and CF 3 ;
  • R 5 at each occurrence, is selected from CF 3 , C ⁇ - ⁇ alkyl, phenyl , and benzyl ;
  • R 7 at each occurrence, is selected from H, CH 3 , and CH 2 CH 3 ;
  • R 8 at each occurrence, is selected from H and CH 3 .
  • the present invention provides a novel compound, wherein:
  • A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3 -Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl , 2-aminophenyl , and 2- methoxyphenyl ; and,
  • B is selected from the group: 2 -CF3 -phenyl, 2- (aminosulfonyl) phenyl, 2- (methylaminosulfonyl) phenyl,
  • the present invention provides a compound of formula:
  • L n is *CH 2 NHC(0)CH 2 or *CH (R a ) NHC (0) CH 2 , the * indicates where L n is bonded to G;
  • R a is C(0)C(0)0R 3 ;
  • Z is selected from C 1 - 4 alkylene, (CH 2 ) r C(0), and (CH 2 ) r S(0) 2 ;
  • R 2 at each occurrence, is selected from H, C ⁇ _ 6 alkyl, benzyl , and phenyl
  • R 2a at each occurrence, is selected from H, C ⁇ - 6 alkyl, benzyl , and phenyl ;
  • R 2b at each occurrence, is selected from H, C ⁇ _ 6 alkyl, benzyl , and phenyl ;
  • R 2 at each occurrence, is selected from OH, OCH 3 , OCH 2 CH 3 , CH 3 , benzyl , and phenyl ;
  • R 3 at each occurrence, is selected from H, C ⁇ __ 4 alkyl, and phenyl ;
  • A is C 5 -- 6 carbocyclic residue substituted with 0-2 R 4 ;
  • R 5 at each occurrence, is selected from CF 3 , C ⁇ - ⁇ alkyl, phenyl , and benzyl ;
  • p at each occurrence, is selected from 0, 1, and 2;
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein:
  • L n is *CH(R a )NHC(0)CH 2 ;
  • R a is C(0)C(0)OH;
  • Z is selected from CH 2 , (CH 2 ) 2 C(0), and CH 2 S(0) 2 ;
  • A is cyclohexyl or phenyl and is substituted with 0-1 R 4 ;
  • r at each occurrence, is selected from 0, 1, and 2.
  • the present invention provides a compound of formula:
  • L n is *CH 2 NHC(0)CH 2 or *CH (R a ) NHC (O) CH 2 , the * indicates where L n is bonded to G;
  • R a is C(0)C(0)OR 3 ;
  • R is H or NH 2 ;
  • Z is selected from C1.- 4 alkylene, (CH 2 ) r C(0), and (CH 2 ) r S(0) 2 ;
  • R 2 at each occurrence, is selected from H, ⁇ - ⁇ alkyl, benzyl , and phenyl ;
  • R a at each occurrence, is selected from H, . ⁇ alkyl, benzyl, and phenyl;
  • R 2b at each occurrence, is selected from H, C ⁇ _ 6 alkyl, benzyl, and phenyl
  • R 2c at each occurrence, is selected from OH, OCH 3 , 0CH 2 CH 3 , CH 3 , benzyl , and phenyl ;
  • R 3 at each occurrence, is selected from H, C ⁇ _ 4 alkyl, and phenyl ;
  • A is a C 5 _ 6 carbocyclic residue substituted with 0-2 R 4 ;
  • R 5 at each occurrence, is selected from CF 3 , -s alkyl, phenyl , and benzyl ;
  • p at each occurrence, is selected from 0, 1, and 2;
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein:
  • L n is *CH(R a )NHC(0)CH 2 ;
  • R is H
  • R a is C(0)C(0)OH
  • Z is selected from CH 2 , (CH 2 ) 2 C(0), and CH 2 S(0) 2 ;
  • A is cyclohexyl or phenyl and is substituted with 0-1 R 4 ;
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound of formula:
  • L n is *CH 2 NHC(0) CH 2 or *CH (R a ) NHC (O) CH 2 , the * indicates where L n is bonded to G;
  • R is H or NH 2 ;
  • R a is C(0)C(0)OR 3 ;
  • Z is C]__ 4 alkylene
  • R 2 at each occurrence, is selected from H, C ⁇ _g alkyl, benzyl , and phenyl ;
  • R 2a at each occurrence, is selected from H, C ⁇ _g alkyl, benzyl , and phenyl ;
  • R 2b at each occurrence, is selected from H, C ⁇ g alkyl, benzyl , and phenyl ;
  • R 2c at each occurrence, is selected from OH, OCH 3 , OCH CH 3 , CH 3 , benzyl , and phenyl ;
  • R 3 at each occurrence, is selected from H, C 1 - 4 alkyl, and phenyl ;
  • A is phenyl substituted with 0-2 R 4 ;
  • R 4 at each occurrence, is selected from H, (CH ) r OR 2 , F, Cl ,
  • R 5 at each occurrence, is selected from CF 3 , C ⁇ _g alkyl, phenyl , and benzyl ;
  • p at each occurrence, is selected from 0, 1, and 2;
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein:
  • L n is *CH(R a )NHC(0)CH 2 ;
  • R is NH 2 ;
  • R a is C(0)C(0)OH
  • Z is CH 2 ;
  • A is phenyl substituted with 0-1 R 4 ;
  • R 4 at each occurrence, is selected from H, OR 2 , CH 2 OR 2 , F,
  • r at each occurrence, is selected from 0, 1, and 2.
  • L n is *CH 2 NHC(0) or *CH (R a ) NHC (O) and the * indicates where L n is bonded to G;
  • R a is selected from C(0)C(0)OR 3 and C(0)-A;
  • R b is selected from H, phenyl, C ⁇ - ⁇ o alkyl, and C 2 _s alkenyl;
  • R c is selected from H and C ⁇ g alkyl
  • R b and R c together are -(CH 2 ) -;
  • Z is (CR 8 R 9 ) ! _ 4 ;
  • R 2 at each occurrence, is selected from H, CF 3 , and C ⁇ _ alkyl ;
  • R 2a at each occurrence, is selected from H, CF 3 , and C _g alkyl ;
  • R 2b at each occurrence, is selected from H, CF 3 , and C ⁇ _ alkyl;
  • R 2c at each occurrence, is selected from OH, OCH 3 , OCH 2 CH 3 , CH 3 , benzyl , and phenyl ;
  • R 3 at each occurrence, is selected from H, C ⁇ _ 4 alkyl, and phenyl ;
  • A is selected from: C _- L o aromatic carbocyclic residue substituted with 0-2
  • R 4 at each occurrence, is selected from H, (CH 2 ) r OR 2 , F, Cl ,
  • R 5 at each occurrence, is selected from CF 3 , Ci-g alkyl, phenyl , and benzyl ;
  • R 8 at each occurrence, is selected from H, C ⁇ _ 6 alkyl and phenyl ;
  • R 9 at each occurrence, is selected from H, C ⁇ _g alkyl and phenyl ;
  • p at each occurrence, is selected from 0, 1, and 2 ;
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein:
  • L n is *CH(R a )NHC(0) and the * indicates where L n is bonded to G;
  • R a is C(0)C(0)OH or C (O) - (benzothiazol-2-yl) ;
  • R b is selected from H, phenyl, C ⁇ _ ⁇ o alkyl, and C 2 _ 5 alkenyl;
  • R c is selected from H and C ⁇ _g alkyl
  • R b and R c together are -(CH 2 ) 4 -;
  • Z is (CR 8 H) ! _ 2 ;
  • A is selected from phenyl, naphthyl, and thienyl, and A is substituted with 0-1 R 4 ;
  • R 4 at each occurrence, is selected from H, OR 2 , CH 2 OR 2 , F, Cl, Br, I, Ci- 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C(0)R 2c , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , and CF 3 ;
  • R 8 at each occurrence, is selected from H, methyl and phenyl
  • r at each occurrence, is selected from 0, 1, and 2.
  • the present invention provides a compound of formula:
  • L n is *CH 2 NHC(0) or *CH (R a ) NHC (0) and the * indicates where L n is bonded to G;
  • R a is selected from C(0)C(0)OR 3 and C(0)-A;
  • R b is selected from H, phenyl, alkyl, and C 2 _ 5 alkenyl;
  • R c is selected from H and C ⁇ _ alkyl
  • R b and R c together are -(CH 2 ) 4 -;
  • R is selected from H, benzyl, C ⁇ _ 4 alkyl, and NH 2 ;
  • Z is (CR 8 R 9 ) 1-4;
  • R 2 at each occurrence, is selected from H, CF , and C ⁇ g alkyl ;
  • R 2a at each occurrence, is selected from H, CF 3 , and C ⁇ _g alkyl;
  • R 2b at each occurrence, is selected from H, CF 3 , and C ⁇ _g alkyl ;
  • R 2c at each occurrence, is selected from OH, OCH 3 , OCH 2 CH 3 , CH 3 , benzyl , and phenyl ;
  • R 3 at each occurrence, is selected from H, C ⁇ _ alkyl, and phenyl ;
  • A is selected from:
  • R 4 at each occurrence, is selected from H, (CH 2 ) r 0R 2 , F, Cl , Br, I, C 1 - 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2c , NR 2 C(0)R 2b , C(0)NRR 2a , S0 2 NR 2 R 2a , S(0) p R 5 , and CF 3 ; R 5 , at each occurrence, is selected from CF 3 , C ⁇ _ alkyl, phenyl, and benzyl;
  • R 8 at each occurrence, is selected from H, C]__g alkyl and phenyl ;
  • R 9 at each occurrence, is selected from H, . 6 alkyl and phenyl ;
  • p at each occurrence, is selected from 0, 1, and 2;
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein:
  • L n is *CH (R a )NHC (O) and the * indicates where L n is bonded to G;
  • R a is C(0)C(0)OH or C (0) - (benzothiazol-2-yl) ;
  • R b is selected from H, phenyl, C ⁇ - ⁇ o alkyl, and C _ 5 alkenyl;
  • R c is selected from H and C ⁇ _ 6 alkyl
  • R b and R c together are -(CH 2 ) 4 -;
  • A is selected from phenyl, naphthyl, and thienyl, and A is substituted with 0-1 R 4 ;
  • R 4 at each occurrence, is selected from H, OR 2 , CH 2 0R 2 , F, Cl, Br, I, Ci- 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C(0)R 2c , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , and CF 3 ;
  • R 8 at each occurrence, is selected from H, C ⁇ _g alkyl and phenyl ;
  • r at each occurrence, is selected from 0, 1, and 2.
  • the present invention provides a compound of formula:
  • L n is *CH 2 NHC(0) or *CH (R a ) NHC (0) and the * indicates where L n is bonded to G;
  • R la is selected from -(CH 2 ) r -R 1 ' and NHO ⁇ R 1 " ;
  • R 1 ' is selected from H, OR 2 , NR 2 R 2a , and NR 2 S0 2 (CH 2 ) r R 2b ;
  • R 1 " is selected from C(0)NR 2 R 2a , S(0) 2 R b , and S0 2 NR 2 R 2a ;
  • R 2 at each occurrence, is selected from H, C ⁇ _ alkyl, benzyl, and phenyl;
  • R 2a at each occurrence, is selected from H, C ⁇ _g alkyl, benzyl , and phenyl ;
  • R 2b is selected from C ⁇ _ alkoxy, C ⁇ _g alkyl, benzyl, phenyl substituted with 0-2 R 4b , and 5-6 membered heterocyclic system containing from 1-2 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4b ;
  • R 2c at each occurrence, is selected from OH, OCH 3 , OCH 2 CH 3 , CH 3 , benzyl , and phenyl ;
  • R 2 and R 2a together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R 4b and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
  • R 3 at each occurrence, is selected from H, C _ 4 alkyl, and phenyl;
  • A is phenyl substituted with 0-2 R 4 ;
  • a 1 is H or A
  • a and A 1 and the carbon to which they are attached combine to form fluorene
  • a 2 is selected from H, A, and CHA 3 A 4 ;
  • a 3 is selected from H, A, C.- 4 alkyl, and - (CH 2 ) r NR 2 R 2a ;
  • a 4 is H or A
  • R 4 at each occurrence, is selected from H, (CH ) r OR 2 , F, Cl, Br, I, Ci- 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2 , NR 2 C(0)R 2b , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , S(0) p R 5 , and CF 3 ;
  • R 4b at each occurrence, is selected from H, (CH 2 ) r OR 2 , F, Cl, Br, I, Ci- 4 alkyl, -CN, N0 2 , (CH 2 ) r NR 2 R 2a , (CH 2 ) r C(0)R 2c , NR 2 C(0)R 2b , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , S(0) p R 5 , and CF 3 ;
  • R 5 at each occurrence, is selected from CF 3 , C ⁇ _g alkyl, phenyl , and benzyl ;
  • p at each occurrence, is selected from 0, 1, and 2;
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein:
  • L n is *CHNHC(0) and the * indicates where L n is bonded to G;
  • R la is selected from -(CH ⁇ r-R 1 ' and NHCH 2 R 1 " ;
  • R 1 ' is selected from OH, NR 2 R 2a , and NR 2 S0 (CH 2 ) r R 2b ;
  • R 1 " is selected from C(0)NR 2 R 2a , S(0) 2 R 2b , and S0 2 NR 2 R 2a ;
  • R 2 at each occurrence, is selected from H, C]__g alkyl, benzyl , and phenyl ;
  • R 2a at each occurrence, is selected from H, C]__g alkyl, benzyl , and phenyl ;
  • R 2b at each occurrence, is selected from C ⁇ _ 4 alkoxy, C ⁇ _g alkyl, benzyl, phenyl substituted with 0-1 R 4b , and pyrrolidinyl substituted with 0-1 R 4b ;
  • R 2c at each occurrence, is selected from OH, 0CH 3 , OCH CH 3 , CH 3 , benzyl, and phenyl; alternatively, R 2 and R 2a , together with the atom to which they are attached, combine to form a piperidine ring substituted with 0-1 R 4b ;
  • r at each occurrence, is selected from 0, 1, and 2.
  • the present invention provides a compound of formula:
  • L n O or S
  • M 2 is N or CR f ;
  • M 3 is N or CR d ;
  • R e is selected from H, N(CH 3 ) (CH 2 C0 2 H) and S- (5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4 ) ;
  • R f is selected from H, F, and Cl;
  • Z is 0, provided that Z does not form a N-0 or NCH 2 0 bond with the groups to which Z is attached;
  • R lb is selected from H, C ⁇ _ alkyl, and C ⁇ . alkyl substituted with A;
  • R 2 at each occurrence, is selected from H, - 6 alkyl, benzyl , and phenyl ;
  • R 2a at each occurrence, is selected from H, C ⁇ _g alkyl, benzyl , and phenyl ;
  • R 2b at each occurrence, is selected from H, C ⁇ _g alkyl, benzyl , and phenyl ;
  • R c at each occurrence, is selected from OH, OCH 3 , OCH CH 3 , CH 3 , benzyl, and phenyl;
  • R 3 at each occurrence, is selected from H, C ⁇ - 4 alkyl, and phenyl ;
  • A is selected from:
  • Y is selected from:
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein:
  • L n O
  • R e is N(CH 3 ) (CH 2 C0 2 H) ;
  • R d is H or F
  • R d and R e combine to form -NR 3 -C (0) -C (R lb R 3 .
  • NR 3 - or -N CR 2 -NR 3 -;
  • R f is H or F ;
  • R lb is selected from H, C ⁇ -2 alkyl and benzyl
  • A is phenyl substituted with 0-2 R 4 ;
  • B is H or Y
  • Y is 5 membered heterocyclic system containing from 1-2 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R 4a ;
  • R 4 at each occurrence, is selected from H, C _ 4 alkyl, and NR 2 R 2a.
  • R 4a at each occurrence, is selected from H, C 1 . 4 alkyl, and NR 2 R a .
  • the present invention provides a compound of formula:
  • L n is *CH 2 NHC(0)CH 2 or *CH (R a ) NHC (0) CH 2 and the * indicates where L n is bonded to G;
  • M 1 is absent or is CHR;
  • R is selected from H, Cl, F, Br, I, OR 3 , C ⁇ _ 4 alkyl, OCF 3 , CF 3 , and NH 2 ;
  • Z is Ci_ 4 alkylene
  • R 2 at each occurrence, is selected from H, C ⁇ _g alkyl, benzyl , and phenyl ;
  • R 2a at each occurrence, is selected from H, C x _g alkyl, benzyl, and phenyl;
  • R 2c at each occurrence, is selected from OH, OCH 3 , OCH 2 CH 3 , CH 3 , benzyl , and phenyl ;
  • R 3 at each occurrence, is selected from H, C ⁇ _ 4 alkyl, and phenyl ;
  • A is selected from:
  • C 3 _ 6 carbocyclic residue substituted with 0-2 R 4 , and 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R 4 ;
  • R 4 at each occurrence, is selected from H, (CH 2 ) r OR 2 , F, Cl, Br, I, C ⁇ - 4 alkyl, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (O) R 2c , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , and CF 3 ; and,
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein: L n is *CH 2 NHC (O) CH 2 and the * indicates where L n is bonded to G;
  • R is selected from H and C 1 - 4 alkyl
  • Z is CH 2 ;
  • A is C 3 _ 6 carbocyclic residue substituted with 0-1 R 4 ;
  • R 4 at each occurrence, is selected from H, C ⁇ __ alkyl, (CH 2 ) r NR 2 R 2a , and CF 3 ; and,
  • r at each occurrence, is selected from 0, 1, and 2.
  • the present invention provides a compound of formula:
  • R 2 at each occurrence, is selected from H, C ⁇ g alkyl, benzyl, and phenyl;
  • R 2a at each occurrence, is selected from H, C ⁇ _ 6 alkyl, benzyl, and phenyl;
  • R 2c at each occurrence, is selected from OH, OCH 3 , OCH 2 CH 3 , CH 3 , benzyl, and phenyl;
  • Y is selected from:
  • R 4a at each occurrence, is selected from H, OR 2 , CH 2 OR 2 , F, Cl, Br, I, Ci- 4 alkyl, (CH 2 ) r NR R 2a , (CH 2 ) r C (O) R c , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , and CF 3 ; and,
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein:
  • X is S0 2 ;
  • Y is selected from phenyl substituted with 0-2 R 4a and naphthyl substituted with 0-2 R 4a ;
  • R 4a at each occurrence, is selected from H, OH, CH 2 OH, F, Cl, Br, C 1 - 4 alkyl, and C(0)R 2c ; and,
  • r at each occurrence, is selected from 0, 1, and 2.
  • R 2 at each occurrence, is selected from H, C ⁇ _ 6 alkyl, benzyl , and phenyl ;
  • R 2a at each occurrence, is selected from H, C ⁇ g alkyl, benzyl , and phenyl ;
  • R 2c at each occurrence, is selected from OH, OCH 3 , OCH 2 CH 3 , CH 3 , benzyl , and phenyl ;
  • R 2 and R 2a together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
  • Y is selected from:
  • R 4a at each occurrence, is selected from H, OR 2 , CH 2 OR 2 , F, Cl, Br, I, Ci- 4 alkyl, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2c , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , and CF 3 ;
  • r at each occurrence, is selected from 0, 1, 2, and 3
  • the present invention provides a compound wherein:
  • X is S0 2 ;
  • Y is phenyl substituted with 0-2 R 4a or naphthyl substituted with 0-2 R 4a ;
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound of formula:
  • R 2 at each occurrence, is selected from H, C ⁇ _g alkyl, benzyl , and phenyl ;
  • R 2a at each occurrence, is selected from H, C ⁇ _g alkyl, benzyl , and phenyl ;
  • R 2c at each occurrence, is selected from OH, OCH 3 , OCH 2 CH 3 , CH 3 , benzyl , and phenyl ;
  • R 2 and R 2a together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
  • Y is selected from:
  • R 4 at each occurrence, is selected from H, OR 2 , CH 2 0R 2 , F, Cl, Br, I, C ⁇ - 4 alkyl, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2c , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , and CF 3 ;
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein:
  • X is S0 2 ;
  • Y is phenyl substituted with 0-2 R 4a or naphthyl substituted with 0-2 R a ;
  • R 4a at each occurrence, is selected from H, OR 2 , CH 2 OR 2 , F, Cl, Br, I, C ⁇ _ 4 alkyl, NH 2 , (CH 2 ) r C (O) R c , and C(0)NR 2 R 2a ; and,
  • r at each occurrence, is selected from 0, 1, and 2.
  • the present invention provides a compound of formula:
  • R a is C(0)-(6 membered heterocyclic system containing 1 N atom and substituted with 0-2 R 4 ) ;
  • R 2 at each occurrence, is selected from H, C ⁇ _g alkyl, benzyl , and phenyl ;
  • R 2a at each occurrence, is selected from H, C ⁇ _ alkyl, benzyl , and phenyl ;
  • R 2c at each occurrence, is selected from OH, OCH 3 , OCH 2 CH 3 , CH 3 , benzyl , and phenyl ;
  • R 2 and R 2a together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
  • A is a 10 membered bicyclic heterocyclic system containing 1 N atom and substituted with 0-2 R 4 ;
  • B is H or Y
  • Y is selected from:
  • the present invention provides a compound wherein:
  • R a is C (O) - (N-1, 2 , 3 , 6-tetrahydropyridine substituted with C0 2 H) ;
  • R a is C (0) - (N-1, 2 , 3 , 6-tetrahydropyridine substituted with CH 3 ) ;
  • A is 1, 2, 3 , 4-tetrahydroisoquinoline substituted with 1-2 R 4 ;
  • r at each occurrence, is selected from 0, 1, and 2
  • the present invention provides a compound of formula:
  • R 2 at each occurrence, is selected from H, C ⁇ _g alkyl, benzyl, and phenyl;
  • R 2a at each occurrence, is selected from H, C ⁇ _ alkyl, benzyl , and phenyl
  • R 2c at each occurrence, is selected from OH, 0CH 3 , OCH 2 CH 3 , CH 3 , benzyl , and phenyl ;
  • R 2 and R 2a together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
  • X is OS0 2 ;
  • Y is selected from:
  • R 4 is H
  • R 4a at each occurrence , is selected from H , ( CH 2 ) r 0R 2 , F ,
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein:
  • R is methyl
  • Y is selected from phenyl substituted with 0-2 R 4a , naphtyl substituted with 0-2 R 4a , and quinolinyl substituted with 0-2 R 4a ;
  • R 4a at each occurrence, is selected from H, (CH ) r OR 2 , F . Cl, Br, I, Ci. 4 alkyl, (CH 2 ) r NRR 2a , and CF 3 ;
  • r at each occurrence, is selected from 0, 1, and 2.
  • the present invention provides a compound of formula:
  • R9 is selected from H, CH 2 OR 3 , CH 2 C(0)OR 3 , C ⁇ _ 4 alkyl, C(0)NH 2 , and NH 2 ;
  • R 2 at each occurrence, is selected from H, C . 6 alkyl, benzyl , and phenyl ;
  • R 2a at each occurrence, is selected from H, C _g alkyl, benzyl , and phenyl ;
  • R 2c at each occurrence, is selected from OH, OCH 3 , OCH 2 CH 3 , CH 3 , benzyl, and phenyl;
  • R 2 and R 2a together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
  • R 3 at each occurrence, is selected from H, C ⁇ _ 4 alkyl, and phenyl ;
  • A is selected from: C ⁇ -io aromatic ring substituted with 0-2 R 4 , and
  • B is H or Y
  • Y is selected from:
  • R 4 at each occurrence, is selected from H, (CH 2 ) r 0R 2 , F, Cl , Br, I, Ci_ 4 alkyl, -CN, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2c , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , S(0) p R 5 , and CF 3 ;
  • R 4a at each occurrence, is selected from H, (CH 2 ) r OR 2 , Cl , Br, F, I, C ⁇ - 4 alkyl, -CN, (CH 2 ) r NR 2 R 2a , (CH 2 ) r C (0) R 2c , C(0)NR 2 R 2a , S0 2 NR 2 R 2a , S(0) p R 5 , and CF 3 ;
  • R 5 at each occurrence, is selected from CF 3 , C ⁇ _g alkyl, phenyl, and benzyl;
  • p at each occurrence, is selected from 0, 1, and 2;
  • r at each occurrence, is selected from 0, 1, 2, and 3.
  • the present invention provides a compound wherein: R9 is selected from CH 2 OR 3 , and CH 2 C (0) OCH 3 ;
  • A is phenyl
  • Y is phenyl substituted with 0-2 R 4a ;
  • R 4a at each occurrence, is selected from H, OR 2 , Cl, Br, F, I, Ci_ 4 alkyl, (CH ) r NRR 2a , C(0)NR 2 R 2a , and CF 3 ; and,
  • r at each occurrence, is selected from 0, 1, and 2.
  • the present invention provides a compound of formula:
  • R 1 is selected from S0 2 CH 2 C (O) OR 3 , C (0) CH 2 C (0) OR 3 , and C(0)OR 3 ;
  • X is O
  • Y is pyrrolidinyl substituted with 1-2 R 4a or piperidinyl substituted with 1-2 R 4a ;
  • R 2 at each occurrence, is selected from H, C ⁇ _g alkyl, benzyl, and phenyl
  • R 2a at each occurrence, is selected from H, C -e alkyl, benzyl, and phenyl
  • R 2 and R 2a together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
  • R 3 at each occurrence, is selected from H, C ⁇ _ 4 alkyl, and phenyl ;
  • R 4 at each occurrence, is selected from H, F, Cl, Br, I, C ⁇ _ 4 alkyl, NR R 2a , and CF 3 ; and,
  • R 4a at each occurrence, is selected from H, C ⁇ _ 4 alkyl,
  • the present invention provides a compound wherein:
  • R 1 is selected from S0 2 CH 2 C (O) OR 3 and C (0) CH 2 C (O) OR 3 ;
  • Y is piperidinyl substituted with 1-2 R 4a ;
  • R 3 at each occurrence, is selected from H and C ! _ 4 alkyl;
  • R 4 is H
  • the present invention provides a compound of formula:
  • R i is selected from S0 2 CH 2 C (0) OR 3 , C (0) CH 2 C (O) OR 3 , and C(0)OR 3 ;
  • X is O
  • Y is pyrrolidinyl substituted with 1-2 R 4a or piperidinyl substituted with 1-2 R 4a ;
  • R 2 at each occurrence, is selected from H, C ⁇ _ alkyl, benzyl , and phenyl ;
  • R 2a at each occurrence, is selected from H, C ⁇ _ alkyl, benzyl , and phenyl ;
  • R 2 and R 2a together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
  • R 3 at each occurrence, is selected from H, C ⁇ - 4 alkyl, and phenyl ;
  • R 4 at each occurrence, is selected from H, F, Cl, Br, I, Ci- 4 alkyl, NR 2 R 2a , and CF 3 ; and,
  • the present invention provides a compound wherein:
  • R 1 is selected from S0 2 CH 2 C (0) OR 3 and C (0) CH 2 C (O) OR 3 ;
  • Y is piperidinyl substituted with 1-2 R 4a ;
  • R 3 at each occurrence, is selected from H and C ⁇ _ 4 alkyl
  • R 4 is H
  • the present invention provides compounds selected from the group:
  • G is selected from:
  • R a is selected from C(0)C(0)OH and C(O) (benzothiazol-2-yl) ;
  • R9 is selected from H, CH 2 OR 3 , CH 2 C(0)OR 3 , C 1 -. 4 alkyl, C(0)NH 2 , and NH 2 ;
  • R 1 is selected from S0 2 CH 2 C(0)OH and C (0) CH 2 C (O) OH, and C(0)OR 3 ;
  • R at each occurrence, is selected from H, methyl, ethyl, benzyl , and NH 2 ;
  • R 2 at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl ;
  • R 2a at each occurrence, is selected from H, CF 3 , CH 3 , benzyl, and phenyl; alternatively, R 2 and R 2a combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino ;
  • R 3 at each occurrence, is selected from H, C ⁇ _ 4 alkyl, and phenyl ;
  • Z is C(0)CH 2 or CONH
  • A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R 4 ;
  • B is selected from Y, X-Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R 4a ;
  • R 4 at each occurrence, is selected from OH, (CH 2 ) r OR 2 , halo,
  • R a is selected from C ⁇ _ 4 alkyl, CF 3 , S(0) 2 R 5 , S0 2 NR 2 R 2a , and l-CF 3 -tetrazol-2-yl;
  • R 5 at each occurrence, is selected from CF 3 , C ⁇ _g alkyl, phenyl , and benzyl ;
  • X is CH 2 or C(O) ;
  • Y is selected from NR 2 R 2a and CH 2 NR 2 R 2a ;
  • p is selected from 0, 1, and 2;
  • r is selected from 0, 1, and 2.
  • the present invention provides novel pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of present invention or a pharmaceutically acceptable salt form thereof.
  • the present invention provides a novel method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt form thereof .
  • the present invention provides novel compounds for use in therapy.
  • the present invention provides the use of novel compounds for the manufacture of a medicament for the treatment of thrombosis or a disease mediated by factor Xa .
  • the compounds herein described may have asymmetric centers.
  • Substituted is intended to indicate that one or more hydrogens on the atom indicated in the expression using “substituted” is replaced with a selection from the indicated group (s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound.
  • the present invention is intended to include all isotopes of atoms occurring in the present compounds .
  • Isotopes include those atoms having the same atomic number but different mass numbers.
  • isotopes of hydrogen include tritium and deuterium.
  • isotopes of carbon include C-13 and C-14.
  • any variable e.g., R ⁇
  • its definition at each occurrence is independent of its definition at every other occurrence.
  • R 6 at each occurrence is selected independently from the definition of R 6 .
  • combinations of substituents and/or variables are permissible only if such combinations result in stable compounds .
  • alkyl or “alkylene” is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
  • Cx-io alkyl or alkylene
  • Cis Ci, C 2 , C 3 , C 4 , C 5 , Cg, C 7 , C 8 , C 9 , and Cio alkyl groups.
  • alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl.
  • haloalkyl examples include, but are not limited to, trifluoromethyl, trichloromethyl , pentafluoroethyl, and pentachloroethyl .
  • Alkoxy represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • C ⁇ _ ⁇ o alkoxy is intended to include Ci, C 2 , C 3 , C 4 ,
  • alkoxy examples include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy.
  • Cycloalkyl is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl.
  • C 3 _ cycloalkyl is intended to include C 3 , C 4 , C 5 , C , and C 7 cycloalkyl groups.
  • alkenyl or “alkenylene”' is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl and propenyl .
  • C 2 - ⁇ o alkenyl (or alkenylene), is intended to include C , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , and C ⁇ 0 alkenyl groups.
  • Alkynyl or
  • alkynylene is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl .
  • C 2 - ⁇ o alkynyl is intended to include C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , and C ⁇ 0 alkynyl groups.
  • Halo or “halogen” as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion” is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate.
  • carbocycle or “carbocyclic group” is intended to mean any stable 3, 4, 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12, or 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0] bicyclooctane, [4.3.0] bicyclononane, [4.4.0] bicyclodecane, [2.2.2] bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl , adamantyl, and tetrahydronaphthyl .
  • heterocycle or “heterocyclic group”' is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S and including any bicyclic group in which any of the above- defined heterocyclic rings is fused to a benzene ring.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized.
  • the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure.
  • heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
  • a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.
  • aromatic heterocyclic group or “heteroaryl ' ' is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and 1, 2, 3, or 4 heterotams independently selected from the group consisting of N, NH, O and S. It is to be noted that total number of S and O atoms in the aromatic heterocycle is not more than 1.
  • heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl , benzofuranyl , benzothiofuranyl, benzothiophenyl , benzoxazolyl , benzthiazolyl , benztriazolyl, benztetrazolyl, benzisoxazolyl , benzisothiazolyl , benzimidazolinyl, carbazolyl, 4aH-carbazolyl , carbolinyl, chromanyl, chromenyl , cinnolinyl, decahydroquinolinyl , 2H, 6H- 1 , 5, 2- dithiazinyl, dihydrofuro [2 , 3 -jb] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl , imidazolyl, 1H- indazo
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non- toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington ' s Pharmaceutical
  • Prodrugs are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs of a compound of formula (I) are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
  • Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I), and the like.
  • Solid compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent .
  • “Therapeutically effective amount” is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to inhibit factor Xa or thrombin or treat diseases related to factor Xa or thrombin in a host .
  • the combination of compounds is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv. Enzyme Regul . 22:27-55 (1984), occurs when the effect (in this case, inhibition of factor Xa or thrombin) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at suboptimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components.
  • the compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis.
  • the compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below.
  • the reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention.
  • Compounds of the above formulas can be prepared by coupling corresponding acid and amine precursors.
  • the acid precursors can be prepared as shown in W098/28326, WO 98/09987, WO /28326, W096/19483, and WO98/05333, the contents of which are incorporated herein by reference.
  • the G-CH(R a )NH precursors can be prepared as shown in the above- identified publications or as shown in the present application.
  • Compounds of the above formulas can be prepared by coupling corresponding acid and amine precursors.
  • the acid precursors can be prepared as shown in WO98/05333, the contents of which are incorporated herein by reference.
  • the G-CH(R a )NH 2 precursors can be prepared as shown in the above- identified publications or as shown in the present application.
  • Compounds of the above formula can be prepared by coupling the corresponding acid and amine precursors.
  • the acid precursors can be prepared as shown in U.S. Patent No. 5,798,377, the contents of which are incorporated herein by reference.
  • the G-CH 2 NH 2 precursors can be prepared as shown in the above-identified publication or as shown in the present application.
  • Compounds of the above formula can be prepared by coupling corresponding G-leaving group and alcohol-pyridyl or thiol-pyridyl precursors.
  • the alcohol and thio precursors can be prepared as shown in U.S. Patent No. 5,693,641, W096/28427, WO97/29067, WO98/07725, and W098/15547, the contents of which are incorporated herein by reference.
  • the G-leaving group precursors can be prepared as shown in the above- identified publications or as shown in the present application.
  • the compounds of the above formula can be prepared by displacing a leaving group from the pyridyl precursor with the corresponding G-OH precursor. Leaving groups for this type of coupling can be SCH 3 or S0 2 CH 3 .
  • Compounds of the above formula can be prepared by coupling corresponding acid and amine precursors .
  • the acid precursors can be prepared as shown in W098/17274, the contents of which are incorporated herein by reference.
  • the G-CH 2 NH 2 precursors can be prepared as shown in the above- identified publication or as shown in the present application.
  • G-benzoic acid precursors can be prepared similarily to the methods shown in W098/21188, the contents of which are incorporated herein by reference.
  • the G-benzoic acid precursors can be prepared by coupling an activated G (e.g., a metallated ring) with a leaving group- benzoic acid (e.g., halo-benzoic acid) as shown in the above-identified publication.
  • the piperazine precursors can be prepared by coupling of the desired piperizine with the desired X-Y group, wherein X contains a leaving group, as shown in the above-identified application or in the present application.
  • G-piperidinyl acid or G-piperazinyl acid precursors can be prepared similarily to the methods shown in WO96/10022, the contents of which are incorporated herein by reference.
  • the G-piperidinyl acid or G- piperazinyl acid precursors can be prepared by coupling a G- leaving group (e.g., G-halogen) with a piperidinyl acid or piperazinyl acid as shown in the above- identified publication.
  • the piperidine and piperazine precursors can be prepared by coupling of the desired piperizine with the desired X-Y group, wherein X contains a leaving group, as shown in the above-identified application or in the present application.
  • Compounds of the above formula can be prepared by coupling corresponding sulfonic acid and amine precursors.
  • the sulfonic acid precursors can be prepared as shown in W096/33993, the contents of which are incorporated herein by reference.
  • the G-CH CH (R a ) NH 2 precursors can be prepared as shown in the above-identified publication or as shown in the present application.
  • G contains an amine linker can be prepared by displacing a leaving group off of the remainder of the molecule with corresponding G-amine precursor.
  • the remainder of the molecule can be prepared as shown in JP10/1467, the contents of which are incorporated herein by reference.
  • the G-NH precursors can be prepared as shown in the above-identified publications or as shown in the present application.
  • Compounds of the above formula can be prepared by coupling corresponding G- (CH 2 ) 3 - leaving group and phenol precursors .
  • the phenol precursors can be prepared as shown in WO97/36580, the contents of which are incorporated herein by reference or as shown in the present application.
  • the G- (CH ) 3 - leaving group precursors can be prepared as shown in the above-identified publication or other publications described herein or as shown in the present application.
  • G-(CH 2 ) 2 C0 2 H precursors The aniline precursors can be prepared as shown in EP/0540051, JP10/1467, and WO96/16940, the contents of which are incorporated herein by reference.
  • the G- (CH 2 ) 3 -leaving group or G-(CH 2 ) 2 C0 2 H precursors can be prepared as shown in the above-identified publication or other publications described herein or as shown in the present application.
  • G-NH 2 represents a residue which is either the PI residue described above, a suitably protected form of the PI residue, or an intermediate which can be transformed at a later stage of the synthesis into the PI residue.
  • Scheme I describes procedures by which the amino residue of G-NH 2 can be transformed into a variety of different functionalities which are useful for assembling the compounds of the present invention.
  • G-NH 2 I can be diazotized with sodium nitrite in the presence of aqueous sulfuric acid to produce the hydroxy derivative II.
  • the bromo derivative is a very useful intermediate for further functionalization.
  • Treatment of III with magnesium metal generates a Grignard reagent which can react with suitably protected bromoglycinate derivatives to afford amino acid derivatives IV.
  • an organolithium reagent such as tert-butyllithium or ⁇ -butyllithium is readily accomplished at low temperature.
  • the formed organolithium species can react with a wide variety of electrophiles . For example, reaction with dimethylformamide produces the aldehyde derivative V, while reaction with an alkyl chloroformate or an alkyl cyanoformate produces an ester derivative.
  • the ester functionality can be reduced with a variety of hydride reducing agents such as lithium aluminum hydride or diisobutylaluminum hydride to afford the alcohol VI.
  • the alcohol VI can also be prepared by reduction of aldehyde V, such as with sodium borohydride .
  • the bromide III can also react through palladium-mediated processes. For example, reaction of III with an alcohol or amine and a catalyst such as tetrakis-triphenylphosphine palladium under a carbon monoxide atmosphere leads to esters G-C0 2 R or amides G-CONR 2 via a carbonyl insertion reaction.
  • a particularly useful amide G-CONR 2 available by this procedure is the N-methyl-N- methoxy amide, obtained when N-methyl-N-methoxyamine is used in the carbonyl insertion reaction.
  • This amide is readily reduced to aldehyde V with hydride reducing agents such as diisobutylaluminum hydride.
  • the alcohol VI readily available by a variety of methods as described above can be converted to the bromide derivative VII by many methods, such as by treatment with carbon tetrabromide and triphenylphosphine.
  • Another method for the preparation of bromide VII, not shown in Scheme I involves the radical bromination of an intermediate G-CH 3 , which is readily available by methods known to those skilled in the art of organic synthesis.
  • This radical bromination is readily accomplished by treating G-CH 3 with N-bromosuccinimide in refluxing carbon tetrachloride in the presence of a radical initiator such as AIBN.
  • the bromide VII is a particularly useful intermediate for the preparation of the compounds of the present invention. Displacement of the bromide can be accomplished by treatment with sodium or potassium cyanide in a solvent such as DMF or DMSO at room temperature or elevated temperature to give a cyano derivative. Reduction of the nitrile, such as by catalytic hydrogenation or by treatment with sodium borohydride and cobalt (II) chloride, gives the amino derivative VIII.
  • the bromide can also be displaced by appropriate N-protected glycinates, such as N- (diphenylmethylene) glycine ethyl ester, to give the amino acid derivatives IX.
  • N-protected glycinates such as N- (diphenylmethylene) glycine ethyl ester
  • This reaction is accomplished by heating VII and the glycinate in the presence of a base such as potassium carbonate and a quaternary ammonium salt such as tetrabutylammonium bromide in a solvent such as acetonitrile.
  • the bromide can also be displaced with sodium azide in a solvent such as DMF or DMSO at elevated temperatures to give an azide intermediate.
  • the azide is readily reduced by a variety of reducing agents, such as by catalytic hydrogenation or by tin (II) chloride, to afford the amino derivative XI.
  • a variety of other methods are available for the preparation of
  • the amine G-NH 2 I can be diazotized as described above and reacted with copper (I) cyanide to afford the nitrile X.
  • the nitrile can be reduced to form amine XI by a variety of methods, such as by catalytic hydrogenation or by reduction with sodium borohydride in the presence of cobalt (II) chloride.
  • a variety of other methods for the preparation of the intermediates described in Scheme I are available and are known to those skilled in the art .
  • the particular method used for the preparation of the required intermediates will depend on additional functionality present on group "G'", and it will be appreciated by those skilled in the art that certain protecting group strategies may be required and that reaction conditions and the order of steps may require modification.
  • the amino group can be further manipulated as described in Scheme I above .
  • Scheme III describes the preparation of mono-protected 2 -methylaminoaniline intermediates .
  • the mono-protected 2-methylaminoaniline intermediates required to make the 2-methylaminophenyl analogs of this invention can be prepared from the known anthranilic acids by the route outlined in Scheme IV.
  • the anthranilic acid is simultaneously reduced to the benzyl alcohol and N-protected by formation of the mixed anhydride/N-carbamoyl compound followed by selective reduction of the anhydride functionality with aqueous sodium borohydride.
  • the benzylalcohol is then transformed to the benzylazide by a two-step sequence involving methanesulfonate ester formation followed by displacement of the sulfonate ester with sodium azide in dimethylformamide .
  • the 2-methylaminoaniline can be obtained from the benzylazide by removal of the carbamoyl group with ethanolic sodium hydroxide followed by catalytic reduction of the azide group.
  • Scheme IV describes the preparation of 1,4- disubstituted-6-aminophthalazine intermediates.
  • Scheme VI describes the preparation of 7-amino-2- aminoquinoline intermediates.
  • Scheme VII describes the preparation of 6 - aminoquinazoline intermediates .
  • Scheme VIII describes the preparation of 7- aminoquinazoline intermediates.
  • Scheme IX describes the preparation of 7- aminoisoquinazoline intermediates.
  • Scheme X describes the preparation of 6- aminoisoquinazoline intermediates .
  • Scheme XII describes the preparation of 6- aminophthalazine intermediates.
  • the A-B moieties of the present can be prepared by methods known to those of skill in the art.
  • the A-B moieties of the present can be prepared by methods described in the above-identified publications. For example, the following publications, the contents of which are incorporated herein by reference, describe and exemplify means of preparing A-B moieties: W097/23212, WO97/30971, WO98/06694, WO98/01428, W098/28269, and W098/28282.
  • the compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals.
  • thromboembolic disorders includes arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolisms, and pulmonary embolisms.
  • the anticoagulant effect of compounds of the present invention is believed to be due to inhibition of factor Xa, thrombin, or both.
  • the effectiveness of compounds of the present invention as inhibitors of factor Xa can be determined using purified human factor Xa and synthetic substrate.
  • the rate of factor Xa hydrolysis of chromogenic substrate S2222 (Kabi Pharmacia, Franklin, OH) can be measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA, which can be monitored spectrophotometrically by measuring the increase in absorbance at 405 nM. A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition.
  • the results of this assay are expressed as inhibitory constant, Kj_ .
  • K m The Michaelis constant, K m , for substrate hydrolysis can be determined at 25°C using the method of Lineweaver and Burk. Values of Kj . were determined by allowing 0.2-0.5 nM human factor Xa (Enzyme Research Laboratories, South Bend, IN) to react with the substrate (0.20 mM-1 mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship can be used to calculate Ki values :
  • v 0 is the velocity of the control in the absence of inhibitor
  • v s is the velocity in the presence of inhibitor
  • I is the concentration of inhibitor
  • Ki is the dissociation constant of the enzyme : inhibitor complex
  • Preferred compounds of the present invention have Kj . ' s of ⁇ 1 ⁇ M. More preferred compounds of the present invention have Kj . ' s of
  • the antithrombotic effect of compounds of the present invention can be demonstrated in a rabbit arterio-venous (AV) shunt thrombosis model.
  • AV arterio-venous
  • rabbits weighing 2-3 kg anesthetized with a mixture of xylazine (10 mg/kg i.m.) and ketamine (50 mg/kg i.m.) are used.
  • a saline-filled AV shunt device is connected between the femoral arterial and the femoral venous cannulae .
  • the AV shunt device consists of a piece of 6 -cm tygon tubing which contains a piece of silk thread. Blood will flow from the femoral artery via the AV-shunt into the femoral vein.
  • the exposure of flowing blood to a silk thread will induce the formation of a significant thrombus.
  • the shunt is disconnected and the silk thread covered with thrombus is weighed.
  • Test agents or vehicle will be given (i.v., i.p., s.c, or orally) prior to the opening of the AV shunt .
  • the percentage inhibition of thrombus formation is determined for each treatment group.
  • the ID50 values dose which produces 50% inhibition of thrombus formation) are estimated by linear regression.
  • the compounds of formula (I) may also be useful as inhibitors of serine proteases, notably human thrombin, plasma kallikrein and plasmin. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes. Specifically, the compounds have utility as drugs for the treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes.
  • serine proteases notably human thrombin, plasma kallikrein and plasmin. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes.
  • the compounds have utility as drugs for the treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as rea
  • Compounds of the present invention can be shown to be direct acting inhibitors of the serine protease thrombin by their ability to inhibit the cleavage of small molecule substrates by thrombin in a purified system.
  • vi tro inhibition constants were determined by the method described by Kettner et al . in J. Biol . Chem . 265, 18289-18297 (1990), herein incorporated by reference.
  • thrombin-mediated hydrolysis of the chromogenic substrate S2238 Helena Laboratories, Beaumont, TX
  • Addition of an inhibitor to the assay mixture results in decreased absorbance and is indicative of thrombin inhibition.
  • Human thrombin (Enzyme Research Laboratories, Inc., South Bend, IN) at a concentration of 0.2 nM in 0.10 M sodium phosphate buffer, pH 7.5, 0.20 M NaCl, and 0.5% PEG 6000, can be incubated with various substrate concentrations ranging from 0.20 to 0.02 mM. After 25 to 30 minutes of incubation, thrombin activity can be assayed by monitoring the rate of increase in absorbance at 405 nm which arises owing to substrate hydrolysis. Inhibition constants were derived from reciprocal plots of the reaction velocity as a function of substrate concentration using the standard method of Lineweaver and Burk .
  • Preferred compounds of the present invention have Ki ' s of ⁇ 1 ⁇ M. More preferred compounds of the present invention have Ki ' s of ⁇ 0.1 ⁇ M. Even more preferred compounds of the present invention have Ki ' s of ⁇ 0.01 ⁇ M. Still more preferred compounds of the present invention have Ki ' s of ⁇ 0.001 ⁇ M.
  • the compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents.
  • additional therapeutic agents include other anticoagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents, thrombin inhibitors, or thrombolytic or fibrinolytic agents.
  • the compounds are administered to a mammal in a therapeutically effective amount.
  • therapeutically effective amount it is meant an amount of a compound of Formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease.
  • administered in combination or “combination therapy” it is meant that the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated.
  • each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect.
  • anticoagulant agents or coagulation inhibitory agents
  • warfarin and heparin as well as other factor Xa inhibitors such as those described in the publications identified above under Background of the Invention.
  • anti-platelet agents or platelet inhibitory agents
  • Such agents include, but are not limited to, the various known non-steroidal anti- inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof.
  • NSAIDS non-steroidal anti- inflammatory drugs
  • aspirin acetylsalicyclic acid or ASA
  • piroxicam are preferred.
  • Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof.
  • Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use.
  • Still other suitable platelet inhibitory agents include Ilb/lIIa antagonists, thromboxane-A2-receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof.
  • thrombin inhibitors denotes inhibitors of the serine protease thrombin.
  • various thrombin-mediated processes such as thrombin-mediated platelet activation
  • thrombin inhibitors include, but are not limited to, boroarginine derivatives, boropeptides, heparins, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof.
  • Boroarginine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal a-aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof.
  • the term hirudin includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin.
  • Boropeptide thrombin inhibitors include compounds described in Kettner et al., U.S. 5,187,157 and EP 293 881 A2 , the disclosures of which are hereby incorporated herein by reference .
  • Other suitable boroarginine derivatives and boropeptide thrombin inhibitors include those disclosed in WO92/07869 and EP 471,651 A2 , the disclosures of which are hereby incorporated herein by reference.
  • thrombolytics or fibrinolytic agents
  • fibrinolytics or fibrinolytics agents that lyse blood clots (thrombi) .
  • agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof.
  • anistreplase refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosure of which is hereby incorporated herein by reference herein.
  • urokinase as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase .
  • Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each.
  • a lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.
  • the compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the inhibition of factor Xa .
  • Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving factor Xa .
  • a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound.
  • compounds according to the present invention could be used to test their effectiveness.
  • the compounds of the present invention may also be used in diagnostic assays involving factor Xa.
  • the presence of factor Xa in an unknown sample could be determined by addition of chromogenic substrate S2222 to a series of solutions containing test sample and optionally one of the compounds of the present invention. If production of pNA is observed in the solutions containing test sample, but not in the presence of a compound of the present invention, then one would conclude factor Xa was present .
  • the compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion) , intraperitoneal , subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired.
  • a physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder.
  • the daily oral dosage of each active ingredient when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day.
  • the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion.
  • Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.
  • Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches.
  • suitable intranasal vehicles or via transdermal routes, using transdermal skin patches.
  • the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
  • the compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
  • suitable pharmaceutical diluents, excipients, or carriers suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
  • the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
  • suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture.
  • Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
  • Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like.
  • Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
  • the compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
  • Liposomes can be formed from a variety of phospholipids , such as cholesterol, stearylamine, or phosphatidylcholines .
  • Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers .
  • soluble polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol , polyhydroxyethylaspartamidephenol , or polyethyleneoxide- polylysine substituted with palmitoyl residues.
  • the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels.
  • Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
  • Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract .
  • powdered carriers such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract .
  • Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
  • water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances.
  • Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
  • citric acid and its salts and sodium EDTA are also used.
  • parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol .
  • Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.
  • a large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
  • a mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil may be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient.
  • the capsules should be washed and dried. Tablets
  • Tablets may be prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption. Injectable
  • a parenteral composition suitable for administration by injection may be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution should be made isotonic with sodium chloride and sterilized. Suspension An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S. P., and 0.025 mL of vanillin.
  • a daily dosage may be about 0.1 to 100 milligrams of the compound of Formula I and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight.
  • the compounds of this invention generally may be present in an amount of about 5 to 10 milligrams per dosage unit, and the second anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit.
  • a daily dosage may be about 0.01 to 25 milligrams of the compound of Formula I and about 50 to 150 milligrams of the anti-platelet agent, preferably about 0.1 to 1 milligrams of the compound of Formula I and about 1 to 3 milligrams of antiplatelet agents, per kilogram of patient body weight .
  • a daily dosage may be about 0.1 to 1 milligrams of the compound of Formula I, per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the thrombolyic agent when administered alone may be reduced by about 70-80% when administered with a compound of Formula I.
  • two or more of the foregoing second therapeutic agents are administered with the compound of Formula I, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination.
  • one active ingredient may be enteric coated.
  • enteric coating one of the active ingredients it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines.
  • One of the active ingredients may also be coated with a material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients.
  • the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine.
  • Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low- viscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components.
  • HPMC hydroxypropyl methylcellulose
  • the polymer coating serves to form an additional barrier to interaction with the other component.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.

Description

TITLE
Thrombin or Factor Xa Inhibitors
FIELD OF THE INVENTION
This invention relates generally to inhibitors of trypsin-like serine protease enzymes, especially factor Xa or thrombin, pharmaceutical compositions containing the same, and methods of using the same as anticoagulant agents for treatment and prevention of thromboembolic disorders.
BACKGROUND OF THE INVENTION Activated factor Xa, whose major practical role is the generation of thrombin by the limited proteolysis of prothrombin, holds a central position that links the intrinsic and extrinsic activation mechanisms in the final common pathway of blood coagulation. The generation of thrombin, the final serine protease in the pathway to generate a fibrin clot, from its precursor is amplified by formation of prothrombinase complex (factor Xa, factor V,
Ca2+ and phospholipid) . Since it is calculated that one molecule of factor Xa can generate 138 molecules of thrombin (Elodi, S., Varadi, K. : Optimiza tion of condi tions for the ca talytic effect of the factor IXa - factor VIII Complex: Probable role of the complex in the amplification of blood coagulation . Thromb . Res . 1979, 15, 617-629) , inhibition of factor Xa may be more efficient than inactivation of thrombin in interrupting the blood coagulation system. Therefore, efficacious and specific inhibitors of factor Xa, thrombin, or both are needed as potentially valuable therapeutic agents for the treatment of thromboembolic disorders. It is thus desirable to discover new factor Xa, thrombin, or both inhibitors.
SUMMARY OF THE INVENTION
Accordingly, one object of the present invention is to provide novel nitrogen containing aromatic heterocycles, with ortho-substituted PI groups, which are useful as factor Xa inhibitors or pharmaceutically acceptable salts or prodrugs thereof .
It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof . It is another object of the present invention to provide a method for treating thromboembolic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
It is another object of the present invention to provide novel compounds for use in therapy.
It is another object of the present invention to provide the use of novel compounds for the manufacture of a medicament for the treatment of thrombosis or a disease mediated by factor Xa.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS [1] Thus, in a first embodiment, the present invention provides a novel compound selected from the group:
Figure imgf000005_0001
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein;
G is selected from the group:
Figure imgf000006_0001
Figure imgf000006_0002
Figure imgf000007_0001
Ln is a linker which is absent or is selected from O, S, CH2 , *CH2NHC(0), *CH(Ra)NHC(0) , *CH2NHC (O) CH2 , and *CH(Ra)NHC(0) CH2, provided that Ln and M do not form an O-N or S-N bond and the * indicates where Ln is bonded to G;
M1 is absent or is CHR;
M2 is N or CRf;
M3 is N or CRd;
provided that only one of M2 and M3 is N;
Ra is selected from C(0)C(0)OR3, C (0) C (O) NR2R2a, and C(0)-A; Rb is selected from H, R, phenyl, Cχ_ιo alkyl, and C2-5 alkenyl ;
Rc is selected from H and Cχ-6 alkyl;
alternatively, Rb and Rc together are -(0-2)4-;
Rd is selected from H, F, and Cl;
Re is selected from H, N(CH3) (CH2C02H) and S- (5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4) ;
alternatively, Rd and Re combine to form -NR3-C (O) -C (RlbR3) - NR3- or -N=CR2-NR3-;
Rf is selected from H, F, and Cl ;
alternatively, Re and Rf combine to form -NR3-C (RlbR3) -C (0) - NR3- or -NR3-CR2=N-;
R9 is selected from H, CH2OR3 , CH2C(0)OR3, C - alkyl,
C(0)NH2, and NH2 ;
Rh is selected from H, CH2-phenyl, CH2CH2 -phenyl , and CH=CH- phenyl ;
R1 is selected from S02CH2C (0) OR3 , C (0) CH2C (0) OR3 , and C(0)OR3;
R is selected from H, Cl, F, Br, I, (CH2)tOR3, Cι_4 alkyl, benzyl, 0CF3 , CF3 , C(0)NR7R8, and (CR8R9) tNR7R8; Z is selected from (CR8R9)!-4, (CR8R9) rO (CR8R9) r, (CR8R9) rNR3 (CR8R9) r, (CR8R9) rC (0) (CR8R9) r, (CR8R9) rC (O) 0 (CR8R9) r, (CR8R9) rOC (O) (CR8R9) r, (CR8R9)rC(0)NR3(CR8R9)r (CR8R9) rNR3C (0) (CR8R9)r, (CR8R9)rOC(0)0(CR8R9)r, (CH2) rOC (O) NR3 (CR8R9) r,
(CR8R9) rNR3C (O) 0 (CR8R9) r, (CH2) rNR3C (O) NR3 (CR8R9) r, (CR8R9) rS (O) p (CR8R9) r, (CR8R9) rS (O) 2 (CH=CH) , (CCR8R9)rS02NR3 (CR8R9)r, (CR8R9) rNR3S02 (CR8R9) r, and (CR8R9)rNR3S02NR3 (CR8R9)r, provided that Z does not form a N-N, N-O, N-S, NCH2N, NCH20, or NCH2S bond with the groups to which Z is attached;
Rla is absent or selected from -(CH2)r-R1'/ -CH=CH-R1' , NHCH2R1", OCH2R1", SCH2R1", NH(CH2)2 (CH2)tR1' / 0(CH2 )2(CH2 )tR1' and S (CH2 ) 2 (CH2 ) tR1' ;
R1' is selected from H, Cχ-3 alkyl, F, Cl, Br, I, -CN, -CHO,
(CF2)rCF3, (CH2)rOR2, NR2R2a, C(0)R2c, OC(0)R2,
(CF2)rC02R2c, S(0)p(CH2)rR2b, NR2 (CH2 ) rOR2 , C(=NR )NR2R2a, NR2C(0)R2b, NR2C (0) NHR2b, NR2C(0)2R2a,
OC(0)NR2aR2b, C(0)NR2R2a, C (0) NR2 (CH2) rOR2 , S02NR2R2a,
NR2S02R2b, C3-6 carbocyclic residue substituted with 0-2
R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4 ;
R1" is selected from H, CH(CH2OR2)2, C(0)R2c, C(0)NR2R2a, S(0)R2b, S(0)2R2b, and S02NR2R2a;
Rlb is selected from H, Cι_6 alkyl, and Cι_6 alkyl substituted with A; R2 , at each occurrence, is selected from H, CF3 , Cι_6 alkyl, benzyl, C3-6 carbocyclic residue substituted with 0-2
R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4b;
R2a, at each occurrence, is selected from H, CF3 , Cχ-6 alkyl, benzyl, C3-6 cycloalkylmethyl substituted with 0-2 R4b, C3--6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
R2b, at each occurrence, is selected from CF3 , Cι_4 alkoxy, Cι_s alkyl, benzyl, C3-6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
R2c, at each occurrence, is selected from CF3 , OH, C1-4 alkoxy, C .ζ alkyl, benzyl, C3-.S carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R3 , at each occurrence, is selected from H, Cι_ alkyl, and phenyl ;
R3a, at each occurrence, is selected from H, C!_4 alkyl, and phenyl ;
R3b, at each occurrence, is selected from H, C1_4 alkyl, and phenyl ;
R3c, at each occurrence, is selected from C -4 alkyl, and phenyl ;
A is selected from:
C3-10 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4 ;
A1 is H or A;
alternatively, A and A1 and the carbon to which they are attached combine to form fluorene;
A2 is selected from H, A, and CHA3A4 ;
A3 is selected from H, A, C^ alkyl, and - (CH2) rNR2R2a;
A4 is H or A;
B is selected from: H, Y, and X-Y
X is selected from Cι_4 alkylene, -CR2 (CR2R2b) (CH2)t-< -C(O)-, -CR2(NR1"R2) -, -CR2(OR2)-, ~CR2(SR2)-, -C (O) CR2R2a- , -CR2R2aC(0), -OS(0)2-, -S(0)p-, -S(0)pCR2R2a-, -CR2R2aS(0)p-, -S(0)2NR2-, -NR2S(0)2-, -NR2S (0) 2CR2R2a- , -CR2R2aS(0)2NR2-, -NR2S(0)2NR2-, -C(0)NR2-, -NR2C(0) -,
-C(0)NR2CR2R2a-, -NR2C(0)CR2R2a-, -CR2R2aC (O) NR2- , -CR2R2aNR2C(0) -, -NR2C(0)0-, -OC(0)NR2-, -NR2C (0) NR2- , -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, 0, -CR2R2aO-, and -OCR2R2a-;
Y is selected from:
(CH2) rNR2R2a, provided that X-Y do not form a N-N, O-N, or S-N bond, C3_io carbocyclic residue substituted with 0-2 R4a, and
5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4a;
alternatively, Z-A-B combine to form S-Cι_6 alkyl;
R4, at each occurrence, is selected from H, =0, (CH2)rOR2, F,
Cl, Br, I, C1-4 alkyl, -CN, N02 , (CH2) rNR2R2a,
(CH2)rC(0)R , NR2C(0)R2b, C(0)NR2R2a, NR2C (O) NR2R2a, C(=NR2)NR2R a, C (=NS (0) 2R5) NR2R2a, NHC (=NR2) NR R2a,
C(0)NHC(=NR2)NR2R2a, S02NR2R2a, NR2S02NR2R2a, NR2S02-Cι_4 alkyl, NR2S02R5, S(0)pR5, (CF2)rCF3, NHO^R1" , OO^R1" ,
SCHsR1" , N(CH2)2(CH2)tR1' , 0 (CH2) 2 (CH2) tR1' . and
Figure imgf000012_0001
alternatively, one R4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S;
R4a, at each occurrence, is selected from H, =0, (CH2)r0R2,
(CH2)r-F, (CH2)r-Br, (CH2)r-Cl, Cl , Br, F, I, C1-4 alkyl, -CN, N02, (CH2)rNR2R2a, (CH2) rC (O) R2 , NR2C(0)R2b, C(0)NR2R2a, C(0)NH(CH2)2NR2R2a, NR2C (O) NR2R2a, C(=NR2)R3 , C(=NR2)NR2R2a, NHC(=NR2)NR2R2a, S02NR2R2a, NR2S02NR2R a, NR2S02-Cι_4 alkyl, C (O) NHS02-C!_4 alkyl, NR2S02R5, S(0)pR5, and (CF2)rCF3;
alternatively, one R4a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-1 R5 ;
R4b, at each occurrence, is selected from H, =0, (CH2)rOR3, F, Cl, Br, I, C3..-4 alkyl, -CN, N02 , (CH2) rNR3R3a,
(CH2)rC(0)R3, (CH2)rC(0)OR3c, NR3C(0)R3a, C(0)NR3R3a, NR3C(0)NR3R3a, C(=NR3)NR3R3a, NR3C (=NR3 ) NR3R3a, S02NR3R3a, NR3S02NR3R3a, NR3S02-Cι_4 alkyl, NR3S02CF3, NR3S02-phenyl , S(0)pCF3, S(0)p-Cι_4 alkyl, S (O) p-phenyl, and (CF2)rCF3;
R5, at each occurrence, is selected from CF3 , Cι_6 alkyl, phenyl substituted with 0-2 R6 , and benzyl substituted with 0-2 R6;
R6 , at each occurrence, is selected from H, OH, (CH2)rOR2, halo, C!_4 alkyl, CN, N02 , (CH2) rNR2R2a, (CH2) rC (0) R2b, NR2C(0)R2b, NR2C(0)NR2R2a, C(=NH)NH2, NHC(=NH)NH2, S02NR2Ra, NR2S02NR2R2a, and NR2S02C1_4 alkyl;
R7, at each occurrence, is selected from H, OH, C]__6 alkyl, Cχ-6 alkylcarbonyl, Cχ-6 alkoxy, Cχ-4 alkoxycarbonyl, (CH2)n-phenyl, C6-ιo aryloxy, C6-ι0 aryloxycarbonyl, C6_ι0 arylmethylcarbonyl, Cι_4 alkylcarbonyloxy Cι_4 alkoxycarbonyl, Cg-io arylcarbonyloxy Cι_4 alkoxycarbonyl, Cι_6 alkylaminocarbonyl, phenylaminocarbonyl , and phenyl C1_4 alkoxycarbonyl; R8, at each occurrence, is selected from H, Cι_g alkyl and (CH2)n-phenyl;
alternatively, R7 and R8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R9, at each occurrence, is selected from H, Cι_6 alkyl and (CH2)n-phenyl;
n, at each occurrence, is selected from 0, 1, 2, and 3;
m, at each occurrence, is selected from 0, 1, and 2 ;
p, at each occurrence, is selected from 0, 1, and 2;
r, at each occurrence, is selected from 0, 1, 2, and 3;
s, at each occurrence, is selected from 0, 1, and 2; and,
t, at each occurrence, is selected from 0, 1, 2, and 3.
[2] In a preferred embodiment, the present invention provides a novel compound, wherein:
G is selected from the group:
Figure imgf000015_0001
Figure imgf000015_0002
Figure imgf000015_0003
[3] In a more preferred embodiment, the present invention provides a novel compound, wherein:
G is selected from:
Figure imgf000015_0004
Figure imgf000016_0001
[4] In an even more preferred embodiment, the present invention provides a novel compound, wherein:
R is selected from H, Cl, F, Br, I, (CH2)tOR3, Cι-4 alkyl, OCF3, CF3, C(0)NR7R8, and (CR8R9) tNR7R8 ;
Z is selected from CH20, OCH2 , CH2NH, NHCH2, C(O), CH2C(0), C(0)CH2, NHC(O), C(0)NH, CH2S(0) , S(0)2(CH2), S02NH, and NHS0 , provided that Z does not form a N-N, N-O, NCH2N, or NCH20 bond with ring M or group A;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl , pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl , triazolyl, 1, 2 , 3 -oxadiazolyl, 1,2, 4 -oxadiazolyl, 1,2, 5-oxadiazolyl, 1,3, -oxadiazolyl , 1,2, 3 -thiadiazolyl , 1,2, 4 -thiadiazolyl, 1,2, 5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1, 3 , 4 -triazolyl, benzofuranyl, benzothiofuranyl , indolyl, benzimidazolyl , benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl , benzisothiazolyl, and isoindazolyl ; B is selected from: H, Y, and X-Y;
X is selected from C - alkylene, -C(O)-, -C(=NR)-,
-CR2 (NR2R2a) -, -C(0)CR2R2a-, -CR2RaC(0), -C(0)NR2-, -NR2C(0)-, -C(0)NR2CR2R2a-, -NR2C (0) CR2R2a- ,
-CR2R2aC(0)NR2-, -CR2R2aNR2C(0) -, -NR2C (O) NR2- , -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, O, -CR2R2aO-, and -OCR2R2 -;
Y is NR2R2a or CH2NR2R2a, provided that X-Y do not form a N-N or O-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3 -oxadiazolyl, 1,2, 4 -oxadiazolyl , 1,2, 5 -oxadiazolyl , 1,3, 4 -oxadiazolyl, 1,2, 3 -thiadiazolyl, 1,2, 4 -thiadiazolyl, 1,2, 5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1, 3 , 4-triazolyl , benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl , benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl , benzisothiazolyl, and isoindazolyl ;
alternatively, Y is selected from the following bicyclic heteroaryl ring systems :
Figure imgf000018_0001
K is selected from O, S, NH, and N.
[5] In a still more preferred embodiment, the present invention provides a novel compound, wherein:
Z is C(0)CH2 and CONH, provided that Z does not form a N-N bond with group A;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4 ; and,
B is selected from Y, X-Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R4a; B is selected from: Y and X-Y;
X is selected from CH2 , -C(O)-, and 0;
Y is NR2R2a or CH2NR2R2a, provided that X-Y does not form an O-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3- triazolyl; R2 , at each occurrence, is selected from H, CF3 , CH3 , benzyl, and phenyl ;
R2a, at each occurrence, is selected from H, CF3 , CH3 , CH(CH3)2, eyelopropylmethyl, benzyl, and phenyl;
alternatively, R2 and R2a combine to form a ring system substituted with 0-2 R4b, the ring system being selected from pyrrolidinyl, piperazinyl and morpholino;
R4 , at each occurrence, is selected from OH, (CH2)rOR2, Cl ,
F, C1-4 alkyl, (CH2) rNR2R2a, and (CF2)rCF3;
R4a is selected from Cl, F, Cι_ alkyl, CF3 , (CH2) rNR2R a, S(0)pR5, S02NR2R2a, and l-CF3-tetrazol-2-yl ■
R4b, at each occurrence, is selected from OH, Cl, F, CH3 , and CF3;
R5, at each occurrence, is selected from CF3 , Cχ-ζ alkyl, phenyl , and benzyl ;
R7, at each occurrence, is selected from H, CH3 , and CH2CH3; and,
R8, at each occurrence, is selected from H and CH3.
[6] In an even further preferred embodiment, the present invention provides a novel compound, wherein:
A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3 -Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl , 2-aminophenyl , and 2- methoxyphenyl ; and,
B is selected from the group: 2 -CF3 -phenyl, 2- (aminosulfonyl) phenyl, 2- (methylaminosulfonyl) phenyl,
2- (dimethylaminosulfonyl) phenyl , 1-pyrrolidinocarbonyl,
2- (methylsulfonyl) phenyl, 2- (N,N- dimethylaminomethyl) phenyl , 2-
(isopropylaminomethyl) phenyl, 2- ( eyelopropylaminomethyl) phenyl, 2-(N- pyrrolidinylmethyl) phenyl, 2- (3-hydroxy-N- pyrrolidinylmethyl) phenyl, 4-morpholino, 2-(l'-CF3- tetrazol-2 -yl) phenyl, 4-morpholinocarbonyl , 1-methyl-2- imidazolyl, 2 -methyl- 1- imidazolyl , 5 -methyl- 1- imidazolyl, 2- (N,N-dimethylaminomethyl) imidazolyl, 2- methylsulfonyl-1- imidazolyl and, 5-methyl-1, 2 , 3- triazolyl .
[7] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000020_0001
Ln is *CH2NHC(0)CH2 or *CH (Ra) NHC (0) CH2 , the * indicates where Ln is bonded to G;
Ra is C(0)C(0)0R3;
Z is selected from C1-4 alkylene, (CH2)rC(0), and (CH2)rS(0)2;
R2, at each occurrence, is selected from H, Cχ_6 alkyl, benzyl , and phenyl ; R2a, at each occurrence, is selected from H, Cχ-6 alkyl, benzyl , and phenyl ;
R2b, at each occurrence, is selected from H, Cι_6 alkyl, benzyl , and phenyl ;
R2 , at each occurrence, is selected from OH, OCH3, OCH2CH3, CH3 , benzyl , and phenyl ;
R3 , at each occurrence, is selected from H, Cτ__4 alkyl, and phenyl ;
A is C5--6 carbocyclic residue substituted with 0-2 R4 ;
R4, at each occurrence, is selected from H, =0, (CH2)rOR2, F, Cl, Br, I, C1-4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2c, NR2C(0)R2b, C(0)NR2R2a, C (=NR2) NR2R2a, NHC(=NR2)NR2Ra, S02NR2R2a, S(0)pR5, and CF3 ;
R5, at each occurrence, is selected from CF3 , C±-β alkyl, phenyl , and benzyl ;
p, at each occurrence, is selected from 0, 1, and 2; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
[8] In another still more preferred embodiment, the present invention provides a compound wherein:
Ln is *CH(Ra)NHC(0)CH2;
Ra is C(0)C(0)OH; Z is selected from CH2 , (CH2)2C(0), and CH2S(0)2;
A is cyclohexyl or phenyl and is substituted with 0-1 R4 ;
R4, at each occurrence, is selected from H, =0, OR2, CH OR2, F, Cl, Br, I, Ci- alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2c, C(0)NR2R a, S02NR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, and 2.
[9] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000022_0001
Ln is *CH2NHC(0)CH2 or *CH (Ra) NHC (O) CH2 , the * indicates where Ln is bonded to G;
Ra is C(0)C(0)OR3;
R is H or NH2;
Z is selected from C1.-4 alkylene, (CH2)rC(0), and (CH2)rS(0)2;
R2 , at each occurrence, is selected from H, ±-ξ alkyl, benzyl , and phenyl ;
R a, at each occurrence, is selected from H, . ζ alkyl, benzyl, and phenyl;
R2b, at each occurrence, is selected from H, Cι_6 alkyl, benzyl, and phenyl; R2c, at each occurrence, is selected from OH, OCH3 , 0CH2CH3, CH3 , benzyl , and phenyl ;
R3, at each occurrence, is selected from H, Cχ_4 alkyl, and phenyl ;
A is a C5_6 carbocyclic residue substituted with 0-2 R4 ;
R4, at each occurrence, is selected from H, =0, (CH2)rOR2. F. Cl, Br, I, Cι_4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2c, NR2C(0)R2b, C(0)NR2R2a, S02NRR2a, S(0)pR5, and CF3;
R5, at each occurrence, is selected from CF3, -s alkyl, phenyl , and benzyl ;
p, at each occurrence, is selected from 0, 1, and 2; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
[10] In another still more preferred embodiment, the present invention provides a compound wherein:
Ln is *CH(Ra)NHC(0)CH2;
R is H;
Ra is C(0)C(0)OH;
Z is selected from CH2, (CH2)2C(0), and CH2S(0)2;
A is cyclohexyl or phenyl and is substituted with 0-1 R4 ; R4, at each occurrence, is selected from H, =0, OR2, CH2OR2, F, Cl, Br, I, C!_4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
r, at each occurrence, is selected from 0, 1, 2, and 3.
[11] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000024_0001
Ln is *CH2NHC(0) CH2 or *CH (Ra) NHC (O) CH2 , the * indicates where Ln is bonded to G;
R is H or NH2;
Ra is C(0)C(0)OR3;
Z is C]__4 alkylene;
R2 , at each occurrence, is selected from H, Cι_g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2b, at each occurrence, is selected from H, C^g alkyl, benzyl , and phenyl ;
R2c, at each occurrence, is selected from OH, OCH3 , OCH CH3, CH3 , benzyl , and phenyl ; R3 , at each occurrence, is selected from H, C1-4 alkyl, and phenyl ;
A is phenyl substituted with 0-2 R4 ;
R4, at each occurrence, is selected from H, (CH )rOR2, F, Cl ,
Br, I, C1-4 alkyl, -CN, N02 , (CH2) rNR2R a, (CH2) rC (O) R2c,
NR2C(0)R2b, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ;
R5, at each occurrence, is selected from CF3, Cι_g alkyl, phenyl , and benzyl ;
p, at each occurrence, is selected from 0, 1, and 2; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
[12] In another still more preferred embodiment, the present invention provides a compound wherein:
Ln is *CH(Ra)NHC(0)CH2;
R is NH2;
Ra is C(0)C(0)OH;
Z is CH2;
A is phenyl substituted with 0-1 R4 ;
R4, at each occurrence, is selected from H, OR2, CH2OR2, F,
Cl, Br, Cχ_4 alkyl, -CN, N02 , (CH2) rNR2R2a,
(CH2)rC(0)R2 , C(0)NR2R2a, S02NR2R a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, and 2. [13] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000026_0001
Ln is *CH2NHC(0) or *CH (Ra) NHC (O) and the * indicates where Ln is bonded to G;
Ra is selected from C(0)C(0)OR3 and C(0)-A;
Rb is selected from H, phenyl, Cι-ιo alkyl, and C2_s alkenyl;
Rc is selected from H and C^g alkyl;
alternatively, Rb and Rc together are -(CH2) -;
Z is (CR8R9)!_4;
R2 , at each occurrence, is selected from H, CF3 , and Cι_ alkyl ;
R2a, at each occurrence, is selected from H, CF3 , and C _g alkyl ;
R2b, at each occurrence, is selected from H, CF3 , and Cι_ alkyl;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3 , benzyl , and phenyl ; R3 , at each occurrence, is selected from H, Cι_4 alkyl, and phenyl ;
A is selected from: C _-Lo aromatic carbocyclic residue substituted with 0-2
R4 , and
5-10 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R ;
R4, at each occurrence, is selected from H, (CH2)rOR2, F, Cl ,
Br, I, d-4 alkyl, -CN, N02, (CH2) rNR2R2a, (CH2) rC (0) R2c,
NR2C(0)R2b, C(0)NRR2a, S02NR2R2a, S(0)pR5, and CF3 ;
R5, at each occurrence, is selected from CF3 , Ci-g alkyl, phenyl , and benzyl ;
R8 , at each occurrence, is selected from H, Cι_6 alkyl and phenyl ;
R9, at each occurrence, is selected from H, Cι_g alkyl and phenyl ;
p, at each occurrence, is selected from 0, 1, and 2 ;
r, at each occurrence, is selected from 0, 1, 2, and 3.
[14] In another still more preferred embodiment, the present invention provides a compound wherein:
Ln is *CH(Ra)NHC(0) and the * indicates where Ln is bonded to G;
Ra is C(0)C(0)OH or C (O) - (benzothiazol-2-yl) ; Rb is selected from H, phenyl, Cι_ιo alkyl, and C2_5 alkenyl;
Rc is selected from H and Cι_g alkyl;
alternatively, Rb and Rc together are -(CH2)4-;
Z is (CR8H)!_2;
A is selected from phenyl, naphthyl, and thienyl, and A is substituted with 0-1 R4 ;
R4, at each occurrence, is selected from H, OR2, CH2OR2, F, Cl, Br, I, Ci-4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
R8 , at each occurrence, is selected from H, methyl and phenyl; and,
r, at each occurrence, is selected from 0, 1, and 2.
[15] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000028_0001
Ln is *CH2NHC(0) or *CH (Ra) NHC (0) and the * indicates where Ln is bonded to G;
Ra is selected from C(0)C(0)OR3 and C(0)-A; Rb is selected from H, phenyl, alkyl, and C2_5 alkenyl;
Rc is selected from H and Cι_ alkyl;
alternatively, Rb and Rc together are -(CH2)4-;
R is selected from H, benzyl, Cι_4 alkyl, and NH2 ;
Z is (CR8R9) 1-4;
R2 , at each occurrence, is selected from H, CF , and C^g alkyl ;
R2a, at each occurrence, is selected from H, CF3 , and Cχ_g alkyl;
R2b, at each occurrence, is selected from H, CF3 , and Cχ_g alkyl ;
R2c, at each occurrence, is selected from OH, OCH3, OCH2CH3, CH3 , benzyl , and phenyl ;
R3 , at each occurrence, is selected from H, Cι_ alkyl, and phenyl ;
A is selected from:
C6_10 aromatic ring substituted with 0-2 R4 , and
5-10 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4 ;
R4, at each occurrence, is selected from H, (CH2)r0R2, F, Cl , Br, I, C1-4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2) rC (0) R2c, NR2C(0)R2b, C(0)NRR2a, S02NR2R2a, S(0)pR5, and CF3 ; R5, at each occurrence, is selected from CF3 , Cι_ alkyl, phenyl, and benzyl;
R8 , at each occurrence, is selected from H, C]__g alkyl and phenyl ;
R9, at each occurrence, is selected from H, .6 alkyl and phenyl ;
p, at each occurrence, is selected from 0, 1, and 2;
r, at each occurrence, is selected from 0, 1, 2, and 3.
[16] In another still more preferred embodiment, the present invention provides a compound wherein:
Ln is *CH (Ra)NHC (O) and the * indicates where Ln is bonded to G;
Ra is C(0)C(0)OH or C (0) - (benzothiazol-2-yl) ;
Rb is selected from H, phenyl, Cχ-ιo alkyl, and C _5 alkenyl;
Rc is selected from H and Cι_6 alkyl;
alternatively, Rb and Rc together are -(CH2)4-;
Figure imgf000030_0001
A is selected from phenyl, naphthyl, and thienyl, and A is substituted with 0-1 R4; R4, at each occurrence, is selected from H, OR2, CH20R2, F, Cl, Br, I, Ci-4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
R8, at each occurrence, is selected from H, Cι_g alkyl and phenyl ;
r, at each occurrence, is selected from 0, 1, and 2.
[17] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000031_0001
Ln is *CH2NHC(0) or *CH (Ra) NHC (0) and the * indicates where Ln is bonded to G;
Rla is selected from -(CH2)r-R1' and NHO^R1" ;
R1' is selected from H, OR2, NR2R2a, and NR2S02 (CH2) rR2b;
R1" is selected from C(0)NR2R2a, S(0)2Rb, and S02NR2R2a;
R2, at each occurrence, is selected from H, Cι_ alkyl, benzyl, and phenyl;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2b, at each occurrence, is selected from Cι_ alkoxy, Cχ_g alkyl, benzyl, phenyl substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-2 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3 , benzyl , and phenyl ;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
R3 , at each occurrence, is selected from H, C _4 alkyl, and phenyl;
A is phenyl substituted with 0-2 R4 ;
A1 is H or A;
alternatively, A and A1 and the carbon to which they are attached combine to form fluorene;
A2 is selected from H, A, and CHA3A4;
A3 is selected from H, A, C.-4 alkyl, and - (CH2) rNR2R2a;
A4 is H or A;
R4, at each occurrence, is selected from H, (CH )rOR2, F, Cl, Br, I, Ci-4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2) rC (0) R2 , NR2C(0)R2b, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ;
R4b, at each occurrence, is selected from H, (CH2)rOR2, F, Cl, Br, I, Ci-4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2c, NR2C(0)R2b, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3;
R5, at each occurrence, is selected from CF3 , Cι_g alkyl, phenyl , and benzyl ;
p, at each occurrence, is selected from 0, 1, and 2;
r, at each occurrence, is selected from 0, 1, 2, and 3.
[18] In another still more preferred embodiment, the present invention provides a compound wherein:
Ln is *CHNHC(0) and the * indicates where Ln is bonded to G;
Rla is selected from -(CH^r-R1' and NHCH2R1" ;
R1' is selected from OH, NR2R2a, and NR2S0 (CH2) rR2b;
R1" is selected from C(0)NR2R2a, S(0)2R2b, and S02NR2R2a;
R2 , at each occurrence, is selected from H, C]__g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, C]__g alkyl, benzyl , and phenyl ;
R2b, at each occurrence, is selected from Cι_4 alkoxy, Cι_g alkyl, benzyl, phenyl substituted with 0-1 R4b, and pyrrolidinyl substituted with 0-1 R4b;
R2c, at each occurrence, is selected from OH, 0CH3 , OCH CH3, CH3, benzyl, and phenyl; alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a piperidine ring substituted with 0-1 R4b;
R4, at each occurrence, is selected from H, =0, OR2, CH2OR2 , F, Cl, Br, I, Cι_4 alkyl, -CN, N02, (CH2) rNR2R2a, (CH2)rC(0)R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
R4b, at each occurrence, is selected from H, =0, OH, F, Cl , Ci- alkyl, and NH2 ; and,
r, at each occurrence, is selected from 0, 1, and 2.
[19] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000034_0001
Ln is O or S;
M2 is N or CRf;
M3 is N or CRd;
provided that only one of M2 and M3 is N;
Re is selected from H, N(CH3) (CH2C02H) and S- (5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4) ;
Rd is selected from H, F, and Cl; alternatively, Rd and Re combine to form -NR3-C (O) -C (RlbR3) NR3- or -N=CR2-NR3-;
Rf is selected from H, F, and Cl;
alternatively, Re and Rf combine to form -NR3~C (RlbR3) -C (O) - NR3- or -NR3-CR2=N-;
Z is 0, provided that Z does not form a N-0 or NCH20 bond with the groups to which Z is attached;
Rlb is selected from H, Cι_ alkyl, and Cλ. alkyl substituted with A;
R2, at each occurrence, is selected from H, -6 alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2b, at each occurrence, is selected from H, Cι_g alkyl, benzyl , and phenyl ;
R c, at each occurrence, is selected from OH, OCH3 , OCH CH3, CH3 , benzyl, and phenyl;
R3 , at each occurrence, is selected from H, Cχ-4 alkyl, and phenyl ;
A is selected from:
C5_g carbocyclic residue substituted with 0-2 R4 , and
5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4 ; B is H or Y ;
Y is selected from:
C5_g carbocyclic residue substituted with 0-2 R4a, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, =0, (CH )rOR2, F, Cl, Br, I, Ci-4 alkyl, -CN, N02 , (CH2) rNR2R2a,
(CH2)rC(0)R2c, NR2C(0)R2b, C(0)NR2R2a, C (=NR2 ) NRR2a, NHC(=NR2)NR2R2a, S02NR2R2a, and CF3 ;
R4a, at each occurrence, is selected from H, =0, (CH )r0R2, (CH2)r-F, (CH2)r-Br, (CH2)r-Cl, Cl , Br, F, I, C3...4 alkyl, -CN, N02, (CH2)rNR2R2a, (CH2) rC (O) R2c, NR2C(0)R2b, C(0)NR2R2a, C(=NR )NR2R2a, NHC (=NR2) NR2R2a, S02NR2R2a, and CF3; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
[20] In another still more preferred embodiment, the present invention provides a compound wherein:
Ln is O;
Re is N(CH3) (CH2C02H) ;
Rd is H or F;
alternatively, Rd and Re combine to form -NR3-C (0) -C (RlbR3. NR3- or -N=CR2-NR3-; Rf is H or F ;
alternatively, Re and Rf combine to form -NR3-C (RlbR3) -C (O) - NR3- or -NR3-CR2=N-;
Rlb is selected from H, Cχ-2 alkyl and benzyl;
A is phenyl substituted with 0-2 R4 ;
B is H or Y;
Y is 5 membered heterocyclic system containing from 1-2 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4 , at each occurrence, is selected from H, C _4 alkyl, and NR2R2a. and
R4a, at each occurrence, is selected from H, C1.4 alkyl, and NR2R a.
[21] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000037_0001
Ln is *CH2NHC(0)CH2 or *CH (Ra) NHC (0) CH2 and the * indicates where Ln is bonded to G;
M1 is absent or is CHR; R is selected from H, Cl, F, Br, I, OR3, Cι_4 alkyl, OCF3 , CF3, and NH2 ;
Z is Ci_4 alkylene;
R2 , at each occurrence, is selected from H, Cι_g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cx_g alkyl, benzyl, and phenyl;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3 , benzyl , and phenyl ;
R3 , at each occurrence, is selected from H, Cχ_4 alkyl, and phenyl ;
A is selected from:
C3_6 carbocyclic residue substituted with 0-2 R4 , and 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4 ;
R4, at each occurrence, is selected from H, (CH2)rOR2, F, Cl, Br, I, Cχ-4 alkyl, (CH2) rNR2R2a, (CH2) rC (O) R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
[22] In another still more preferred embodiment, the present invention provides a compound wherein: Ln is *CH2NHC (O) CH2 and the * indicates where Ln is bonded to G;
M1 is absent;
R is selected from H and C1-4 alkyl;
Z is CH2;
A is C3_6 carbocyclic residue substituted with 0-1 R4 ;
R4 , at each occurrence, is selected from H, Cι__ alkyl, (CH2)rNR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, and 2.
[23] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000039_0001
Ln is absent;
R2 , at each occurrence, is selected from H, C^g alkyl, benzyl, and phenyl;
R2a, at each occurrence, is selected from H, Cι_6 alkyl, benzyl, and phenyl;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3, benzyl, and phenyl; X is S02 or S02 ( CH=CH ) ;
Y is selected from:
Cg-io carbocyclic residue substituted with 0-2 R4a, and 5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4a;
R4 , at each occurrence, is selected from H, =0, OR2, CH2OR2 , F, Cl, Br, I, C3...4 alkyl, (CH2) rNR2R2a, (CH2) rC (0) R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
R4a, at each occurrence, is selected from H, OR2, CH2OR2, F, Cl, Br, I, Ci-4 alkyl, (CH2) rNR R2a, (CH2) rC (O) R c, C(0)NR2R2a, S02NR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
[24] In another still more preferred embodiment, the present invention provides a compound wherein:
X is S02;
Y is selected from phenyl substituted with 0-2 R4a and naphthyl substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, =0, OH, CH20H, F, Cl, Br, Ci-4 alkyl, C(0)NR2R2a, and C(0)R2 ;
R4a, at each occurrence, is selected from H, OH, CH2OH, F, Cl, Br, C1-4 alkyl, and C(0)R2c; and,
r, at each occurrence, is selected from 0, 1, and 2. [25] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000041_0001
Ln is absent;
R2 , at each occurrence, is selected from H, Cχ_6 alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, C^g alkyl, benzyl , and phenyl ;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3 , benzyl , and phenyl ;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
X is S02 or S02 (CH=CH) ;
Y is selected from:
Cg_10 carbocyclic residue substituted with 0-2 R4a, and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a; R4 , at each occurrence, is selected from H, =0, OR2, CH2OR2 , F, Cl, Br, I, Cχ-4 alkyl, (CH2) rNR2R2a, (CH2) rC (0) R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
R4a, at each occurrence, is selected from H, OR2, CH2OR2, F, Cl, Br, I, Ci-4 alkyl, (CH2) rNR2R2a, (CH2) rC (0) R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
r, at each occurrence, is selected from 0, 1, 2, and 3
[26] In another still more preferred embodiment, the present invention provides a compound wherein:
X is S02;
Y is phenyl substituted with 0-2 R4a or naphthyl substituted with 0-2 R4a;
R4 , at each occurrence, is selected from H, =0, OR2, CH OR2, F, Cl, Br, I, Ci-4 alkyl, NH2 , (CH2) rC (0) R2c, and C(0)NR2R2a;
R4a, at each occurrence, is selected from H, =0, OR2, CH20R2, F, Cl, Br, I, Cι_4 alkyl, NH2 , (CH2) rC (0) R2c, and C(0)NR2R2a;
r, at each occurrence, is selected from 0, 1, 2, and 3.
[27] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000043_0001
Ln is absent;
R2 , at each occurrence, is selected from H, Cι_g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3 , benzyl , and phenyl ;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
X is S02 or S02(CH=CH);
Y is selected from:
Cg-10 carbocyclic residue substituted with 0-2 R4a, and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, =0, OR2, CH20R2 , F, Cl, Br, I, Ci-4 alkyl, (CH2) rNR2R2a, (CH2) rC (0) R2 , C(0)NR2R2 , S02NR2R a, and CF3 ; R4 , at each occurrence, is selected from H, OR2, CH20R2, F, Cl, Br, I, Cχ-4 alkyl, (CH2) rNR2R2a, (CH2) rC (0) R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
r, at each occurrence, is selected from 0, 1, 2, and 3.
[28] In another still more preferred embodiment, the present invention provides a compound wherein:
X is S02;
Y is phenyl substituted with 0-2 R4a or naphthyl substituted with 0-2 Ra;
R4, at each occurrence, is selected from H, =0, OR2, CH2OR2 ,
F, Cl, Br, I, Ci_4 alkyl, NH2 , (CH2) rC (O) R c, and
C(0)NR2R2a;
R4a, at each occurrence, is selected from H, OR2, CH2OR2 , F, Cl, Br, I, Cχ_4 alkyl, NH2, (CH2) rC (O) R c, and C(0)NR2R2a; and,
r, at each occurrence, is selected from 0, 1, and 2.
[29] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000044_0001
Ra is C(0)-(6 membered heterocyclic system containing 1 N atom and substituted with 0-2 R4) ; R2 , at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cι_ alkyl, benzyl , and phenyl ;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3 , benzyl , and phenyl ;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
A is a 10 membered bicyclic heterocyclic system containing 1 N atom and substituted with 0-2 R4 ;
B is H or Y;
Y is selected from:
C3_g carbocyclic residue substituted with 0-2 R4a, and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4 , at each occurrence, is selected from H, =0, OR2, F, Cl,
Br, I, Cι_4 alkyl, NR2R2a, (CH2) rC (0) R2c, C(0)NR2R2a, and CF3;
R4a, at each occurrence, is selected from H, =0, OR2, F, Cl, Br, I, Ci_4 alkyl, NRR2a, (CH2) rC (0) R2c, C(0)NR2R2a, and CF3; r, at each occurrence, is selected from 0, 1, 2, and 3.
[30] In a still more preferred embodiment, the present invention provides a compound wherein:
Ra is C (O) - (N-1, 2 , 3 , 6-tetrahydropyridine substituted with C02H) ;
alternatively, Ra is C (0) - (N-1, 2 , 3 , 6-tetrahydropyridine substituted with CH3) ;
A is 1, 2, 3 , 4-tetrahydroisoquinoline substituted with 1-2 R4 ;
B is H;
R4, at each occurrence, is selected from H, methyl, =0, OR2, F, Cl, Br, I, Ci-4 alkyl, NR2R2a, (CH2) rC (O) R2c,
C(0)NR2R2a, S02NR2R2a, and CF3 ;
r, at each occurrence, is selected from 0, 1, and 2
[31] In another even more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000046_0001
R2, at each occurrence, is selected from H, Cι_g alkyl, benzyl, and phenyl;
R2a, at each occurrence, is selected from H, Cι_ alkyl, benzyl , and phenyl ; R2c, at each occurrence, is selected from OH, 0CH3 , OCH2CH3, CH3 , benzyl , and phenyl ;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
X is OS02;
Y is selected from:
C6_10 aromatic ring substituted with 0-2 R4a, and
5-10 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4 is H;
R4a , at each occurrence , is selected from H , ( CH2 ) r0R2 , F ,
Cl , Br, I , Ci_4 alkyl , -CN, (CH2) rNR2R2a, (CH2) rC (0) R2 c , C (0) NR2R2a, S02NR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
[32] In a still more preferred embodiment, the present invention provides a compound wherein:
R is methyl;
Y is selected from phenyl substituted with 0-2 R4a, naphtyl substituted with 0-2 R4a, and quinolinyl substituted with 0-2 R4a; R4a, at each occurrence, is selected from H, (CH )rOR2, F. Cl, Br, I, Ci.4 alkyl, (CH2) rNRR2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, and 2.
[33] In another more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000048_0001
R9 is selected from H, CH2OR3 , CH2C(0)OR3, Cι_4 alkyl, C(0)NH2, and NH2 ;
Rh is selected from H, CH2-phenyl, CH2CH2-phenyl , and CH=CH- phenyl ;
R2 , at each occurrence, is selected from H, C .6 alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, C _g alkyl, benzyl , and phenyl ;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3 , benzyl, and phenyl;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R3 , at each occurrence, is selected from H, Cχ_4 alkyl, and phenyl ;
A is selected from: Cβ-io aromatic ring substituted with 0-2 R4 , and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4 ;
B is H or Y;
Y is selected from:
Cβ-io aromatic ring substituted with 0-2 R4a, and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, (CH2)r0R2, F, Cl , Br, I, Ci_4 alkyl, -CN, (CH2) rNR2R2a, (CH2) rC (0) R2c, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ;
R4a, at each occurrence, is selected from H, (CH2)rOR2, Cl , Br, F, I, Cχ-4 alkyl, -CN, (CH2) rNR2R2a, (CH2) rC (0) R2c, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ;
R5, at each occurrence, is selected from CF3, Cι_g alkyl, phenyl, and benzyl;
p, at each occurrence, is selected from 0, 1, and 2; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
[34] In a still more preferred embodiment, the present invention provides a compound wherein: R9 is selected from CH2OR3 , and CH2C (0) OCH3 ;
Rh is selected from CH2-phenyl, CH2CH2-phenyl , and CH=CH- phenyl ;
A is phenyl;
B is Y;
Y is phenyl substituted with 0-2 R4a;
R4a, at each occurrence, is selected from H, OR2, Cl, Br, F, I, Ci_4 alkyl, (CH ) rNRR2a, C(0)NR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, and 2.
[35] In another more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000050_0001
R1 is selected from S02CH2C (O) OR3 , C (0) CH2C (0) OR3 , and C(0)OR3;
X is O;
Y is pyrrolidinyl substituted with 1-2 R4a or piperidinyl substituted with 1-2 R4a;
R2, at each occurrence, is selected from H, Cι_g alkyl, benzyl, and phenyl; R2a, at each occurrence, is selected from H, C -e alkyl, benzyl, and phenyl;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R3, at each occurrence, is selected from H, Cι_4 alkyl, and phenyl ;
R4 , at each occurrence, is selected from H, F, Cl, Br, I, Cι_4 alkyl, NR R2a, and CF3 ; and,
R4a, at each occurrence, is selected from H, Cι_4 alkyl,
CH2NRR2a, and C(=NR2)CH3.
[36] In a still more preferred embodiment, the present invention provides a compound wherein:
R1 is selected from S02CH2C (O) OR3 and C (0) CH2C (O) OR3 ;
Y is piperidinyl substituted with 1-2 R4a;
R3 , at each occurrence, is selected from H and C!_4 alkyl;
R4 is H; and,
R4a, at each occurrence, is selected from H, χ.4 alkyl, CH2NR2R2a, and C(=NR2)CH3. [37] In another more preferred embodiment, the present invention provides a compound of formula:
Figure imgf000052_0001
Ri is selected from S02CH2C (0) OR3 , C (0) CH2C (O) OR3 , and C(0)OR3;
X is O;
Y is pyrrolidinyl substituted with 1-2 R4a or piperidinyl substituted with 1-2 R4a;
R2 , at each occurrence, is selected from H, Cι_ alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cι_ alkyl, benzyl , and phenyl ;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R3, at each occurrence, is selected from H, Cχ-4 alkyl, and phenyl ;
R4, at each occurrence, is selected from H, F, Cl, Br, I, Ci-4 alkyl, NR2R2a, and CF3 ; and,
R4a, at each occurrence, is selected from H, Cι_4 alkyl, CH2NR2R a, and C ( =NR2 ) CH3. [38] In a still more preferred embodiment, the present invention provides a compound wherein:
R1 is selected from S02CH2C (0) OR3 and C (0) CH2C (O) OR3 ;
Y is piperidinyl substituted with 1-2 R4a;
R3 , at each occurrence, is selected from H and Cχ_4 alkyl;
R4 is H; and,
R4a, at each occurrence, is selected from H, Cι_ alkyl, CH2NR2R2a , and C ( =NR ) CH3.
[39] In a second embodiment, the present invention provides compounds selected from the group:
Figure imgf000054_0001
stereoisomer or pharmaceutically acceptable salt thereof , wherein; G is selected from:
Figure imgf000055_0001
Figure imgf000055_0002
Ra is selected from C(0)C(0)OH and C(O) (benzothiazol-2-yl) ;
R9 is selected from H, CH2OR3 , CH2C(0)OR3, C1-.4 alkyl, C(0)NH2, and NH2 ;
Rh is selected from H, CH2-phenyl, CH2CH2 -phenyl, and CH=CH- phenyl ;
R1 is selected from S02CH2C(0)OH and C (0) CH2C (O) OH, and C(0)OR3;
R, at each occurrence, is selected from H, methyl, ethyl, benzyl , and NH2 ;
R2, at each occurrence, is selected from H, CF3 , CH3 , benzyl, and phenyl ;
R2a, at each occurrence, is selected from H, CF3, CH3 , benzyl, and phenyl; alternatively, R2 and R2a combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino ;
R3 , at each occurrence, is selected from H, Cι_4 alkyl, and phenyl ;
Z is C(0)CH2 or CONH;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4 ; and,
B is selected from Y, X-Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R4a;
R4, at each occurrence, is selected from OH, (CH2)rOR2, halo,
C!_4 alkyl, (CH2) rNR2R2a, and (CF2)rCF3;
R a is selected from Cι_4 alkyl, CF3 , S(0)2R5, S02NR2R2a, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3 , Cι_g alkyl, phenyl , and benzyl ;
X is CH2 or C(O) ;
Y is selected from NR2R2a and CH2NR2R2a;
p is selected from 0, 1, and 2; and,
r is selected from 0, 1, and 2.
In another embodiment, the present invention provides novel pharmaceutical compositions, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of present invention or a pharmaceutically acceptable salt form thereof.
In another embodiment, the present invention provides a novel method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt form thereof .
In another embodiment, the present invention provides novel compounds for use in therapy.
In another embodiment, the present invention provides the use of novel compounds for the manufacture of a medicament for the treatment of thrombosis or a disease mediated by factor Xa .
DEFINITIONS The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racemic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and trans geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention.
"Substituted" is intended to indicate that one or more hydrogens on the atom indicated in the expression using "substituted" is replaced with a selection from the indicated group (s), provided that the indicated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substituent is keto (i.e., =0) group, then 2 hydrogens on the atom are replaced.
The present invention is intended to include all isotopes of atoms occurring in the present compounds . Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.
When any variable (e.g., R^) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 R6 , then said group may optionally be substituted with up to two R6 groups and R6 at each occurrence is selected independently from the definition of R6. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds .
When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds . As used herein, "alkyl" or "alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Cx-io alkyl (or alkylene), is intended to include Ci, C2, C3, C4, C5, Cg, C7, C8, C9, and Cio alkyl groups.
Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogen (for example -CVFW where v = 1 to 3 and w = 1 to (2v+l) ) . Examples of haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl , pentafluoroethyl, and pentachloroethyl . "Alkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge. Cχ_ιo alkoxy, is intended to include Ci, C2, C3 , C4,
C5, C6, C7, Cs, C9, and Cι0 alkoxy groups. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy. "Cycloalkyl" is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl. C3_ cycloalkyl, is intended to include C3 , C4 , C5, C , and C7 cycloalkyl groups. "Alkenyl" or "alkenylene"' is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl and propenyl . C2-ιo alkenyl (or alkenylene), is intended to include C , C3 , C4, C5, C6, C7, C8, C9, and Cι0 alkenyl groups. "Alkynyl" or
"alkynylene"' is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl . C2-ιo alkynyl (or alkynylene), is intended to include C2, C3 , C4, C5, C6, C7, C8, C9 , and Cι0 alkynyl groups. "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate. As used herein, "carbocycle" or "carbocyclic group" is intended to mean any stable 3, 4, 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12, or 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0] bicyclooctane, [4.3.0] bicyclononane, [4.4.0] bicyclodecane, [2.2.2] bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl , adamantyl, and tetrahydronaphthyl .
As used herein, the term "heterocycle" or "heterocyclic group"' is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S and including any bicyclic group in which any of the above- defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. As used herein, the term
"aromatic heterocyclic group"' or "heteroaryl ' ' is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and 1, 2, 3, or 4 heterotams independently selected from the group consisting of N, NH, O and S. It is to be noted that total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl , benzofuranyl , benzothiofuranyl, benzothiophenyl , benzoxazolyl , benzthiazolyl , benztriazolyl, benztetrazolyl, benzisoxazolyl , benzisothiazolyl , benzimidazolinyl, carbazolyl, 4aH-carbazolyl , carbolinyl, chromanyl, chromenyl , cinnolinyl, decahydroquinolinyl , 2H, 6H- 1 , 5, 2- dithiazinyl, dihydrofuro [2 , 3 -jb] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl , imidazolyl, 1H- indazolyl, indolenyl, indolinyl, indolizinyl, indolyl , 3H- indolyl, isobenzofuranyl , isochromanyl, isoindazolyl, isoindolinyl , isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl , octahydroisoquinolinyl , oxadiazolyl, 1,2,3- oxadiazolyl, 1 , 2 , 4 -oxadiazolyl, 1, 2 , 5 -oxadiazolyl , 1,3,4- oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl , phenazinyl, phenothiazinyl, phenoxathiinyl , phenoxazinyl , phthalazinyl , piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl , pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl , tetrahydroquinolinyl , tetrazolyl, 6H-1,2, 5-thiadiazinyl, 1 , 2 , 3-thiadiazolyl, 1,2,4- thiadiazolyl , 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl , thiazolyl, thienyl, thienothiazolyl, thienooxazolyl , thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4- triazolyl, and xanthenyl . Also included are fused ring and spiro compounds containing, for example, the above heterocycles .
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non- toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2- acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington ' s Pharmaceutical
Sciences, 17th ed., Mack Publishing Company, Easton, PA,
1985, p. 1418, the disclosure of which is hereby incorporated by reference.
"Prodrugs" are intended to include any covalently bonded carriers which release the active parent drug according to formula (I) in vivo when such prodrug is administered to a mammalian subject. Prodrugs of a compound of formula (I) are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of formula (I) wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug or compound of formula (I) is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of formula (I), and the like.
"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent .
"Therapeutically effective amount" is intended to include an amount of a compound of the present invention or an amount of the combination of compounds claimed effective to inhibit factor Xa or thrombin or treat diseases related to factor Xa or thrombin in a host . The combination of compounds is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv. Enzyme Regul . 22:27-55 (1984), occurs when the effect (in this case, inhibition of factor Xa or thrombin) of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at suboptimal concentrations of the compounds. Synergy can be in terms of lower cytotoxicity, increased antiviral effect, or some other beneficial effect of the combination compared with the individual components.
SYNTHESIS The compounds of the present invention can be prepared in a number of ways known to one skilled in the art of organic synthesis. The compounds of the present invention can be synthesized using the methods described below, together with synthetic methods known in the art of synthetic organic chemistry, or by variations thereon as appreciated by those skilled in the art. Preferred methods include, but are not limited to, those described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Groups In
Organic Synthesis, Wiley and Sons, 1991) . All references cited herein are hereby incorporated in their entirety herein by reference.
Figure imgf000065_0001
Compounds of the above formulas can be prepared by coupling corresponding acid and amine precursors. The acid precursors can be prepared as shown in W098/28326, WO 98/09987, WO /28326, W096/19483, and WO98/05333, the contents of which are incorporated herein by reference. The G-CH(Ra)NH precursors can be prepared as shown in the above- identified publications or as shown in the present application.
Figure imgf000065_0002
Compounds of the above formulas can be prepared by coupling corresponding acid and amine precursors. The acid precursors can be prepared as shown in WO98/05333, the contents of which are incorporated herein by reference. The G-CH(Ra)NH2 precursors can be prepared as shown in the above- identified publications or as shown in the present application.
Figure imgf000065_0003
Compounds of the above formula can be prepared by coupling the corresponding acid and amine precursors. The acid precursors can be prepared as shown in U.S. Patent No. 5,798,377, the contents of which are incorporated herein by reference. The G-CH2NH2 precursors can be prepared as shown in the above-identified publication or as shown in the present application.
Figure imgf000066_0001
Compounds of the above formula can be prepared by coupling corresponding G-leaving group and alcohol-pyridyl or thiol-pyridyl precursors. The alcohol and thio precursors can be prepared as shown in U.S. Patent No. 5,693,641, W096/28427, WO97/29067, WO98/07725, and W098/15547, the contents of which are incorporated herein by reference. The G-leaving group precursors can be prepared as shown in the above- identified publications or as shown in the present application. Alternatively, the compounds of the above formula can be prepared by displacing a leaving group from the pyridyl precursor with the corresponding G-OH precursor. Leaving groups for this type of coupling can be SCH3 or S02CH3.
Figure imgf000066_0002
Compounds of the above formula can be prepared by coupling corresponding acid and amine precursors . The acid precursors can be prepared as shown in W098/17274, the contents of which are incorporated herein by reference. The G-CH2NH2 precursors can be prepared as shown in the above- identified publication or as shown in the present application.
Figure imgf000067_0001
Compounds of the above formula can be prepared by coupling corresponding G-benzoic acid and piperazine precursors. The G-benzoic acid precursors can be prepared similarily to the methods shown in W098/21188, the contents of which are incorporated herein by reference. For example, the G-benzoic acid precursors can be prepared by coupling an activated G (e.g., a metallated ring) with a leaving group- benzoic acid (e.g., halo-benzoic acid) as shown in the above-identified publication. The piperazine precursors can be prepared by coupling of the desired piperizine with the desired X-Y group, wherein X contains a leaving group, as shown in the above-identified application or in the present application.
Figure imgf000067_0002
Compounds of the above formulas can be prepared by coupling corresponding benzoic acid and piperazine precursors. The G-piperidinyl acid or G-piperazinyl acid precursors can be prepared similarily to the methods shown in WO96/10022, the contents of which are incorporated herein by reference. For example, the G-piperidinyl acid or G- piperazinyl acid precursors can be prepared by coupling a G- leaving group (e.g., G-halogen) with a piperidinyl acid or piperazinyl acid as shown in the above- identified publication. The piperidine and piperazine precursors can be prepared by coupling of the desired piperizine with the desired X-Y group, wherein X contains a leaving group, as shown in the above-identified application or in the present application.
Figure imgf000068_0001
Compounds of the above formula can be prepared by coupling corresponding sulfonic acid and amine precursors. The sulfonic acid precursors can be prepared as shown in W096/33993, the contents of which are incorporated herein by reference. The G-CH CH (Ra) NH2 precursors can be prepared as shown in the above-identified publication or as shown in the present application.
Figure imgf000068_0002
Compounds of the above formula can be prepared by coupling corresponding G-CHO or G-CH2Br and
(R9) CH2CH2 (Rh)N(R3) C (0) -A-B precursors. The
(R9) CH2CH (Rh) N (R3) C (0) -A-B precursors can be prepared as shown in W097/24118, the contents of which are incorporated herein by reference. The G-CHO and G-CH2Br precursors can be prepared as shown in the above- identified publication or as shown in the present application.
Figure imgf000068_0003
Compounds of the above formula can be prepared by coupling corresponding G- (CH2) 3-leaving group and ester precursors . The ester precursors can be prepared as shown in EP/0540051, the contents of which are incorporated herein by reference. The G- (CH2) 3- leaving group precursors can be prepared as shown in the above-identified publication or other publications described herein or as shown in the present application.
Compounds of the above formula when G contains an amine linker can be prepared by displacing a leaving group off of the remainder of the molecule with corresponding G-amine precursor. The remainder of the molecule can be prepared as shown in JP10/1467, the contents of which are incorporated herein by reference. The G-NH precursors can be prepared as shown in the above-identified publications or as shown in the present application.
Figure imgf000069_0001
Compounds of the above formula can be prepared by coupling corresponding G- (CH2) 3- leaving group and phenol precursors . The phenol precursors can be prepared as shown in WO97/36580, the contents of which are incorporated herein by reference or as shown in the present application. The G- (CH ) 3- leaving group precursors can be prepared as shown in the above-identified publication or other publications described herein or as shown in the present application.
Figure imgf000069_0002
Compounds of the above formulas can be prepared by coupling corresponding aniline and G- (CH2) 3-leaving group or
G-(CH2)2C02H precursors. The aniline precursors can be prepared as shown in EP/0540051, JP10/1467, and WO96/16940, the contents of which are incorporated herein by reference. The G- (CH2) 3-leaving group or G-(CH2)2C02H precursors can be prepared as shown in the above-identified publication or other publications described herein or as shown in the present application.
Many of the compounds of the present invention can be prepared from G-NH2 where G represents a residue which is either the PI residue described above, a suitably protected form of the PI residue, or an intermediate which can be transformed at a later stage of the synthesis into the PI residue. Scheme I describes procedures by which the amino residue of G-NH2 can be transformed into a variety of different functionalities which are useful for assembling the compounds of the present invention. G-NH2 I can be diazotized with sodium nitrite in the presence of aqueous sulfuric acid to produce the hydroxy derivative II.
Diazotization of I in acidic media followed by treatment with copper (I) bromide affords the bromo derivative III.
The bromo derivative is a very useful intermediate for further functionalization. Treatment of III with magnesium metal generates a Grignard reagent which can react with suitably protected bromoglycinate derivatives to afford amino acid derivatives IV. There are a wide variety of methods available for introducing simple carbon-atom based functionality starting with bromide III. Transmetallation with an organolithium reagent such as tert-butyllithium or π-butyllithium is readily accomplished at low temperature. The formed organolithium species can react with a wide variety of electrophiles . For example, reaction with dimethylformamide produces the aldehyde derivative V, while reaction with an alkyl chloroformate or an alkyl cyanoformate produces an ester derivative. The ester functionality can be reduced with a variety of hydride reducing agents such as lithium aluminum hydride or diisobutylaluminum hydride to afford the alcohol VI. The alcohol VI can also be prepared by reduction of aldehyde V, such as with sodium borohydride . The bromide III can also react through palladium-mediated processes. For example, reaction of III with an alcohol or amine and a catalyst such as tetrakis-triphenylphosphine palladium under a carbon monoxide atmosphere leads to esters G-C02R or amides G-CONR2 via a carbonyl insertion reaction. A particularly useful amide G-CONR2 available by this procedure is the N-methyl-N- methoxy amide, obtained when N-methyl-N-methoxyamine is used in the carbonyl insertion reaction. This amide is readily reduced to aldehyde V with hydride reducing agents such as diisobutylaluminum hydride. The alcohol VI, readily available by a variety of methods as described above can be converted to the bromide derivative VII by many methods, such as by treatment with carbon tetrabromide and triphenylphosphine. Another method for the preparation of bromide VII, not shown in Scheme I, involves the radical bromination of an intermediate G-CH3, which is readily available by methods known to those skilled in the art of organic synthesis. This radical bromination is readily accomplished by treating G-CH3 with N-bromosuccinimide in refluxing carbon tetrachloride in the presence of a radical initiator such as AIBN. The bromide VII is a particularly useful intermediate for the preparation of the compounds of the present invention. Displacement of the bromide can be accomplished by treatment with sodium or potassium cyanide in a solvent such as DMF or DMSO at room temperature or elevated temperature to give a cyano derivative. Reduction of the nitrile, such as by catalytic hydrogenation or by treatment with sodium borohydride and cobalt (II) chloride, gives the amino derivative VIII. The bromide can also be displaced by appropriate N-protected glycinates, such as N- (diphenylmethylene) glycine ethyl ester, to give the amino acid derivatives IX. This reaction is accomplished by heating VII and the glycinate in the presence of a base such as potassium carbonate and a quaternary ammonium salt such as tetrabutylammonium bromide in a solvent such as acetonitrile. The bromide can also be displaced with sodium azide in a solvent such as DMF or DMSO at elevated temperatures to give an azide intermediate. The azide is readily reduced by a variety of reducing agents, such as by catalytic hydrogenation or by tin (II) chloride, to afford the amino derivative XI. A variety of other methods are available for the preparation of the amino derivative XI.
For example, reductive amination of aldehyde V with ammonium acetate and sodium cyanoborohydride affords XI.
Alternatively, the amine G-NH2 I can be diazotized as described above and reacted with copper (I) cyanide to afford the nitrile X. The nitrile can be reduced to form amine XI by a variety of methods, such as by catalytic hydrogenation or by reduction with sodium borohydride in the presence of cobalt (II) chloride. A variety of other methods for the preparation of the intermediates described in Scheme I are available and are known to those skilled in the art . The particular method used for the preparation of the required intermediates will depend on additional functionality present on group "G'", and it will be appreciated by those skilled in the art that certain protecting group strategies may be required and that reaction conditions and the order of steps may require modification.
Scheme I
Figure imgf000073_0001
02 R
NP
IX
The compound wherein G is a 2 , 5-bis (aminomethyl) phenyl group can be prepared from commercially available amino- terephthalate as shown in the Scheme II below. Scheme I I
Figure imgf000074_0001
The amino group can be further manipulated as described in Scheme I above .
Scheme III describes the preparation of mono-protected 2 -methylaminoaniline intermediates .
Scheme I I I
Figure imgf000074_0002
selective protection of benzylamine
Figure imgf000074_0003
Figure imgf000074_0004
The following are some examples of conditions required for selective protection of the benzylamine functionality.
Figure imgf000075_0001
The mono-protected 2-methylaminoaniline intermediates required to make the 2-methylaminophenyl analogs of this invention can be prepared from the known anthranilic acids by the route outlined in Scheme IV. The anthranilic acid is simultaneously reduced to the benzyl alcohol and N-protected by formation of the mixed anhydride/N-carbamoyl compound followed by selective reduction of the anhydride functionality with aqueous sodium borohydride.
The benzylalcohol is then transformed to the benzylazide by a two-step sequence involving methanesulfonate ester formation followed by displacement of the sulfonate ester with sodium azide in dimethylformamide . The 2-methylaminoaniline can be obtained from the benzylazide by removal of the carbamoyl group with ethanolic sodium hydroxide followed by catalytic reduction of the azide group.
Representitive methods for the selective protection of the more reactive benzylamine functionality with a few of the protecting groups (-P.G.) that may be contemplated for the realization of this invention are illustrated in the above table .
Scheme IV describes the preparation of 1,4- disubstituted-6-aminophthalazine intermediates. Scheme IV
Figure imgf000076_0001
Synthesis of 1, 4-disubstituted-6-aminophthalazines in which the 1 and 4 -positions may be a protected amine could be accomplished starting from the commercially available 3 , 4-dicyanonitrobenzene . Addition of hydrazine to bis- nitrile would form the phthalazine core. Suitable protection and reduction of the aryl nitro group would provide the desired compound.
Scheme V describes the preparation of 6-amino-2- aminoquinoline intermediates.
Scheme V
Figure imgf000076_0002
NH2P
Scheme VI describes the preparation of 7-amino-2- aminoquinoline intermediates.
Scheme VI
Figure imgf000076_0003
Scheme VII describes the preparation of 6 - aminoquinazoline intermediates . Scheme VI I
Figure imgf000077_0001
X = H, NH2, alkyl Y = H, NP, alkyl
Synthesis of 6-aminoquinazolines in which the 2- position may be a hydrogen, a protected amine, or an alkyl group and the 4-position is a protected amine could be accomplished starting from commercially available 3-cyano-4- fluoronitrobenzene . Reaction of guanidine or amidine nucleophiles at the nitrile followed by fluorine displacement to ring closure would yield the quinazoline core (J". Heterocyclic Chem . , 1991, 28, 1357). Suitable protection and reduction of the aryl nitro group wiould provide the title compound.
Scheme VIII describes the preparation of 7- aminoquinazoline intermediates.
Figure imgf000077_0002
Synthesis of 7-aminoquinazolines in which the 2- position may be a hydrogen, a protected amine, or an alkyl group and the 4-position is a protected amine could be accomplished starting from commercially available 2-fluoro- 4-nitrobenzoic acid. Conversion of carboxylic acid to nitrile via standard manipulations would give 2-fluoro-4- nitrobenzonitrile . Reaction of guanidine or amidine nucleophiles at the nitrile followed by fluorine displacement to ring closure would yield the quinazoline core (J". Heterocyclic Chem. , 1991, 28, 1357). Suitable protection and reduction of the aryl nitro group would provide the 7-aminoquinazoline .
Scheme IX describes the preparation of 7- aminoisoquinazoline intermediates.
Scheme IX
Figure imgf000078_0001
Synthesis of 7-aminoisoquinolines in which the 1 or 4- position may be a protected amine could be accomplished from the corresponding known 7-nitroisoquinoline by published methods (see for example, U.S. Patent No. 4,673,676). Suitable protection and reduction of the aryl nitro group would provide the 7-aminoisoquinoline .
Scheme X describes the preparation of 6- aminoisoquinazoline intermediates .
Scheme X
Figure imgf000078_0002
Synthesis of 6-aminoisoquinolines in which the 1 or 4- position may be a protected amine could be accomplished starting from commercially available 1,2,3,4- tetrahydroisoquinoline . Conversion to the known 6 -nitro isoquinoline [ Chem . Pharm . Bull . 1958, 6, 497, 499) and on to the 1- and 4-amino derivatives (see for example U.S. Patent No. 4,673,676) followed by suitable protection and reduction of the aryl nitro group would provide the desired compound . Scheme XI describes the preparation of 7- aminophthalazine intermediates.
Scheme XI
Figure imgf000079_0001
Synthesis of 7-aminophthalazines in which the 1- position may be a protected amine could be accomplished starting from commercially available 2-cyano-4-nitrotoluene , Bromination of tolyl methyl to give a benzyl bromide followed by displacement with hydrazine would afford benzyl hydazine intermediate. Ring closure by subsequent addition to the nitrile under thermal conditions would yield the phthalazine core. Suitable protection and reduction of the aryl nitro group would provide the desired compound.
Scheme XII describes the preparation of 6- aminophthalazine intermediates.
Scheme XI I
Figure imgf000079_0002
Synthesis of 6-aminophthalazines in which the 1- position may be a protected amine could be accomplished starting from commercially available 2-bromo-5-nitrotoluene . Displacement of bromide with cyanide followed by bromination of tolyl methyl will give a benzyl bromide. Displacement of bromide with hydrazine would afford benzyl hydazine intermediate suitable for ring closure by subsequent addition to the nitrile under thermal conditions to yield the phthalazine core. Suitable protection and reduction of the aryl nitro group would provide the title compound.
The A-B moieties of the present can be prepared by methods known to those of skill in the art. The A-B moieties of the present can be prepared by methods described in the above-identified publications. For example, the following publications, the contents of which are incorporated herein by reference, describe and exemplify means of preparing A-B moieties: W097/23212, WO97/30971, WO98/06694, WO98/01428, W098/28269, and W098/28282.
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
EXAMPLES Example 1 3 , 5-Difluoro-4-d.imethylamino-l- (2-aminoπιethylphenoxy) -6- ( (2' -sulfamido- [1, 1' ] -biphen-4-oxy) ) pyridine
Figure imgf000081_0001
KO-t-Bu DMF 60°C 18h
Figure imgf000081_0002
1. Hydrogenation
2. 100% TFA, 55°C, 2h
Figure imgf000081_0003
Synthesis of compound (A)
To the solution of 4- (dimethylamino) -2 , 3 , 5 , 6- tetrafluoropyridine (10.3 mmol, 2.0 g) in dimethylformamide (10 mL) was added the mixture of 2-cyanophenol (1.227g, 1.0 eq.) and potassium t-butoxide (1.156 g, 1.0 eq.) in dimethylformamide (15 mL) slowly. This reaction mixture was heated at 60°C for 18h. The reaction mixture was cooled to ambient temperature and to this mixture was added water (10 mL) to give precipitate, which was collected by filtration. This crude product was purified by flash chromatography on a silica gel column (5 g) eluted with 4:1 hexane: ethyl acetate to give 1.116 g of pure product (37 %) .
Synthesis of compound (B) A mixture of 3-bromophenol (0.01 mol, 1.73 g) , boronic acid (2.57 g, 1.0 eq.), tetrakis (triphenylphosphine) palladium (0) (0.347 g, 0.03 eq.), and sodium carbonate (3.18 g, 3.0 eq.) in tetrahydrofuran (100 mL) and water (50 mL) was stirred at ambient temperature for 30 min. while nitrogen gas was bubbling to remove oxygen. This reaction mixture was then refluxed for 18 h. The reaction mixture was filtered through celite to remove catalyst and washed with tetrahydrofuran (50 mL) . The filtrate was evaporated in vacuo and the residue was taken up in water then extracted with ethyl acetate (3x) . The ethyl acetate extracts were washed with brine, dried (MgS04), and evaporated. This residue was purified by flash chromatography on a silica gel column (10 g) eluted with 2.5 : 1 hexane : ethyl acetate to give 2.508 g of pure product (82%) .
Synthesis of compound (C)
To the solution of (A) (3.8056 mmol, 1.116 g) in dimethylformamide (10 mL) was added the mixture of (B) (1.162g, 1.0 eq.) and potassium t-butoxide (0.427g, 1.0 eq.) in dimethylformamide (10 mL) slowly. This reaction mixture was heated at 60°C for 18h. The reaction mixture was cooled to ambient temperature and to this mixture was added water (10 mL) to give precipitate, which was collected by filtration. This crude product was purified by by HPLC on a C-18 column eluted with solvent mixture A (water : TFA 99.95 : 0.05) and solvent mixture B (acetonitrile : TFA 99.95 : 0.05) using a gradient starting with A at 50 % and changing to B at 100 % over 50 min. After lyophylization, 0.35 g of pure product (16%) was obtained.
Synthesis of compound (D)
To a solution of (C) (0.5703 mmol, 0.33g) in methanol (10 mL) was added palladium hydroxide on carbon (0.066g, 20 wt%) , palladium on carbon from Fluka (0.033g, 10 wt%) , and 2 drops of cone, hydrochloric acid. This reaction mixture was stirred under house vacuum for 10 minutes at ambient temperature to remove oxygen. Then subjected to 1 atm H2 via balloon method for 18 h. The reaction mixture was filtered through celite to remove catalyst and washed with methanol (10 mL) . The filtrate was evaporated under vacuum. This residue was dissolved in 100% trifluoroacetic acid (5 o mL) and this reaction mixture was heated at 55 C for 2h. After removing trifluoroacetic acid, the crude product was purified by HPLC on a C-18 column eluted with solvent mixture A (water: TFA 99.95 : 0.05) and solvent mixture B (acetonitrile : TFA 99.95 : 0.05) using a gradient starting with A at 80 % and changing to B at 80 % over 40 min. to give 0.15g of pure product (50%) ; HRMS for C26H25F2N404S m/z
(M+H)+ calc. 527.5751, found 527.1566.
Utility The compounds of this invention are useful as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The term "thromboembolic disorders" as used herein includes arterial or venous cardiovascular or cerebrovascular thromboembolic disorders, including, for example, unstable angina, first or recurrent myocardial infarction, ischemic sudden death, transient ischemic attack, stroke, atherosclerosis, venous thrombosis, deep vein thrombosis, thrombophlebitis, arterial embolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolisms, and pulmonary embolisms. The anticoagulant effect of compounds of the present invention is believed to be due to inhibition of factor Xa, thrombin, or both.
The effectiveness of compounds of the present invention as inhibitors of factor Xa can be determined using purified human factor Xa and synthetic substrate. The rate of factor Xa hydrolysis of chromogenic substrate S2222 (Kabi Pharmacia, Franklin, OH) can be measured both in the absence and presence of compounds of the present invention. Hydrolysis of the substrate resulted in the release of pNA, which can be monitored spectrophotometrically by measuring the increase in absorbance at 405 nM. A decrease in the rate of absorbance change at 405 nm in the presence of inhibitor is indicative of enzyme inhibition. The results of this assay are expressed as inhibitory constant, Kj_ .
Factor Xa determinations were made in 0.10 M sodium phosphate buffer, pH 7.5, containing 0.20 M NaCl, and 0.5 % PEG 8000. The Michaelis constant, Km, for substrate hydrolysis can be determined at 25°C using the method of Lineweaver and Burk. Values of Kj. were determined by allowing 0.2-0.5 nM human factor Xa (Enzyme Research Laboratories, South Bend, IN) to react with the substrate (0.20 mM-1 mM) in the presence of inhibitor. Reactions were allowed to go for 30 minutes and the velocities (rate of absorbance change vs time) were measured in the time frame of 25-30 minutes. The following relationship can be used to calculate Ki values :
(v0-vs)/vs = I/(Ki (1 + S/Km) ) where : v0 is the velocity of the control in the absence of inhibitor; vs is the velocity in the presence of inhibitor; I is the concentration of inhibitor;
Ki is the dissociation constant of the enzyme : inhibitor complex;
S is the concentration of substrate; Km is the Michaelis constant.
Compounds tested in the above assay are considered to be active if they exhibit a Ki of <10 μM. Preferred compounds of the present invention have Kj. ' s of <1 μM. More preferred compounds of the present invention have Kj. ' s of
<0.1 μM. Even more preferred compounds of the present invention have Ki ' s of <0.01 μM. Still more preferred compounds of the present invention have Ki ' s of <0.001 μM.
The antithrombotic effect of compounds of the present invention can be demonstrated in a rabbit arterio-venous (AV) shunt thrombosis model. In this model, rabbits weighing 2-3 kg anesthetized with a mixture of xylazine (10 mg/kg i.m.) and ketamine (50 mg/kg i.m.) are used. A saline-filled AV shunt device is connected between the femoral arterial and the femoral venous cannulae . The AV shunt device consists of a piece of 6 -cm tygon tubing which contains a piece of silk thread. Blood will flow from the femoral artery via the AV-shunt into the femoral vein. The exposure of flowing blood to a silk thread will induce the formation of a significant thrombus. After forty minutes, the shunt is disconnected and the silk thread covered with thrombus is weighed. Test agents or vehicle will be given (i.v., i.p., s.c, or orally) prior to the opening of the AV shunt . The percentage inhibition of thrombus formation is determined for each treatment group. The ID50 values (dose which produces 50% inhibition of thrombus formation) are estimated by linear regression.
The compounds of formula (I) may also be useful as inhibitors of serine proteases, notably human thrombin, plasma kallikrein and plasmin. Because of their inhibitory action, these compounds are indicated for use in the prevention or treatment of physiological reactions, blood coagulation and inflammation, catalyzed by the aforesaid class of enzymes. Specifically, the compounds have utility as drugs for the treatment of diseases arising from elevated thrombin activity such as myocardial infarction, and as reagents used as anticoagulants in the processing of blood to plasma for diagnostic and other commercial purposes. Compounds of the present invention can be shown to be direct acting inhibitors of the serine protease thrombin by their ability to inhibit the cleavage of small molecule substrates by thrombin in a purified system. In vi tro inhibition constants were determined by the method described by Kettner et al . in J. Biol . Chem . 265, 18289-18297 (1990), herein incorporated by reference. In these assays, thrombin-mediated hydrolysis of the chromogenic substrate S2238 (Helena Laboratories, Beaumont, TX) can be monitored spectrophotometrically. Addition of an inhibitor to the assay mixture results in decreased absorbance and is indicative of thrombin inhibition. Human thrombin (Enzyme Research Laboratories, Inc., South Bend, IN) at a concentration of 0.2 nM in 0.10 M sodium phosphate buffer, pH 7.5, 0.20 M NaCl, and 0.5% PEG 6000, can be incubated with various substrate concentrations ranging from 0.20 to 0.02 mM. After 25 to 30 minutes of incubation, thrombin activity can be assayed by monitoring the rate of increase in absorbance at 405 nm which arises owing to substrate hydrolysis. Inhibition constants were derived from reciprocal plots of the reaction velocity as a function of substrate concentration using the standard method of Lineweaver and Burk . Compounds tested in the above assay are considered to be active if they exhibit a Ki of <10 μM. Preferred compounds of the present invention have Ki ' s of <1 μM. More preferred compounds of the present invention have Ki ' s of <0.1 μM. Even more preferred compounds of the present invention have Ki ' s of <0.01 μM. Still more preferred compounds of the present invention have Ki ' s of <0.001 μM.
The compounds of the present invention can be administered alone or in combination with one or more additional therapeutic agents. These include other anticoagulant or coagulation inhibitory agents, anti-platelet or platelet inhibitory agents, thrombin inhibitors, or thrombolytic or fibrinolytic agents.
The compounds are administered to a mammal in a therapeutically effective amount. By "therapeutically effective amount" it is meant an amount of a compound of Formula I that, when administered alone or in combination with an additional therapeutic agent to a mammal, is effective to prevent or ameliorate the thromboembolic disease condition or the progression of the disease. By "administered in combination" or "combination therapy" it is meant that the compound of Formula I and one or more additional therapeutic agents are administered concurrently to the mammal being treated. When administered in combination each component may be administered at the same time or sequentially in any order at different points in time. Thus, each component may be administered separately but sufficiently closely in time so as to provide the desired therapeutic effect. Other anticoagulant agents (or coagulation inhibitory agents) that may be used in combination with the compounds of this invention include warfarin and heparin, as well as other factor Xa inhibitors such as those described in the publications identified above under Background of the Invention. The term anti-platelet agents (or platelet inhibitory agents) , as used herein, denotes agents that inhibit platelet function such as by inhibiting the aggregation, adhesion or granular secretion of platelets. Such agents include, but are not limited to, the various known non-steroidal anti- inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, naproxen, sulindac, indomethacin, mefenamate, droxicam, diclofenac, sulfinpyrazone, and piroxicam, including pharmaceutically acceptable salts or prodrugs thereof. Of the NSAIDS, aspirin (acetylsalicyclic acid or ASA) , and piroxicam are preferred. Other suitable anti-platelet agents include ticlopidine, including pharmaceutically acceptable salts or prodrugs thereof.
Ticlopidine is also a preferred compound since it is known to be gentle on the gastro-intestinal tract in use. Still other suitable platelet inhibitory agents include Ilb/lIIa antagonists, thromboxane-A2-receptor antagonists and thromboxane-A2-synthetase inhibitors, as well as pharmaceutically acceptable salts or prodrugs thereof.
The term thrombin inhibitors (or anti-thrombin agents) , as used herein, denotes inhibitors of the serine protease thrombin. By inhibiting thrombin, various thrombin-mediated processes, such as thrombin-mediated platelet activation
(that is, for example, the aggregation of platelets, and/or the granular secretion of plasminogen activator inhibitor- 1 and/or serotonin) and/or fibrin formation are disrupted. A number of thrombin inhibitors are known to one of skill in the art and these inhibitors are contemplated to be used in combination with the present compounds. Such inhibitors include, but are not limited to, boroarginine derivatives, boropeptides, heparins, hirudin and argatroban, including pharmaceutically acceptable salts and prodrugs thereof. Boroarginine derivatives and boropeptides include N-acetyl and peptide derivatives of boronic acid, such as C-terminal a-aminoboronic acid derivatives of lysine, ornithine, arginine, homoarginine and corresponding isothiouronium analogs thereof. The term hirudin, as used herein, includes suitable derivatives or analogs of hirudin, referred to herein as hirulogs, such as disulfatohirudin. Boropeptide thrombin inhibitors include compounds described in Kettner et al., U.S. 5,187,157 and EP 293 881 A2 , the disclosures of which are hereby incorporated herein by reference . Other suitable boroarginine derivatives and boropeptide thrombin inhibitors include those disclosed in WO92/07869 and EP 471,651 A2 , the disclosures of which are hereby incorporated herein by reference.
The term thrombolytics (or fibrinolytic) agents (or thrombolytics or fibrinolytics) , as used herein, denotes agents that lyse blood clots (thrombi) . Such agents include tissue plasminogen activator, anistreplase, urokinase or streptokinase, including pharmaceutically acceptable salts or prodrugs thereof. The term anistreplase, as used herein, refers to anisoylated plasminogen streptokinase activator complex, as described, for example, in European Patent Application No. 028,489, the disclosure of which is hereby incorporated herein by reference herein. The term urokinase, as used herein, is intended to denote both dual and single chain urokinase, the latter also being referred to herein as prourokinase .
Administration of the compounds of Formula I of the invention in combination with such additional therapeutic agent, may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each. A lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.
The compounds of the present invention are also useful as standard or reference compounds, for example as a quality standard or control, in tests or assays involving the inhibition of factor Xa . Such compounds may be provided in a commercial kit, for example, for use in pharmaceutical research involving factor Xa . For example, a compound of the present invention could be used as a reference in an assay to compare its known activity to a compound with an unknown activity. This would ensure the experimenter that the assay was being performed properly and provide a basis for comparison, especially if the test compound was a derivative of the reference compound. When developing new assays or protocols, compounds according to the present invention could be used to test their effectiveness.
The compounds of the present invention may also be used in diagnostic assays involving factor Xa. For example, the presence of factor Xa in an unknown sample could be determined by addition of chromogenic substrate S2222 to a series of solutions containing test sample and optionally one of the compounds of the present invention. If production of pNA is observed in the solutions containing test sample, but not in the presence of a compound of the present invention, then one would conclude factor Xa was present .
Dosage and Formulation The compounds of this invention can be administered in such oral dosage forms as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. They may also be administered in intravenous (bolus or infusion) , intraperitoneal , subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired. A physician or veterinarian can determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the thromboembolic disorder. By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to 1000 mg/kg of body weight, preferably between about 0.01 to 100 mg/kg of body weight per day, and most preferably between about 1.0 to 20 mg/kg/day. Intravenously, the most preferred doses will range from about 1 to about 10 mg/kg/minute during a constant rate infusion. Compounds of this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.
Compounds of this invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using transdermal skin patches. When administered in the form of a transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of administration, that is, oral tablets, capsules, elixirs, syrups and the like, and consistent with conventional pharmaceutical practices.
For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl callulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like; for oral administration in liquid form, the oral drug components can be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents, and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta- lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like. The compounds of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids , such as cholesterol, stearylamine, or phosphatidylcholines .
Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers . Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol , polyhydroxyethylaspartamidephenol , or polyethyleneoxide- polylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacylates, and crosslinked or amphipathic block copolymers of hydrogels. Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 100 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be present in an amount of about 0.5-95% by weight based on the total weight of the composition.
Gelatin capsules may contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract .
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. In general, water, a suitable oil, saline, aqueous dextrose (glucose) , and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol .
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field.
Representative useful pharmaceutical dosage- forms for administration of the compounds of this invention can be illustrated as follows: Capsules
A large number of unit capsules can be prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
Soft Gelatin Capsules
A mixture of active ingredient in a digestable oil such as soybean oil, cottonseed oil or olive oil may be prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules should be washed and dried. Tablets
Tablets may be prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption. Injectable
A parenteral composition suitable for administration by injection may be prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol and water. The solution should be made isotonic with sodium chloride and sterilized. Suspension An aqueous suspension can be prepared for oral administration so that each 5 mL contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S. P., and 0.025 mL of vanillin. Where the compounds of this invention are combined with other anticoagulant agents, for example, a daily dosage may be about 0.1 to 100 milligrams of the compound of Formula I and about 1 to 7.5 milligrams of the second anticoagulant, per kilogram of patient body weight. For a tablet dosage form, the compounds of this invention generally may be present in an amount of about 5 to 10 milligrams per dosage unit, and the second anti-coagulant in an amount of about 1 to 5 milligrams per dosage unit.
Where the compounds of Formula I are administered in combination with an anti-platelet agent, by way of general guidance, typically a daily dosage may be about 0.01 to 25 milligrams of the compound of Formula I and about 50 to 150 milligrams of the anti-platelet agent, preferably about 0.1 to 1 milligrams of the compound of Formula I and about 1 to 3 milligrams of antiplatelet agents, per kilogram of patient body weight .
Where the compounds of Formula I are adminstered in combination with thrombolytic agent, typically a daily dosage may be about 0.1 to 1 milligrams of the compound of Formula I, per kilogram of patient body weight and, in the case of the thrombolytic agents, the usual dosage of the thrombolyic agent when administered alone may be reduced by about 70-80% when administered with a compound of Formula I. Where two or more of the foregoing second therapeutic agents are administered with the compound of Formula I, generally the amount of each component in a typical daily dosage and typical dosage form may be reduced relative to the usual dosage of the agent when administered alone, in view of the additive or synergistic effect of the therapeutic agents when administered in combination.
Particularly when provided as a single dosage unit, the potential exists for a chemical interaction between the combined active ingredients. For this reason, when the compound of Formula I and a second therapeutic agent are combined in a single dosage unit they are formulated such that although the active ingredients are combined in a single dosage unit, the physical contact between the active ingredients is minimized (that is, reduced) . For example, one active ingredient may be enteric coated. By enteric coating one of the active ingredients, it is possible not only to minimize the contact between the combined active ingredients, but also, it is possible to control the release of one of these components in the gastrointestinal tract such that one of these components is not released in the stomach but rather is released in the intestines. One of the active ingredients may also be coated with a material which effects a sustained-release throughout the gastrointestinal tract and also serves to minimize physical contact between the combined active ingredients. Furthermore, the sustained-released component can be additionally enteric coated such that the release of this component occurs only in the intestine. Still another approach would involve the formulation of a combination product in which the one component is coated with a sustained and/or enteric release polymer, and the other component is also coated with a polymer such as a low- viscosity grade of hydroxypropyl methylcellulose (HPMC) or other appropriate materials as known in the art, in order to further separate the active components. The polymer coating serves to form an additional barrier to interaction with the other component.
These as well as other ways of minimizing contact between the components of combination products of the present invention, whether administered in a single dosage form or administered in separate forms but at the same time by the same manner, will be readily apparent to those skilled in the art, once armed with the present disclosure.
Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise that as specifically described herein.

Claims

WHAT IS CLAIMED IS
A compound selected from the group:
Figure imgf000097_0001
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein; G is selected from the group:
Figure imgf000098_0001
Figure imgf000098_0002
Figure imgf000099_0001
Ln is a linker which is absent or is selected from O, S, CH2 , *CH2NHC(0) , *CH(Ra)NHC(0) , *CH2NHC (O) CH2 , and *CH(Ra)NHC(0) CH2, provided that Ln and M do not form an O-N or S-N bond and the * indicates where Ln is bonded to G;
M1 is absent or is CHR;
M2 is N or CRf;
M3 is N or CRd;
provided that only one of M2 and M3 is N;
Ra is selected from C(0)C(0)OR3, C (O) C (O) NR2R2a, and C(0)-A; Rb is selected from H, R, phenyl,
Figure imgf000100_0001
alkyl, and C _5 alkenyl ;
Rc is selected from H and Cχ_6 alkyl;
alternatively, Rb and Rc together are -(CH2) -;
Rd is selected from H, F, and Cl ;
Re is selected from H, N(CH3) (CH2C02H) and S- (5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4) ;
alternatively, Rd and Re combine to form -NR3-C (O) -C (RlbR3) - NR3- or -N=CR2-NR3-;
Rf is selected from H, F, and Cl ;
alternatively, Re and Rf combine to form -NR3-C (RlbR3) -C (O) - NR3- or -NR3-CR2=N-;
R9 is selected from H, CH2OR3, CH2C(0)OR3, Cι_4 alkyl, C(0)NH2, and NH2 ;
Rh is selected from H, CH2-phenyl, CH CH2-phenyl , and CH=CH- phenyl ;
R1 is selected from S0 CH2C (0) OR3 , C (0) CH2C (O) OR3 , and C(0)0R3;
R is selected from H, Cl , F, Br, I, (CH2)tOR3, Cχ.4 alkyl, benzyl, OCF3 , CF3 , C(0)NR7R8, and (CR8R9) tNR7R8 ; Z is selected from (CR8R9);L_4, (CR8R9) rO (CR8R9) r, (CR8R9) rNR3 (CR8R9) r, (CR8R9) rC (O) (CR8R9) r, (CR8R9) rC (O) O (CR8R9) r, (CR8R9) rOC (O) (CR8R9) r, (CR8R9) rC (O) NR3 (CR8R9) r, (CR8R9) rNR3C (O) (CR8R9) r, (CR8R9)rOC(0)0(CR8R9)r, (CH2) rOC (O) NR3 (CR8R9) r,
(CR8R9) rNR3C (O) 0 (CR8R9) r, (CH2) rNR3C (0) NR3 (CR8R9) r, (CR8R9) rS (0) p (CR8R9) r, (CR8R9) rS (O) 2 (CH=CH) , (CCR8R9) rS02NR3 (CR8R9) r, (CR8R9) rNR3S02 (CR8R9) r, and (CR8R9)rNR3S02NR3 (CR8R9)r, provided that Z does not form a N-N, N-O, N-S, NCH2N, NCH20, or NCH2S bond with the groups to which Z is attached;
Rla is absent or selected from -(CH2)r-R1', -CH=CH-R1' , NHCT^R1", OCE^R1", SCH2R1", NH (CH ) 2 (CH2) tRl' , O (CU2 ) 2 (CE2 ) tR1' , and S (CH2) 2 (CH2) tR1' ;
R1' is selected from H, Cχ-3 alkyl, F, Cl, Br, I, -CN, -CHO,
(CF2)rCF3, (CH2)rOR2, NR2R2a, C(0)R2c, OC(0)R2,
(CF2)rC02R2c, S(0)p(CH2)rR2b, NR (CH2 ) rOR2 , C(=NR2 )NR2R2a, NR2C(0)R2b, NR2C (O) NHR2b, NR2C(0)2R2a,
OC(0)NR2aR2b, C(0)NR2R2a, C (O) NR2 (CH2 ) rOR2 , S02NR2R2a,
NR2S02R2b, C3_6 carbocyclic residue substituted with 0-2
R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4 ;
R1" is selected from H, CH(CH2OR2)2, C(0)R2c, C(0)NR2R2a, S(0)R2b, S(0)2R2b, and S02NR2R2a;
Rlb is selected from H, Ci-g alkyl, and Cχ.ζ alkyl substituted with A; R2, at each occurrence, is selected from H, CF3 , Ci-g alkyl, benzyl, C3_g carbocyclic residue substituted with 0-2
R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
R2a, at each occurrence, is selected from H, CF3 , .6 alkyl, benzyl, C3_g cycloalkylmethyl substituted with 0-2 R4b, C3-6 carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
R2b, at each occurrence, is selected from CF3 , Cι_4 alkoxy, Ci-g alkyl, benzyl, C3_g carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
R2c, at each occurrence, is selected from CF3 , OH, C1-4 alkoxy, Cχ-β alkyl, benzyl, C3_ carbocyclic residue substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S; R3, at each occurrence, is selected from H, Cι_ alkyl, and phenyl ;
R3a, at each occurrence, is selected from H, C]__4 alkyl, and phenyl ;
R3b, at each occurrence, is selected from H, Cχ-4 alkyl, and phenyl ;
R3c, at each occurrence, is selected from Cι_4 alkyl, and phenyl ;
A is selected from:
C3-10 carbocyclic residue substituted with 0-2 R4, and 5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4 ;
A1 is H or A;
alternatively, A and A1 and the carbon to which they are attached combine to form fluorene;
A2 is selected from H, A, and CHA3A4 ;
A3 is selected from H, A, C^4 alkyl, and - (CH2) rNR2R2a;
A4 is H or A;
B is selected from: H, Y, and X-Y
X is selected from Cι_4 alkylene, -CR2 (CR2R2b) (CH2) t- , -C(O)-, -CR2(NR1"R2)-, -CR (OR2)-, -CR2(SR2)-, -C (O) CR R2a- , -CR2R2aC(0), -OS (0)2-, -S(0)p-, -S(0)pCR2R2a-, -CR2R2aS(0)p-, -S(0)2NR2-, -NR2S(0)2-, -NR2S (O) 2CR2R2a- , -CR2R2aS(0)2NR2-, -NR2S(0)2NR2-, -C(0)NR2-, -NR2C (O) - ,
-C(0)NR2CR2R2a-, -NR2C(0)CR2R2a-, -CR2R2aC (O) NR2- , -CR2R2aNR2C(0) -, -NR2C(0)0-, -OC(0)NR2-, -NR2C (O) NR2- , -NR2-, -NR2CR2R2a-, -CR2R2aNR2-, O, -CR2R2aO-, and -OCR2R2a-;
Y is selected from:
(CH2)rNR2R2a, provided that X-Y do not form a N-N, O-N, or S-N bond, C3-10 carbocyclic residue substituted with 0-2 R4a, and
5-10 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
alternatively, Z-A-B combine to form S-C]__g alkyl;
R4, at each occurrence, is selected from H, =0, (CH2)r0R2, F,
Cl, Br, I, Ci-4 alkyl, -CN, N02 , (CH2) rNR2R2a,
(CH2)rC(0)R2c, NR2C(0)R2b, C(0)NR2R2a, NR C (O) NR2R2a, C(=NR2)NR2R2a, C (=NS (0) 2R5) NR2R2a, NHC (=NR2) NR2R2a,
C(0)NHC(=NR2)NR2R2a, S02NR2R2a, NR2S02NR2R2a, NR2S02-Cι_4 alkyl, NR2S02R5, S(0)pR5, (CF2)rCF3, NHCH2RX" , OCT^R1" ,
SCHzR1", N(CH2)2(CH2)tR1' , 0 (CH2) 2 (CH2) tR1' , and
S(CH2)2(CH2)tR1' ;
alternatively, one R4 is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S;
R4a, at each occurrence, is selected from H, =0, (CH2)r0R2,
(CH2)r-F, (CH2)r-Br, (CH2)r-Cl, Cl, Br, F, I, Cι_4 alkyl, -CN, N02, (CH2)rNR2R2a, (CH ) rC (0) R2c, NR2C(0)Rb, C(0)NR2R2a, C(0)NH(CH2)2NR2R2a, NR2C (0) NR2R a, C(=NR )R3c, C(=NR2)NR2R2a, NHC(=NR2)NR2R2a, S02NR2R2a, NR2S02NR2R a, NR2S02-C1_4 alkyl, C (0) NHS02-Cχ-4 alkyl, NR2S02R5, S(0)pR5, and (CF2)rCF3;
alternatively, one R4a is a 5-6 membered aromatic heterocycle containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-1 R5;
R4b, at each occurrence, is selected from H, =0, (CH2)rOR3, F, Cl, Br, I, Cι_4 alkyl, -CN, N02 , (CH2) rNR3R3a,
(CH2)rC(0)R3, (CH2)rC(0)OR3c, NR3C(0)R3a, C(0)NR3R3a, NR3C(0)NR3R3a, C(=NR3)NR3R3a, NR3C (=NR3) NR3R3a, S02NR3R3a, NR3S0 NR3R3a, NR3S02-Cι-4 alkyl, NR3S02CF3, NR3S02-phenyl , S(0)pCF3, S(0)p-Ci_4 alkyl, S (O) p-phenyl, and (CF2)rCF3;
R5, at each occurrence, is selected from CF3 , Cχ-6 alkyl, phenyl substituted with 0-2 R6, and benzyl substituted with 0-2 R6;
R6, at each occurrence, is selected from H, OH, (CH )rOR2, halo, Cι_4 alkyl, CN, N02 , (CH2) rNR2R a, (CH2) rC (0) R2b, NR2C(0)R2b, NR2C(0)NR2R2a, C(=NH)NH2, NHC(=NH)NH2, S02NR2R2a, NR2S02NR2R2a, and NR2S02Cι_4 alkyl;
R7, at each occurrence, is selected from H, OH, Cι_ alkyl, Cι_g alkylcarbonyl, Cι_ alkoxy, Cι_4 alkoxycarbonyl, (CH2)n-phenyl, C6-ιo aryloxy, C6-ιo aryloxycarbonyl, C6_10 arylmethylcarbonyl, Cι_4 alkylcarbonyloxy Cχ_4 alkoxycarbonyl, C _ιo arylcarbonyloxy Cχ_4 alkoxycarbonyl, Cχ-g alkylaminocarbonyl, phenylaminocarbonyl, and phenyl Cχ_4 alkoxycarbonyl; R8, at each occurrence, is selected from H, Cι_g alkyl and (CH2)n-phenyl;
alternatively, R7 and R8 combine to form a 5 or 6 membered saturated, ring which contains from 0-1 additional heteroatoms selected from the group consisting of N, O, and S ;
R9, at each occurrence, is selected from H, Cι_g alkyl and (CH2)n-phenyl;
n, at each occurrence, is selected from 0, 1, 2, and 3 ;
m, at each occurrence, is selected from 0, 1, and 2 ;
p, at each occurrence, is selected from 0, 1, and 2 ;
r, at each occurrence, is selected from 0, 1, 2, and 3 ;
s, at each occurrence, is selected from 0, 1, and 2; and,
t, at each occurrence, is selected from 0, 1, 2, and 3.
2. A compound according to Claim 1, wherein:
G is selected from the group:
Figure imgf000107_0001
Figure imgf000107_0002
Figure imgf000107_0003
A compound according to Claim 2, wherein:
G is selected from:
Figure imgf000107_0004
Figure imgf000108_0001
4. A compound according to Claim 3, wherein:
R is selected from H, Cl, F, Br, I, (CH2)tOR3, C1-4 alkyl,
OCF3, CF3, C(0)NR7R8, and (CR8R9) tNR7R8 ;
Z is selected from CH20, OCH2 , CH2NH, NHCH2 , C(0), CH2C(0), C(0)CH2, NHC(O), C(0)NH, CH2S(0)2, S(0)2(CH2), S0NH, and NHS02, provided that Z does not form a N-N, N-O, NCH2N, or NCH 0 bond with ring M or group A;
A is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4 ; phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl , pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1 , 2 , 3 -oxadiazolyl, 1,2, 4 -oxadiazolyl, 1,2, 5-oxadiazolyl, 1,3, 4 -oxadiazolyl, 1,2, 3-thiadiazolyl , 1,2, 4 -thiadiazolyl, 1,2, 5-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1 , 3 , 4 -triazolyl, benzofuranyl, benzothiofuranyl, indolyl, benzimidazolyl , benzoxazolyl, benzthiazolyl, indazolyl, benzisoxazolyl, benzisothiazolyl, and isoindazolyl ;
B is selected from: H, Y, and X-Y; X is selected from Ci_4 alkylene, -C(O)-, -C(=NR)-,
-CR2 (NR2R2a) -, -C(0)CR2R2a-, -CR2R2aC(0), -C(0)NR2-, -NR2C(0)-, -C(0)NR2CR2R2a-, -NR2C (O) CR2R2a- , -CR2R2aC(0)NR2-, -CR2R2aNR2C(0) -, -NR2C (O) NR2- , -NR2- -NR2CR2R2a-, -CR2R2aNR2-, 0, -CR2R2aO-, and -OCR2R2a-
Y is NR2R2a or CH2NR2R2a, provided that X-Y do not form a N-N or O-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; cylcopropyl, cyclopentyl, cyclohexyl, phenyl, piperidinyl, piperazinyl, pyridyl, pyrimidyl, furanyl, morpholinyl, thiophenyl, pyrrolyl, pyrrolidinyl, oxazolyl, isoxazolyl, isoxazolinyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, 1, 2 , 3 -oxadiazolyl, 1,2, 4 -oxadiazolyl , 1,2, 5-oxadiazolyl, 1,3, 4 -oxadiazolyl , 1,2, 3 -thiadiazolyl , 1,2, 4 -thiadiazolyl, 1,2, 5-thiadiazolyl , 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1, 3 , 4-triazolyl , benzofuranyl, benzothiofuranyl , indolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl , indazolyl, benzisoxazolyl , benzisothiazolyl, and isoindazolyl ;
alternatively, Y is selected from the following bicyclic heteroaryl ring systems :
Figure imgf000109_0001
K is selected from 0, S, NH, and N.
5. A compound according to Claim 4, wherein:
Z is C(0)CH2 and CONH, provided that Z does not form a N-N bond with group A;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4 ; and,
B is selected from Y, X-Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R4a;
B is selected from: Y and X-Y;
X is selected from CH2 , -C(O)-, and O;
Y is NR2R2a or CH2NR2R2a, provided that X-Y does not form an O-N bond;
alternatively, Y is selected from one of the following carbocyclic and heterocyclic systems which are substituted with 0-2 R4a; phenyl, piperazinyl, pyridyl, pyrimidyl, morpholinyl, pyrrolidinyl, imidazolyl, and 1,2,3- triazolyl ;
R2, at each occurrence, is selected from H, CF3 , CH3 , benzyl, and phenyl;
R2a, at each occurrence, is selected from H, CF3 , CH3 , CH(CH3) , cyclopropylmethyl, benzyl, and phenyl; alternatively, R2 and R2a combine to form a ring system substituted with 0-2 R4b, the ring system being selected from pyrrolidinyl, piperazinyl and morpholino;
R4, at each occurrence, is selected from OH, (CH2)rOR2, Cl , F, Ci_4 alkyl, (CH2) rNR2R2a, and (CF2)rCF3;
R a is selected from Cl, F, C3.-4 alkyl, CF3 , (CH2) rNR2R2a, S(0)pR5, S02NR2R2a, and l-CF3-tetrazol-2-yl;
Rb, at each occurrence, is selected from OH, Cl, F, CH3 , and CF3;
R5, at each occurrence, is selected from CF3 , C]__6 alkyl, phenyl, and benzyl;
R7, at each occurrence, is selected from H, CH3 , and CH2CH3; and,
R8, at each occurrence, is selected from H and CH3.
6. A compound according to Claim 1, wherein:
A is selected from the group: phenyl, 2-pyridyl, 3-pyridyl, 2-pyrimidyl, 2-Cl-phenyl, 3-Cl-phenyl, 2-F-phenyl, 3-F- phenyl, 2-methylphenyl , 2-aminophenyl , and 2- methoxyphenyl ; and,
B is selected from the group: 2-CF3-phenyl , 2-
(aminosulfonyl) phenyl, 2- (methylaminosulfonyl) phenyl , 2- (dimethylaminosulfonyl) phenyl, 1-pyrrolidinocarbonyl, 2- (methylsulfonyl) phenyl, 2- (N,N- dimethylaminomethyl) phenyl, 2- (isopropylaminomethyl) phenyl, 2- (eyelopropylaminomethyl) phenyl, 2- (N- pyrrolidinylmethyl) phenyl, 2- (3-hydroxy-N- pyrrolidinylmethyl) phenyl, 4-morpholino, 2-(l'-CF3~ tetrazol-2-yl) phenyl, 4-morpholinocarbonyl , 1-methyl-2- imidazolyl, 2 -methyl- 1-imidazolyl, 5-methyl-l- imidazolyl, 2- (N,N-dimethylaminomethyl) imidazolyl , 2- methylsulfonyl-1 -imidazolyl and, 5-methyl-l , 2 , 3- triazolyl .
7. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000112_0001
Ln is *CH2NHC(0)CH2 or *CH (Ra) NHC (O) CH2 , the * indicates where Ln is bonded to G;
Ra is C(0)C(0)OR3;
Z is selected from Cι_4 alkylene, (CH )rC(0), and (CH2) rS (O) 2 ;
R2, at each occurrence, is selected from H, C^g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2b, at each occurrence, is selected from H, Cι_g alkyl, benzyl, and phenyl;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3, benzyl, and phenyl; R3 , at each occurrence, is selected from H, Cι_ alkyl, and phenyl ;
A is C5_6 carbocyclic residue substituted with 0-2 R4;
R4, at each occurrence, is selected from H, =0, (CH2)rOR2, F, Cl, Br, I, Cι_4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2c, NR2C(0)R2b, C(0)NR2R2a, C (=NR2) NR2R2a, NHC(=NR2)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ;
R5, at each occurrence, is selected from CF3, Cι_6 alkyl, phenyl , and benzyl ;
p, at each occurrence, is selected from 0, 1, and 2; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
8. A compound according to Claim 1, wherein:
Ln is *CH(Ra)NHC(0)CH2;
Ra is C(0)C(0)OH;
Z is selected from CH2 , (CH2)2C(0), and CH2S(0)2;
A is cyclohexyl or phenyl and is substituted with 0-1 R4 ;
R4, at each occurrence, is selected from H, =0, OR2, CH2OR2,
F, Cl, Br, I, Cχ-4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, and 2.
Ill
9. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000114_0001
Ln is *CH2NHC(0)CH2 or *CH (Ra) NHC (O) CH2 , the * indicates where Ln is bonded to G;
Ra is C(0)C(0)OR3;
R is H or NH2;
Z is selected from Cι_4 alkylene, (CH2)rC(0), and (CH2) rS (O) ;
R2 , at each occurrence, is selected from H, Cι_ alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2b, at each occurrence, is selected from H, Cι_g alkyl, benzyl, and phenyl;
R2c, at each occurrence, is selected from OH, OCH3 , 0CH2CH3, CH3 , benzyl , and phenyl ;
R3, at each occurrence, is selected from H, C1-4 alkyl, and phenyl ;
A is a C5_6 carbocyclic residue substituted with 0-2 R4; R4, at each occurrence, is selected from H, =0, (CH )rOR2, F, Cl, Br, I, Ci-4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2 , NR2C(0)R2b, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ;
R5, at each occurrence, is selected from CF3 , Cχ-g alkyl, phenyl , and benzyl ;
p, at each occurrence, is selected from 0, 1, and 2; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
10. A compound according to Claim 1, wherein:
Ln is *CH(Ra)NHC(0)CH2;
R is H;
Ra is C(0)C(0)0H;
Z is selected from CH2 , (CH2)2C(0), and CH2S(0)2;
A is cyclohexyl or phenyl and is substituted with 0-1 R4 ;
R4, at each occurrence, is selected from H, =0, OR2, CH2OR2,
F, Cl, Br, I, CX-4 alkyl, -CN, N02 , (CH2) rNR2Ra,
(CH2)rC(0)R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
r, at each occurrence, is selected from 0, 1, 2, and 3.
11. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000116_0001
Ln is *CH2NHC(0)CH2 or *CH (Ra) NHC (O) CH2 , the * indicates where Ln is bonded to G;
R is H or NH2;
Ra is C(0)C(0)OR3;
Z is Cι_4 alkylene;
R2 , at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cι_g alkyl, benzyl , and phenyl ;
R2b, at each occurrence, is selected from H, Cι_g alkyl, benzyl , and phenyl ;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3 , benzyl , and phenyl ;
R3 , at each occurrence, is selected from H, Cχ- alkyl, and phenyl;
A is phenyl substituted with 0-2 R4 ;
R4, at each occurrence, is selected from H, (CH2)rOR2, F, Cl, Br, I, Cx_4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2) rC (O) R2c, NR2C(0)R2b, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ; R5, at each occurrence, is selected from CF3 , Cι_g alkyl, phenyl , and benzyl ;
p, at each occurrence, is selected from 0, 1, and 2; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
12. A compound according to Claim 11 wherein:
Ln is *CH(Ra)NHC(0)CH2;
R is NH2;
Ra is C(0)C(0)OH;
Z is CH2;
A is phenyl substituted with 0-1 R4 ;
R4 , at each occurrence, is selected from H, OR2, CH2OR2 , F,
Cl, Br, Cι_4 alkyl, -CN, N02 , (CH2) rNR2R2a,
(CH2)rC(0)R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, and 2.
13. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000117_0001
Ln is *CH2NHC(0) or *CH (Ra) NHC (0) and the * indicates where Ln is bonded to G;
Ra is selected from C(0)C(0)OR3 and C(0)-A;
Rb is selected from H, phenyl, Cι_χo alkyl, and C2_5 alkenyl;
Rc is selected from H and C]__g alkyl;
alternatively, Rb and Rc together are -(CH2)4-;
Z is (CR8R9)!_4;
R , at each occurrence, is selected from H, CF3 , and Cι_g alkyl;
R2a, at each occurrence, is selected from H, CF3 , and Cι_g alkyl ;
R2b, at each occurrence, is selected from H, CF3 , and Cχ_g alkyl ;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3,
CH3 , benzyl , and phenyl ;
R3 , at each occurrence, is selected from H, Cι_4 alkyl, and phenyl ;
A is selected from: Cg-rio aromatic carbocyclic residue substituted with 0-2
R4 , and
5-10 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4 ; R4, at each occurrence, is selected from H, (CH2)rOR2, F, Cl, Br, I, Cχ_4 alkyl, -CN, N0 , (CH2) rNR2R2a, (CH2) rC (0) R2c, NR2C(0)R2b, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ;
R5, at each occurrence, is selected from CF3 , C]__g alkyl, phenyl , and benzyl ;
R8 , at each occurrence, is selected from H, Cι_g alkyl and phenyl;
R9, at each occurrence, is selected from H, Cχ_g alkyl and phenyl ;
p, at each occurrence, is selected from 0, 1, and 2;
r, at each occurrence, is selected from 0, 1, 2, and 3.
14. A compound according to Claim 13, wherein:
Ln is *CH(Ra)NHC(0) and the * indicates where Ln is bonded to G;
Ra is C(0)C(0)OH or C (O) - (benzothiazol-2-yl) ;
Rb is selected from H, phenyl, C1-3.0 alkyl, and C2_5 alkenyl;
Rc is selected from H and Cχ_g alkyl;
alternatively, Rb and Rc together are -(CH2)4-;
Z is (CR8H)!-2; A is selected from phenyl, naphthyl, and thienyl, and A is substituted with 0-1 R4 ;
R4, at each occurrence, is selected from H, OR2, CH2OR2, F, Cl, Br, I, Cι_ alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
R8 , at each occurrence, is selected from H, methyl and phenyl; and,
r, at each occurrence, is selected from 0, 1, and 2.
15. A compound according to Claim 14, wherein the compound is of the formula:
Figure imgf000120_0001
Ln is *CH2NHC(0) or *CH (Ra) HC (O) and the * indicates where Ln is bonded to G;
Ra is selected from C(0)C(0)OR3 and C(0)-A;
Rb is selected from H, phenyl, Cχ_ιo alkyl, and C2_5 alkenyl;
Rc is selected from H and Cχ_g alkyl;
alternatively, Rb and Rc together are -(CH )4-;
R is selected from H, benzyl, Cι_4 alkyl, and NH2 ;
Z is (CR8R9)i-4; R2, at each occurrence, is selected from H, CF3, and Cι_g alkyl;
R2a, at each occurrence, is selected from H, CF3 , and Cχ_g alkyl ;
R2b, at each occurrence, is selected from H, CF3 , and Cι_g alkyl ;
R2c, at each occurrence, is selected from OH, OCH3 , OCH CH3, CH3 , benzyl , and phenyl ;
R3, at each occurrence, is selected from H, Cι_4 alkyl, and phenyl;
A is selected from:
Cg_ιo aromatic ring substituted with 0-2 R4, and
5-10 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4;
R4, at each occurrence, is selected from H, (CH )rOR2, F, Cl, Br, I, Cι_4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH ) rC (0) R2 , NR2C(0)R2b, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ;
R5, at each occurrence, is selected from CF3 , Ci-g alkyl, phenyl , and benzyl ;
R8, at each occurrence, is selected from H, Cι_g alkyl and phenyl ;
R9, at each occurrence, is selected from H, C _ alkyl and phenyl ; p, at each occurrence, is selected from 0, 1, and 2 ;
r, at each occurrence, is selected from 0, 1, 2, and 3.
16. A compound according to Claim 15, wherein:
Ln is *CH (Ra)NHC (0) and the * indicates where Ln is bonded to G;
Ra is C(0)C(0)OH or C (0) - (benzothiazol-2 -yl) ;
Rb is selected from H, phenyl, Cχ-ιo alkyl, and C _5 alkenyl;
Rc is selected from H and Cι_g alkyl;
alternatively, Rb and Rc together are -(CH2) -;
Z is (CR8H)ι_2;
A is selected from phenyl, naphthyl, and thienyl, and A is substituted with 0-1 R4 ;
R4, at each occurrence, is selected from H, OR2, CH20R2 , F, Cl, Br, I, Cχ_4 alkyl, -CN, N02 , (CH2) rNR2Ra, (CH2)rC(0)R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
R8, at each occurrence, is selected from H, Cι_6 alkyl and phenyl ;
r, at each occurrence, is selected from 0, 1, and 2.
17. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000123_0001
Ln is *CH2NHC(0) or *CH (Ra) NHC (O) and the * indicates where Ln is bonded to G;
Rla is selected from -(CH2 ) r-R1' and NHCH2R1" ;
R1' is selected from H, OR2, NR2R2a, and NR2S02 (CH2) rR2b;
R1" is selected from C(0)NR2R2a, S(0)2R2b, and S02NR2R2a;
R2, at each occurrence, is selected from H, Cι_g alkyl, benzyl, and phenyl;
R2a, at each occurrence, is selected from H, Cι_g alkyl, benzyl , and phenyl ;
R2b, at each occurrence, is selected from Cχ_4 alkoxy, Cι_g alkyl, benzyl, phenyl substituted with 0-2 R4b, and 5-6 membered heterocyclic system containing from 1-2 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4b;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3, benzyl, and phenyl;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring substituted with 0-2 R4b and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R3 , at each occurrence, is selected from H, Cι_4 alkyl, and phenyl ;
A is phenyl substituted with 0-2 R4 ;
A1 is H or A;
alternatively, A and A1 and the carbon to which they are attached combine to form fluorene;
A2 is selected from H, A, and CHA3A4;
A3 is selected from H, A, Cx_4 alkyl, and - (CH2) rNR2Ra;
A4 is H or A;
R4 , at each occurrence, is selected from H, (CH2)r0R2, F, Cl, Br, I, C!_4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2) rC (0) R2c, NR2C(0)R2b, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ;
R4b, at each occurrence, is selected from H, (CH )r0R2, F, Cl, Br, I, C!_4 alkyl, -CN, N02 , (CH2) rNR2R a,
(CH2)rC(0)R2c, NR2C(0)R2b, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3;
R5 , at each occurrence, is selected from CF3 , C]__g alkyl, phenyl, and benzyl;
p, at each occurrence, is selected from 0, 1, and 2;
r, at each occurrence, is selected from 0, 1, 2, and 3.
18. A compound according to Claim 17, wherein:
Ln is *CH2NHC(0) and the * indicates where Ln is bonded to G;
Rla is selected from -(CH2)r-R1' and NHCT^R1" ;
R1' is selected from OH, NR2R2a, and NR2S0 (CH2) rR2b;
R1" is selected from C(0)NR2R2 , S(0)2R2b, and S02NR2R2a;
R2 , at each occurrence, is selected from H, Cχ_g alkyl, benzyl, and phenyl;
R2a, at each occurrence, is selected from H, C _g alkyl, benzyl , and phenyl ;
R2b, at each occurrence, is selected from Cχ- alkoxy, Cχ_g alkyl, benzyl, phenyl substituted with 0-1 R4b, and pyrrolidinyl substituted with 0-1 R4b;
R2c, at each occurrence, is selected from OH, 0CH3, 0CH2CH3, CH3 , benzyl , and phenyl ;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a piperidine ring substituted with 0-1 R4b;
R4, at each occurrence, is selected from H, =0, OR2, CH2OR2, F, Cl, Br, I, Cχ-4 alkyl, -CN, N02 , (CH2) rNR2R2a, (CH2)rC(0)R2 , C(0)NR2R2a, S02NR2R2a, and CF3 ;
R4b, at each occurrence, is selected from H, =0, OH, F, Cl, Cχ_4 alkyl, and NH2 ; and, r, at each occurrence, is selected from 0, 1, and 2
19. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000126_0001
Ln is O or S;
M2 is N or CRf;
M3 is N or CRd;
provided that only one of M2 and M3 is N;
Re is selected from H, N(CH3) (CH2C02H) and S- (5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4) ;
R is selected from H, F, and Cl;
alternatively, Rd and Re combine to form -NR3-C (O) -C (RlbR3) - NR3- or -N=CR2-NR3- ;
Rf is selected from H, F, and Cl ;
alternatively, Re and Rf combine to form -NR3-C (RlbR3) -C (O) - NR3- or -NR3-CR2=N-;
Z is O, provided that Z does not form a N-0 or NCH20 bond with the groups to which Z is attached; Rlb is selected from H, Cχ_g alkyl, and Cχ_ alkyl substituted with A;
R2 , at each occurrence, is selected from H, Cχ-6 alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2b, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2c, at each occurrence, is selected from OH, OCH3, OCH CH3,
CH3 , benzyl , and phenyl ;
R3 , at each occurrence, is selected from H, Cι_4 alkyl, and phenyl ;
A is selected from: C5_g carbocyclic residue substituted with 0-2 R4, and
5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4 ;
B is H or Y;
Y is selected from:
C5_6 carbocyclic residue substituted with 0-2 R4a, and
5-6 membered heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, =0, (CH )rOR2, F, Cl, Br, I, Cχ-4 alkyl, -CN, N02 , (CH2) rNR R2a, (CH2)rC(0)R c, NR2C(0)R2b, C(0)NR2R2a, C (=NR2) NR2R2a, NHC(=NR2)NRR2a, S02NR2R a, and CF3 ;
R4a, at each occurrence, is selected from H, =0, (CH )rOR2, (CH2)r-F, (CH2)r-Br, (CH2)r-Cl, Cl, Br, F, I, Cχ_4 alkyl, -CN, N02, (CH2)rNR2R2a, (CH2) rC (O) R2c, NR2C(0)R2b, C(0)NR2R2a, C(=NR2)NRR2a, NHC (=NR2) NR2R2a, S02NR2R2a, and CF3; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
20. A compound according to Claim 19, wherein:
Ln is O;
Re is N(CH3) (CH2C02H) ;
Rd is H or F;
alternatively, Rd and Re combine to form -NR3-C (O) -C (RlbR3) NR3- or -N=CR2-NR3-;
Rf is H or F;
alternatively, Re and Rf combine to form -NR3-C (RlbR3) -C (O) NR3- or -NR3-CR2=N-;
Rlb is selected from H, Cχ-2 alkyl and benzyl;
A is phenyl substituted with 0-2 R4 ;
B is H or Y; Y is 5 membered heterocyclic system containing from 1-2 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4a;
R4 , at each occurrence, is selected from H, Cχ_4 alkyl, and NR2R2a; and,
R4a, at each occurrence, is selected from H, Cχ_4 alkyl, and
NR2R2a .
21. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000129_0001
Ln is *CH2NHC(0)CH2 or *CH (Ra) NHC (0) CH2 and the * indicates where Ln is bonded to G;
M1 is absent or is CHR;
R is selected from H, Cl , F, Br, I, OR3, Cι_4 alkyl, OCF3 , CF3, and NH2;
Z is Cι_4 alkylene;
R2, at each occurrence, is selected from H, Cι_6 alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl, and phenyl; R2c, at each occurrence, is selected from OH, OCH3, OCH2CH3, CH3 , benzyl , and phenyl ;
R3 , at each occurrence, is selected from H, Cx_4 alkyl, and phenyl ;
A is selected from:
C3_g carbocyclic residue substituted with 0-2 R4 , and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4 ;
R4, at each occurrence, is selected from H, (CH2)r0R2, F, Cl, Br, I, Cι_4 alkyl, (CH2) rNR2R2a, (CH2) rC (0) R2 , C(0)NR2R2a, S02NR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
22. A compound according to Claim 21, wherein:
Ln is *CH2NHC (O) CH2 and the * indicates where Ln is bonded to G;
M1 is absent;
R is selected from H and Cχ_4 alkyl;
Z is CH2;
A is C3_s carbocyclic residue substituted with 0-1 R4 ;
R4 , at each occurrence, is selected from H, C]__4 alkyl, (CH2)rNR2R2a, and CF3 ; and, r, at each occurrence, is selected from 0, 1, and 2
23. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000131_0001
Ln is absent;
R2 , at each occurrence, is selected from H, Cχ-g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl, and phenyl;
R2c, at each occurrence, is selected from OH, OCH3, OCH CH3, CH3 , benzyl , and phenyl ;
X is S02 or S02 (CH=CH) ;
Y is selected from:
C -χo carbocyclic residue substituted with 0-2 R4a, and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, =0, OR2, CHOR2 , F, Cl, Br, I, Cχ_4 alkyl, (CH2) rNR2R2a, (CH2) rC (0) R c, C(0)NR2R2a, S02NR2R2a, and CF3 ; R4a, at each occurrence, is selected from H, OR2, CH2OR2 , F, Cl, Br, I, Cχ_4 alkyl, (CH2) rNR2R2a, (CH2) rC (O) R2c, C(0)NR2R a, S02NR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
24. A compound according to Claim 23, wherein:
X is S02;
Y is selected from phenyl substituted with 0-2 R4a and naphthyl substituted with 0-2 R4a;
R4 , at each occurrence, is selected from H, =0, OH, CH2OH, F, Cl, Br, Cχ_4 alkyl, C(0)NR2R2a, and C(0)R2c;
R4a, at each occurrence, is selected from H, OH, CH2OH, F, Cl, Br, Cχ_4 alkyl, and C(0)R2c; and,
r, at each occurrence, is selected from 0, 1, and 2
25. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000132_0001
Ln is absent;
R2, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ; R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2c, at each occurrence, is selected from OH, OCH3 , OCH CH3, CH3 , benzyl , and phenyl ;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
X is S02 or S02(CH=CH);
Y is selected from:
Cg_χo carbocyclic residue substituted with 0-2 R4a, and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, =0, OR2, CH2OR2, F, Cl, Br, I, C -4 alkyl, (CH2) rNR2R2a, (CH2) rC (O) R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
R4a, at each occurrence, is selected from H, OR2, CH20R2, F,
Cl, Br, I, Cχ_4 alkyl, (CH2) rNR2R2a, (CH2) rC (O) R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
r, at each occurrence, is selected from 0, 1, 2, and 3.
26. A compound according to Claim 25, wherein:
X is S02; Y is phenyl substituted with 0-2 R4a or naphthyl substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, =0, OR2, CH2OR2 , F, Cl, Br, I, Cχ_4 alkyl, NH2 , (CH2) rC (0) R2c, and C(0)NR2R2a;
R4a, at each occurrence, is selected from H, =0, OR2, CH2OR2, F, Cl, Br, I, Cχ_4 alkyl, NH2/ (CH2) rC (0) R2c, and C(0)NR2R2a;
r, at each occurrence, is selected from 0, 1, 2, and 3.
27. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000134_0001
Ln is absent;
R2, at each occurrence, is selected from H, Cχ-g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2 , at each occurrence, is selected from OH, 0CH3 , OCH2CH3,
CH3 , benzyl , and phenyl ;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
X is S02 or S02 (CH=CH) ;
Y is selected from:
Cg-χo carbocyclic residue substituted with 0-2 Ra, and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, =0, OR2, CH2OR2, F, Cl, Br, I, Cχ_4 alkyl, (CH2) rNR R2a, (CH2 ) rC (O) R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
R4a, at each occurrence, is selected from H, OR2, CH2OR2, F, Cl, Br, I, Cχ-4 alkyl, (CH2) rNR2R2a, (CH2) rC (O) R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ;
r, at each occurrence, is selected from 0, 1, 2, and 3.
28. A compound according to Claim 27, wherein:
X is S02;
Y is phenyl substituted with 0-2 R4a or naphthyl substituted with 0-2 R a;
R4, at each occurrence, is selected from H, =0, OR2, CH2OR2, F, Cl, Br, I, Cχ_4 alkyl, NH2 , (CH2) rC (0) R2c, and C(0)NR2R2a; R4a, at each occurrence, is selected from H, OR2, CH OR2, F, Cl, Br, I, C _4 alkyl, NH2 , (CH2) rC (O) R2c, and C(0)NR2R2a; and,
r, at each occurrence, is selected from 0, 1, and 2.
29. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000136_0001
Ra is C(0)-(6 membered heterocyclic system containing 1 N atom and substituted with 0-2 R4) ;
R2, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl, and phenyl;
R2c, at each occurrence, is selected from OH, OCH3 , OCH CH3, CH3 , benzyl , and phenyl ;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
A is a 10 membered bicyclic heterocyclic system containing 1 N atom and substituted with 0-2 R4;
B is H or Y; Y is selected from:
C3_g carbocyclic residue substituted with 0-2 R4a, and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-2 Ra;
R4, at each occurrence, is selected from H, =0, OR2, F, Cl ,
Br, I, Cχ-4 alkyl, NR2R2a, (CH2) rC (0) R2 , C(0)NR2R2a, and CF3;
R4a, at each occurrence, is selected from H, =0, OR2, F, Cl, Br, I, Cχ_4 alkyl, NR2R2 , (CH2) rC (O) R2c, C(0)NR2Ra, and CF3;
r, at each occurrence, is selected from 0, 1, 2, and 3
30. A compound according to Claim 29, wherein:
Ra is C (O) - (N-1, 2 , 3 , 6-tetrahydropyridine substituted with C02H) ;
alternatively, Ra is C (O) - (N-1, 2 , 3 , 6-tetrahydropyridine substituted with CH3) ;
A is 1 , 2 , 3 , 4-tetrahydroisoquinoline substituted with 1-2 R4 ;
B is H;
R4 , at each occurrence, is selected from H, methyl, =0, OR2, F, Cl, Br, I, Cχ-4 alkyl, NR2R2a, (CH2) rC (0) R2c,
C(0)NR2R2a, S02NR2R2a, and CF3 ;
r, at each occurrence, is selected from 0, 1, and 2.
31. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000138_0001
R2 , at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3 , benzyl, and phenyl;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
X is OS02;
Y is selected from:
C6_χo aromatic ring substituted with 0-2 R4a, and
5-10 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4 is H; R4a, at each occurrence, is selected from H, (CH )rOR2, F,
Cl, Br, I, Cχ_4 alkyl, -CN, (CH2) rNR2R2a, (CH2) rC (0) R2c, C(0)NR2R2a, S02NR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
32. A compound according to Claim 31, wherein:
R is methyl;
Y is selected from phenyl substituted with 0-2 R4a, naphtyl substituted with 0-2 R4a, and quinolinyl substituted with 0-2 R4a;
R4a, at each occurrence, is selected from H, (CH2)rOR2, F, Cl, Br, I, Cχ-4 alkyl, (CH2) rNR2R2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, and 2.
33. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000139_0001
R9 is selected from H, CH2OR3, CH2C(0)OR3, Cχ_4 alkyl, C(0)NH2, and NH2 ;
Rh is selected from H, CH2 -phenyl, CH2CH2-phenyl, and CH=CH- phenyl ; R2 , at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2c, at each occurrence, is selected from OH, OCH3 , OCH2CH3, CH3 , benzyl , and phenyl ;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
R3 , at each occurrence, is selected from H, Cχ.4 alkyl, and phenyl ;
A is selected from: Cg_χo aromatic ring substituted with 0-2 R4 , and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4 ;
B is H or Y;
Y is selected from:
Cg_χo aromatic ring substituted with 0-2 R4a, and
5-6 membered aromatic heterocyclic system containing from 1-4 heteroatoms selected from the group consisting of N, 0, and S substituted with 0-2 R4a;
R4, at each occurrence, is selected from H, (CH2)rOR2, F, Cl, Br, I, Cχ_4 alkyl, -CN, (CH2) rNR2R2a, (CH2) rC (0) R2c, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ; R4a, at each occurrence, is selected from H, (CH2)rOR2, Cl, Br, F, I, Cχ_ alkyl, -CN, (CH2) rNR2R2a, (CH ) rC (0) R c, C(0)NR2R2a, S02NR2R2a, S(0)pR5, and CF3 ;
R5, at each occurrence, is selected from CF3 , Cχ_g alkyl, phenyl , and benzyl ;
p, at each occurrence, is selected from 0, 1, and 2; and,
r, at each occurrence, is selected from 0, 1, 2, and 3.
34. A compound according to Claim 33, wherein:
R9- is selected from CH2OR3 , and CH2C(0)OCH3;
Rh is selected from CH2 -phenyl, CH2CH2 -phenyl, and CH=CH- phenyl ;
A is phenyl;
B is Y;
Y is phenyl substituted with 0-2 R4a;
R4a, at each occurrence, is selected from H, OR2, Cl , Br, F, I, Cχ_4 alkyl, (CH2) rNR2R2a, C(0)NRR2a, and CF3 ; and,
r, at each occurrence, is selected from 0, 1, and 2.
35. A compound according to Claim 34, wherein:
Figure imgf000142_0001
R1 is selected from S02CH2C (0) OR3, C (0) CH2C (O) OR3 , and C(0)OR3;
X is O;
Y is pyrrolidinyl substituted with 1-2 R4a or piperidinyl substituted with 1-2 R4a;
R2 , at each occurrence, is selected from H, Cχ_6 alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ_g alkyl, benzyl, and phenyl;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, O, and S;
R3, at each occurrence, is selected from H, Cχ_4 alkyl, and phenyl ;
R4, at each occurrence, is selected from H, F, Cl, Br, I, Cχ_4 alkyl, NR2R2a, and CF3 ; and,
R4a, at each occurrence, is selected from H, Cχ_4 alkyl, CH2NR2R2a, and C(=NR2)CH3.
36. A compound according to Claim 35, wherein: R1 is selected from S02CH2C (O) OR3 and C (0) CH2C (O) OR3 ;
Y is piperidinyl substituted with 1-2 R4a;
R3, at each occurrence, is selected from H and Cχ.4 alkyl;
R4 is H; and,
R4a, at each occurrence, is selected from H, Cχ_4 alkyl, CH2NR2R2a, and C(=NR2)CH3.
37. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000143_0001
R1 is selected from S02CH2C (O) OR3 , C (O) CH2C (O) OR3 , and
C(0)OR3;
X is O;
Y is pyrrolidinyl substituted with 1-2 R4a or piperidinyl substituted with 1-2 R4a;
R2 , at each occurrence, is selected from H, Cχ_g alkyl, benzyl , and phenyl ;
R2a, at each occurrence, is selected from H, Cχ.g alkyl, benzyl, and phenyl;
alternatively, R2 and R2a, together with the atom to which they are attached, combine to form a 5 or 6 membered saturated, partially saturated or unsaturated ring and containing from 0-1 additional heteroatoms selected from the group consisting of N, 0, and S;
R3, at each occurrence, is selected from H, Cχ_ alkyl, and phenyl ;
R , at each occurrence, is selected from H, F, Cl, Br, I, Cχ-4 alkyl, NR2R2a, and CF3 ; and,
R4a, at each occurrence, is selected from H, Cχ- alkyl,
CH2NR2R2a, and C(=NR2)CH3.
38. A compound according to Claim 37, wherein:
Ri is selected from S02CH2C (0) OR3 and C (O) CH2C (O) OR3 ;
Y is piperidinyl substituted with 1-2 R4a;
R3, at each occurrence, is selected from H and C -4 alkyl;
R4 is H; and,
R4a, at each occurrence, is selected from H, Cχ_4 alkyl, CH2NR2R2a, and C(=NR2)CH3.
39. A compound according to Claim 1, wherein the compound is of the formula:
Figure imgf000145_0001
or a stereoisomer or pharmaceutically acceptable salt thereof, wherein; G is selected from:
Figure imgf000146_0001
Figure imgf000146_0002
Ra is selected from C(0)C(0)OH and C(O) (benzothiazol-2-yl) ;
R9 is selected from H, CH2OR3 , CH2C(0)OR3, Cχ_4 alkyl, C(0)NH2, and NH2 ;
Rh is selected from H, CH2 -phenyl, CH2CH2 -phenyl , and CH=CH- phenyl ;
R1 is selected from S02CH2C(0)OH and C (O) CH2C (0) OH, and C(0)OR3;
R, at each occurrence, is selected from H, methyl, ethyl, benzyl , and NH ;
R2, at each occurrence, is selected from H, CF3 , CH3 , benzyl, and phenyl ;
R2a, at each occurrence, is selected from H, CF3 , CH3, benzyl, and phenyl; alternatively, R2 and R2a combine to form a ring system selected from pyrrolidinyl, piperazinyl and morpholino;
R3 , at each occurrence, is selected from H, Cχ_4 alkyl, and phenyl ;
Z is C(0)CH2 or CONH;
A is selected from phenyl, pyridyl, and pyrimidyl, and is substituted with 0-2 R4 ; and,
B is selected from Y, X-Y, phenyl, pyrrolidino, morpholino, 1,2,3-triazolyl, and imidazolyl, and is substituted with 0-1 R4a;
R4, at each occurrence, is selected from OH, (CH2)rOR2, halo,
Cχ_4 alkyl, (CH2) rNR2R2a, and (CF2)rCF3;
R4a is selected from Cχ.4 alkyl, CF3 , S(0)2R5, S02NR2R2a, and l-CF3-tetrazol-2-yl;
R5, at each occurrence, is selected from CF3 , Cχ_6 alkyl, phenyl , and benzyl ;
X is CH2 or C(O) ;
Y is selected from NR2R2a and CH2NR2R2a;
p is selected from 0, 1, and 2; and,
r is selected from 0, 1, and 2.
40. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to one of Claims 1- 39 or a pharmaceutically acceptable salt thereof.
41. A method for treating or preventing a thromboembolic disorder, comprising: administering to a patient in need thereof a therapeutically effective amount of a compound according to one of Claims 1-39 or a pharmaceutically acceptable salt thereof.
42. Use of a compound according to one of Claims 1-39 in therapy.
43. Use of a compound according to one of Claims 1-39 for the manufacture of a medicament for the treatment of thrombosis or a disease mediated by factor Xa.
PCT/US1999/030737 1998-12-23 1999-12-21 THROMBIN OR FACTOR Xa INHIBITORS WO2000038683A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU23816/00A AU2381600A (en) 1998-12-23 1999-12-21 Thrombin or factor xa inhibitors
CA002320730A CA2320730A1 (en) 1998-12-23 1999-12-21 Thrombin or factor xa inhibitors
EP99967554A EP1058549A4 (en) 1998-12-23 1999-12-21 THROMBIN OR FACTOR Xa INHIBITORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11362798P 1998-12-23 1998-12-23
US60/113,627 1998-12-23

Publications (1)

Publication Number Publication Date
WO2000038683A1 true WO2000038683A1 (en) 2000-07-06

Family

ID=22350572

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US1999/030735 WO2000039102A1 (en) 1998-12-23 1999-12-21 THROMBIN OR FACTOR Xa INHIBITORS
PCT/US1999/030737 WO2000038683A1 (en) 1998-12-23 1999-12-21 THROMBIN OR FACTOR Xa INHIBITORS
PCT/US1999/030512 WO2000039108A1 (en) 1998-12-23 1999-12-22 Thrombin or factor xa inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030735 WO2000039102A1 (en) 1998-12-23 1999-12-21 THROMBIN OR FACTOR Xa INHIBITORS

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030512 WO2000039108A1 (en) 1998-12-23 1999-12-22 Thrombin or factor xa inhibitors

Country Status (6)

Country Link
US (4) US6369227B1 (en)
EP (3) EP1058549A4 (en)
JP (1) JP2002537227A (en)
AU (3) AU3127900A (en)
CA (3) CA2320730A1 (en)
WO (3) WO2000039102A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1427415A1 (en) * 2001-09-21 2004-06-16 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
WO2007109812A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
EP2982668A2 (en) 2002-12-03 2016-02-10 Pharmacyclics LLC 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders
US11021458B2 (en) 2018-04-06 2021-06-01 Biocryst Pharmaceuticals, Inc. Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610692B1 (en) * 1998-10-30 2003-08-26 Merck & Co., Inc. Thrombin inhibitors
AR023510A1 (en) * 1999-04-21 2002-09-04 Astrazeneca Ab A TEAM OF PARTS, PHARMACEUTICAL FORMULATION AND USE OF A THROMBIN INHIBITOR.
US6653316B1 (en) 1999-05-19 2003-11-25 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US6867217B1 (en) 1999-05-19 2005-03-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
US6664255B1 (en) 1999-05-19 2003-12-16 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
US6458952B1 (en) 1999-05-19 2002-10-01 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
US6716838B1 (en) 1999-05-19 2004-04-06 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils as anticoagulative agents
US6750342B1 (en) 1999-05-19 2004-06-15 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyrimidinones useful for selective inhibition of the coagulation cascade
US7015230B1 (en) 1999-05-19 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade
SE9902987D0 (en) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
US6468859B1 (en) * 1999-09-20 2002-10-22 Micron Technology, Inc. Method of reducing electrical shorts from the bit line to the cell plate
AU2001243598A1 (en) 2000-03-13 2001-09-24 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted benzenes useful for selective inhibition of the coagulation cascade
US6875791B2 (en) 2000-04-05 2005-04-05 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade
AU2001251315A1 (en) 2000-04-05 2001-10-23 Pharmacia Corporation Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade
US20040171616A9 (en) 2000-04-17 2004-09-02 South Michael S. Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade
US7015223B1 (en) 2000-11-20 2006-03-21 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl 1,2,4-triazinones useful for selective inhibition of the coagulation cascade
WO2002042272A2 (en) 2000-11-20 2002-05-30 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
US7119094B1 (en) 2000-11-20 2006-10-10 Warner-Lambert Company Substituted polycyclic aryl and heteroarpyl pyrazinones useful for selective inhibition of the coagulation cascade
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2002367752A1 (en) 2001-10-03 2003-11-17 Pharmacia Corporation Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
WO2003029216A1 (en) 2001-10-03 2003-04-10 Pharmacia Corporation 6-membered heterocyclic compounds useful for selective inhibition of the coagulation cascade
SE0103818D0 (en) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
WO2003048081A2 (en) 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
OA12771A (en) 2002-02-14 2006-07-04 Pharmacia Corp Substituted pyridinones as modulators of P38 map kinase.
ATE410429T1 (en) 2002-03-07 2008-10-15 Hoffmann La Roche BICYCLIC PYRIDINE AND PYRIMIDINE INHIBITORS OF P38 KINASE
EP1505966A4 (en) 2002-05-10 2006-08-30 Bristol Myers Squibb Co 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
JP2006512313A (en) * 2002-10-31 2006-04-13 アムジェン インコーポレイテッド Anti-inflammatory agent
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
AR044045A1 (en) * 2003-04-23 2005-08-24 Glaxo Group Ltd COMPOSITE OF PIPERIDINCARBONILPIPERAZINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PROCEDURE FOR PREPARATION
WO2004100947A2 (en) * 2003-05-06 2004-11-25 Smithkline Beecham Corporation Novel chemical compounds
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
KR101204247B1 (en) 2003-07-22 2012-11-22 아스텍스 테라퓨틱스 리미티드 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases cdk and glycogen synthase kinase-3 gsk-3 modulators
US20050026944A1 (en) * 2003-07-24 2005-02-03 Patrick Betschmann Thienopyridine and furopyridine kinase inhibitors
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
EP2395000A1 (en) 2004-12-30 2011-12-14 Astex Therapeutics Limited Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
WO2006077424A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
JP5475235B2 (en) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド Pharmaceutical compounds
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
US20070155739A1 (en) * 2005-12-30 2007-07-05 Alantos Pharmaceuticals, Inc. Substituted bis-amide metalloprotease inhibitors
JP5474354B2 (en) 2005-12-30 2014-04-16 アステックス、セラピューティックス、リミテッド Pharmaceutical compounds
DK1984333T3 (en) 2006-02-03 2012-07-23 Bionomics Ltd Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as inhibitors of tubulin polymerization
CA2641254A1 (en) 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
US8324240B2 (en) * 2007-03-20 2012-12-04 Curis, Inc. Fused amino pyridine as HSP90 inhibitors
EP2152707B1 (en) 2007-05-04 2012-06-20 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
WO2008137435A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
CL2008001933A1 (en) 2007-06-29 2009-09-25 Millennium Pharm Inc Pyrimidine derived compounds, raph kinase inhibitors; intermediate compounds; preparation procedure; pharmaceutical composition; and its use to treat proliferative, cardiac, neurodegenerative, inflammatory, bone, immunological, viral disease, among others.
JP2010532381A (en) * 2007-06-29 2010-10-07 サネシス ファーマシューティカルズ， インコーポレイテッド Heterocyclic compounds useful as RAF kinase inhibitors
KR20100051814A (en) 2007-07-17 2010-05-18 브리스톨-마이어스 스큅 컴퍼니 Method for modulating gpr119 g protein-coupled receptor and selected compounds
KR101546111B1 (en) * 2007-10-11 2015-08-20 글락소스미스클라인 엘엘씨 Novel seh inhibitors and their use
AR072297A1 (en) 2008-06-27 2010-08-18 Novartis Ag DERIVATIVES OF INDOL-2-IL-PIRIDIN-3-ILO, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND ITS USE IN MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE SYNTHESIS ALDOSTERONE.
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
GB0813144D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
PE20110830A1 (en) * 2008-12-05 2011-12-14 Abbvie Bahamas Ltd DERIVATIVES OF HAVE [3,2-C] PYRIDINE AS INHIBITORS OF KINASES
MX2011013325A (en) 2009-06-10 2012-04-30 Abbott Lab 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors.
CN101648890B (en) * 2009-09-16 2012-07-25 常州工程职业技术学院 Synthesis method of 2-fluoro-4-nitrobenzonitrile
CA2780922A1 (en) 2010-02-11 2011-08-18 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN103906733A (en) 2011-06-24 2014-07-02 安姆根有限公司 TRMP8 antagonists and their use in treatments
MX2013015058A (en) 2011-06-24 2014-01-20 Amgen Inc Trpm8 antagonists and their use in treatments.
WO2013012909A1 (en) 2011-07-20 2013-01-24 Abbott Laboratories Kinase inhibitor with improved aqueous solubility
JP6134731B2 (en) * 2011-11-29 2017-05-24 ペロスフィア インコーポレイテッド Anticoagulant antagonist
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
CN103073447B (en) * 2013-02-01 2014-09-17 黄河三角洲京博化工研究院有限公司 Synthesis method for 2-para-fluorobenzoylbut benzamide
AU2014236711A1 (en) 2013-03-14 2015-09-17 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN104086457B (en) * 2014-06-10 2016-06-15 蚌埠团结日用化学有限公司 A kind of production technology to Brominal synthesis
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
MX2017003464A (en) 2014-09-16 2017-07-13 Celgene Quanticel Res Inc Histone demethylase inhibitors.
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
PT3472153T (en) 2016-06-16 2021-12-31 Denali Therapeutics Inc Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders
EP3728253B1 (en) * 2017-12-19 2024-03-27 Bristol-Myers Squibb Company 6-azaindole compounds
CA3093963A1 (en) * 2018-03-14 2019-09-19 Aerie Pharmaceuticals, Inc. Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds
KR102135106B1 (en) * 2018-12-11 2020-07-17 재단법인 경기도경제과학진흥원 Antiviral Composition for Middle East Respiratory Syndrome Coronavirus
JP2023509452A (en) 2020-01-03 2023-03-08 バーグ エルエルシー Polycyclic Amides as UBE2K Modulators to Treat Cancer
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use
KR20240035395A (en) 2021-06-14 2024-03-15 스코르피온 테라퓨틱스, 인코퍼레이티드 Urea derivatives that can be used in cancer treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028326A1 (en) * 1996-12-23 1998-07-02 Biochem Pharma Inc. Bicyclic thrombin inhibitors

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1170909B (en) * 1980-04-23 1987-06-03 Wellcome Found COMPOSITION FOR THE TREATMENT OF INFLAMMATIONS BASED ON ADENOSINE ANALOGS AND RELATED PREPARATION PROCEDURE
US4859677A (en) * 1987-04-17 1989-08-22 University Of Kansas Nucleoside analogues having antiviral activity
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9005965D0 (en) 1990-03-16 1990-05-09 Shell Int Research Herbicidal carboxamide derivatives
GB9017694D0 (en) 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
GB9024129D0 (en) 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
JPH04327587A (en) * 1991-04-26 1992-11-17 Asahi Chem Ind Co Ltd 6'-c-alkyl-3-deazaneplanocin a derivative, its production and use
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
IL115420A0 (en) * 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
ATE233240T1 (en) 1994-12-02 2003-03-15 Yamanouchi Pharma Co Ltd NEW AMIDINONAPHTHYL DERIVATIVE OR SALT THEREOF
SK83897A3 (en) * 1994-12-22 1998-05-06 Iaf Biochem Int Low molecular weight bicyclic thrombin inhibitors
JPH08277287A (en) 1995-02-09 1996-10-22 Mitsubishi Chem Corp Indazoles and their use
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
DK0813525T3 (en) * 1995-03-10 2004-02-16 Berlex Lab Benzamidine derivatives, their preparation and use as anticoagulants
WO1996030396A1 (en) * 1995-03-24 1996-10-03 Molecumetics Ltd. β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS
GB9508622D0 (en) * 1995-04-28 1995-06-14 Pfizer Ltd Therapeutic agants
IT1277405B1 (en) * 1995-08-01 1997-11-10 Menarini Farma Ind BICYCLIC LACTAM DERIVATIVES AS THROMBIN INHIBITORS
JP2001502655A (en) 1995-12-21 2001-02-27 デュポン ファーマシューティカルズ カンパニー Isoxazoline, isothiazoline and pyrazoline which are factor Xa inhibitors
CN1273128C (en) 1996-01-02 2006-09-06 阿温蒂斯药物公司 Substituted N-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides
US5994375A (en) * 1996-02-12 1999-11-30 Berlex Laboratories, Inc. Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants
AU720616B2 (en) 1996-02-22 2000-06-08 Merck & Co., Inc. Pyridinone thrombin inhibitors
CA2244851A1 (en) 1996-02-22 1997-08-28 Petrus Fredericus Wilhelmus Stouten M-amidino phenyl analogs as factor xa inhibitors
WO1997036580A1 (en) * 1996-03-29 1997-10-09 3-Dimensional Pharmaceuticals, Inc. Amidinohydrazones as protease inhibitors
AU2733997A (en) 1996-04-17 1997-11-07 Du Pont Pharmaceuticals Company N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
TR199802133T2 (en) * 1996-04-23 2000-09-21 Merck & Co., Inc. Pyrazinone thrombin inhibitor.
JPH101467A (en) * 1996-06-13 1998-01-06 Banyu Pharmaceut Co Ltd Biphenylamidine derivative
EP0906296A1 (en) * 1996-06-18 1999-04-07 Warner-Lambert Company Llc Process for the preparation of chiral keto-heterocycles of basic amino acids
AU3232597A (en) * 1996-06-18 1998-01-07 Warner-Lambert Company Pyrrolo{1,2-a}pyrazine-1,4-dione serine protease inhibitors
US5863929A (en) * 1996-06-25 1999-01-26 Eli Lilly And Company Anticoagulant agents
NZ333696A (en) * 1996-07-08 2000-06-23 Du Pont Pharm Co Amidinoindoles, amidinoazoles, and analogs thereof as inhibitors of trypsin like protease enzymes like thrombin and Xa factor
WO1998005333A1 (en) 1996-08-05 1998-02-12 Molecumetics Ltd. Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors
DE69718194T2 (en) 1996-08-16 2003-10-16 Bristol-Myers Squibb Pharma Co., Wilmington AMIDINOPHENYL-PYRROLIDINE, -PYRROLINE AND -ISOXAZOLIDINE AND THEIR DERIVATIVES
US5693641A (en) 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
US5753635A (en) * 1996-08-16 1998-05-19 Berlex Laboratories, Inc. Purine derivatives and their use as anti-coagulants
WO1998009987A1 (en) * 1996-09-06 1998-03-12 Biochem Pharma, Inc. Lactam inhibitors of thrombin
US6004985A (en) * 1996-10-09 1999-12-21 Berlex Laboratories, Inc. Thio acid derived monocylic N-heterocyclics as anticoagulants
US5798377A (en) 1996-10-21 1998-08-25 Merck & Co., Inc. Thrombin inhibitors
CA2267260A1 (en) 1996-10-24 1998-04-30 Merck & Co., Inc. Thrombin inhibitors
UA56197C2 (en) 1996-11-08 2003-05-15 Зенека Лімітед Heterocyclic derivatives
IL130286A0 (en) * 1996-12-23 2000-06-01 Du Pont Pharm Co Nitrogen containing heteroaromatics as factor Xa inhibitors
ES2196396T3 (en) * 1996-12-23 2003-12-16 Bristol Myers Squibb Pharma Co HETEROAROMATIC COMPOUNDS OF 5 MEMBERS CONTAINING OXYGEN OR SULFUR AS INHIBITORS OF THE XA FACTOR.
WO1998031670A1 (en) 1997-01-22 1998-07-23 Merck & Co., Inc. Thrombin inhibitors
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Serine protease inhibiting antithrombotic agents and pharmaceutical compositions comprising them
CA2293824A1 (en) 1997-06-19 1998-12-23 Mimi Lifen Quan (amidino)6-membered aromatics as factor xa inhibitors
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO1998057937A2 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Inhibitors of factor xa with a neutral p1 specificity group
EP1007037A4 (en) * 1997-06-26 2004-10-06 Lilly Co Eli Antithrombotic agents
CN1279682A (en) * 1997-10-20 2001-01-10 霍夫曼-拉罗奇有限公司 bicyclic kinase inhibitors
IL137517A0 (en) * 1998-01-27 2001-07-24 Aventis Pharm Prod Inc Substituted oxoazaheterocyclyl factor xa inhibitors
AU1917999A (en) * 1998-03-31 1999-10-18 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
EP1086950B1 (en) * 1998-05-26 2010-09-29 Chugai Seiyaku Kabushiki Kaisha Heterocyclic indole derivatives and mono- or diazaindole derivatives
BR9910864A (en) * 1998-06-04 2002-02-05 Abbott Lab Anti-inflammatory compounds for inhibiting cell adhesion
TW555759B (en) * 1998-06-08 2003-10-01 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028326A1 (en) * 1996-12-23 1998-07-02 Biochem Pharma Inc. Bicyclic thrombin inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLUMMER J.S. ET AL.: "Potent and selective bicyclic lactam inhibitors of thrombin: part 3: P1' modifications", BIOORG. MED. CHEM. LETT.,, vol. 9, no. 6, March 1999 (1999-03-01), pages 835 - 840, XP004159613 *
See also references of EP1058549A4 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008207537B8 (en) * 2001-09-21 2011-12-08 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
EP1427415A4 (en) * 2001-09-21 2005-11-02 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
EP1427415A1 (en) * 2001-09-21 2004-06-16 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2002341693B2 (en) * 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
EP2105436A1 (en) * 2001-09-21 2009-09-30 Bristol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor XA inhibitors
EP2982668A2 (en) 2002-12-03 2016-02-10 Pharmacyclics LLC 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors for the treatment of thromboembolic disorders
WO2007109812A3 (en) * 2006-03-23 2007-12-27 Novartis Ag Immunopotentiating compounds
WO2007109812A2 (en) * 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
US11021458B2 (en) 2018-04-06 2021-06-01 Biocryst Pharmaceuticals, Inc. Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
US11370774B2 (en) 2018-04-06 2022-06-28 Biocryst Pharmaceuticals, Inc. Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
US11708347B2 (en) 2018-04-06 2023-07-25 Biocryst Pharmaceuticals, Inc. Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
US11866418B2 (en) 2018-04-06 2024-01-09 Biocryst Pharmaceuticals, Inc. Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
US12043610B2 (en) 2018-04-06 2024-07-23 Biocryst Pharmaceuticals, Inc. Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors

Also Published As

Publication number Publication date
US6403583B1 (en) 2002-06-11
US20020115854A1 (en) 2002-08-22
AU3127900A (en) 2000-07-31
EP1058549A4 (en) 2003-11-12
CA2348740A1 (en) 2000-07-06
US6500855B1 (en) 2002-12-31
EP1140862A1 (en) 2001-10-10
US20030004344A1 (en) 2003-01-02
CA2349557A1 (en) 2000-07-06
US6369227B1 (en) 2002-04-09
CA2320730A1 (en) 2000-07-06
US6602871B2 (en) 2003-08-05
EP1140871A1 (en) 2001-10-10
WO2000039108A1 (en) 2000-07-06
AU2381600A (en) 2000-07-31
AU2375500A (en) 2000-07-31
EP1058549A1 (en) 2000-12-13
EP1140871A4 (en) 2004-05-06
WO2000039102A1 (en) 2000-07-06
JP2002537227A (en) 2002-11-05
EP1140862A4 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
US6602871B2 (en) Thrombin or factor Xa inhibitors
US6426346B1 (en) 6-membered aromatics as factor Xa inhibitors
EP1175419B1 (en) Aryl sulfonyls as factor xa inhibitors
US6599926B2 (en) Heteroaryl-phenyl substituted factor Xa inhibitors
EP1196412B1 (en) Nitrogen containing heterobicycles as factor xa inhibitors
US6998408B2 (en) 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
WO2001032628A1 (en) Cyano compounds as factor xa inhibitors
US20030004167A1 (en) Imidazo-heterobicycles as factor Xa inhibitors
US20030018023A1 (en) 5-6 or 5-7 Heterobicycles as Factor Xa inhibitors
EP0993448A1 (en) (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS
US6790845B2 (en) Fused heterocyclic inhibitors of factor Xa
US6586418B2 (en) Thrombin or factor Xa inhibitors
US20040038980A1 (en) Imidazo-heterobicycles as factor xa inhibitors
US6407256B1 (en) Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors
US6878710B2 (en) Bicyclic inhibitors of factor Xa

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BR CA CN CR CZ DM EE HU IL IN JP KR LT LV MA MK MX NO NZ PL RO SG SI SK TR TZ UA VN ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

ENP Entry into the national phase

Ref document number: 2320730

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999967554

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999967554

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999967554

Country of ref document: EP